{"title": "PDF", "author": "PDF", "url": "https://www.fhi.no/globalassets/dokumenterfiler/rapporter/2014/20142-legemiddelstatistikk---reseptregisteret-drug-consumption-statistics---norpd-20092013-pdf.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "The Norwegian Prescription Database Design/Layout Houston 911 Acknowledgement:Julie 2011: Legemiddelstatistikk til andre form\u00e5l som er Reseptregisteret. Mer use of drugs in the population is increasing. An important goal of the health policies regarding pharmaceuticals in Norway is rational drug use. In order to improve drug use, knowledge about which drugs are used, how they are used and who uses them is vital. In December 2002, the Parliament decided to establish a national prescription database in Norway (NorPD). The task of building up the register was given to the Norwegian Institute of Public Health (NIPH). Since 1st January 2004, the institute has received monthly data on prescriptions from all Norwegian pharmacies. This report is the seventh edition of the annual statistics from NorPD. General information about NorPD, drug statistics, classification of drug and measurement methods is included in part 1 of the report. Part 2 contains some key figures from NorPD and the main tables with informa - tion about the number of individuals who had prescriptions dispensed from pharmacies in Norway during the latest five years period (2009-2013). The information includes particular drug substances as well as drug groups. ATC (Anatomical Therapeutic Chemical) classification is used in the tables. For 2013, information about age, gender and costs are included in the tables. The ATC/DDD version of January 2014 has been used in the report, see also www.whocc.no NorPD also has a website where you can find complementary information. The website is: www. norpd.no (English version) or www.reseptregisteret.no (Norwegian version). It is also possible to apply for data from NorPD for research or for other purposes which are according to the objec - tives of NorPD. More information about this can be found in part 2 of the report, and at the website of the Norwegian Institute of Public Health (www.fhi.no). Department of Pharmacoepidemiology Norwegian Institute of Public Health April 8 D\u00f8gndose (DDD) ..................................................................................................................... 16 1.6 WHO Collaborating Centre for Drug Statistics Methodology ......................................................... 17 2. Reseptregisteret 2009-2013 ...................................................................................................................... 23 2.3 av hovedtabellene .......................................................................................................... 27 2.4 ATC main groups ..................................................................................................................................... 31 2.5 ATC group A - Alimentary tract and metabolism ............................................................................. 32 2.6 ATC group B - Blood and bloodforming organs ................................................................................. 43 2.7 ATC group C - Cardiovascular system ................................................................................................ 46 2.8 ATC group D - Dermatologicals ........................................................................................................... 54 2.9 ATC group G - Genito urinary system and sex hormones ............................................................... 60 2.10 ATC group H - Systemic hormonal preparations, excl. sex hormones and insulins ................... 65 2.11 ATC group J - Antiinfectives for systemic use .................................................................................. 68 2.12 ATC group L - Antineoplastic and immunomodulating agents ...................................................... 74 2.13 ATC group M - Musculo-skeletal system .......................................................................................... 77 2.14 ATC group N - Nervous system ........................................................................................................... 81 2.15 ATC group P - Antiparasitic products, insecticides and repellents ............................................... 91 2.16 ATC group R - Respiratory system ..................................................................................................... 93 2.17 ATC group S - Sensory organs ............................................................................................................. 97 2.18 ATC group V - Various .......................................................................................................................... 101 Noen forkortelser og definisjoner 2014:2 Folkehelseinstituttet 9 Preface ................................................................................................................................................................... 6 1. General information about the Norwegian Prescription Database and drug statistics .................... 11 1.1 About the NorPD .................................................................................................................................... 11 1.2 Prescription statistic in the other Nordic countries ........................................................................ 14 1.3 The Norwegian Drug Wholesales Statistics ...................................................................................... 15 1.4 The Anatomical Therapeutic Chemical (ATC) classification system ............................................. 15 1.5 The Defined Daily Dose (DDD) .............................................................................................................. 16 1.6 The WHO Collaborating Centre for Drug Statistics Methodology ................................................. 17 2. The Norwegian Prescription Database (NorPD) 2009-2013 .................................................................. 19 2.1 Selected key figures from NorPD ....................................................................................................... 19 2.2 Prescription categories and re imbursement of medicinal expenses .......................................... 23 2.3 Description of the main tables ............................................................................................................. 27 2.4 ATC main groups ..................................................................................................................................... 31 2.5 ATC group A - Alimentary tract and metabolism ............................................................................. 32 2.6 ATC group B - Blood and bloodforming organs ................................................................................. 43 2.7 ATC group C - Cardiovascular system ................................................................................................ 46 2.8 ATC group D - Dermatologicals ........................................................................................................... 54 2.9 ATC group G - Genito urinary system and sex hormones ............................................................... 60 2.10 ATC group H - Systemic hormonal preparations, excl. sex hormones and insulins ................... 65 2.11 ATC group J - Antiinfectives for systemic use .................................................................................. 68 2.12 ATC group L - Antineoplastic and immunomodulating agents ...................................................... 74 2.13 ATC group M - Musculo-skeletal system .......................................................................................... 77 2.14 ATC group N - Nervous system ........................................................................................................... 81 2.15 ATC group P - Antiparasitic products, insecticides and repellents ............................................... 91 2.16 ATC group R - Respiratory system ..................................................................................................... 93 2.17 ATC group S - Sensory organs ............................................................................................................. 97 2.18 ATC group V - Various .......................................................................................................................... 101 Some abbreviations and definitions .............................................................................................................. 102 Population in Norway 2009-2013 (as of 1st July) ....................................................................................... 103 Population by age in 2013 (as of 1st July) ...................................................................................................... 103 List of publications based on data from the Norwegian Prescription Database (NorPD) as of about the Norwegian Prescription Databa-se and drug statistics 1.1 About the NorPD Data collection and variables in NorPD New legislation in the Norwegian pharmacy sector came into force on March 1st 2001. According to the new act, pharmacies were obliged to forward prescrip - tion data to a new national drug database. In October 2003, new, detailed regulations for the NorPD were approved (1). The objectives of the NorPD, as defined in authoritative regulations, are to collect and prepare data on drug use in individuals and animals in order to: 1. describe drug use patterns, highlighting changes over time 2. promote and form a basis for research and review of the safety and effectiveness of drug use 3. serve as a management tool for the authorities in order to assure prescribing quality in addition to general surveillance, control and planning 4. give the prescribing doctors a basis for internal control, as part of an audit method to improve the quality of prescribing practices All NorPD data use must be in accordance with these objectives. The regulation also determines what kind of data can be collected from the pharmacies and admin - istrative registers. 1. Generelt om Reseptregisteret tr\u00e5dte kraft 1. mars 2001, og loven ble apotek utredning inn fra apotek og administrative registre. Part 1 Del 1 12 Legemiddelstatistikk 2014:2 Folkehelseinstituttet The NorPD contains the following variables: Patient Person -identifier (encrypted), month/year of birth, month/year of death, gender, place of residence (municipality & county) Prescriber Person -identifier (encrypted), year of birth, gender, profession, speciality Drug Nordic article number (unique product identifier stating brand name, strength, pharmaceutical form and pack size), number of packs, ATC code, number of Defined Daily Doses (DDD), prescription category, reimbursement code (from March 2008: ICD10, ICPC codes or codes defined by the Norwegian Medi - cines Agency, completely implemented from March 2009), intended use and prescribed dose (free-text according to pharmacy label), dispensing date, price (pharmacy retail price) Pharmacy Name , licence number, municipality and county The Nordic article number is the important link to other registries providing detailed information about the drugs. The indication for prescribing was in the first years not recorded in the database, only the code of reimbursement which in some cases, acted as a proxy of diagnosis. From March 2008, prescribers had to use either the International Classification of Diseases version 10 (ICD10), or the International Classification of Primary Care Codes (ICPC) or special codes assigned by the Norwegian Medicines Agency as the code of reimbursement on the prescriptions. This was fully implemented from March 2009. Since 1 st January 2004, the NIPH has received monthly data on prescriptions from all Norwegian pharmacies (2). Monthly electronically reports are automatically generated in all pharmacies, thus avoiding extra work for the pharmacy. NorPD contains information about all drugs prescribed (reimbursed or not) and dispensed at pharmacies to individual patients living outside institutions, i.e. ambulant care. Unlicensed drugs are also included, but drugs sold over-the-counter (OTC) are not recorded in NorPD. However, if the OTC drugs are prescribed by a physician and dispensed, then they will be recorded in the database. The main data in NorPD are based on prescriptions to individual humans, but also prescribed drugs by veter - inarians to animals and prescribing to a physician's own practice are collected in NorPD. For patients in nursing homes and hospitals, the register collects figures on drug use at the level of the institution or the department, i.e. on an aggregate Clas - sification m\u00e5nedlig informasjon protection As illustrated in figure 1.1 the pharmacy records of dispensed drugs are electronically and automatically transferred through Statistics Norway before they arrive at NIPH and are included in NorPD. Statistics Norway acts as a so-called \"trusted third party centre\" and is a part of the data protection to ensure confi - dentiality of personal information. Statistics Norway only has access to the patient personal identification number and the prescriber's health personnel number and replaces both with a pseudonymised identifier. Statistics Norway cannot read any other prescription data because this information is encrypted before Statistics Norway receives the data. When Statistics Norway sends the data including the pseudonymised identifiers to the NIPH, the NIPH is allowed to decrypt the prescription information again. The term \"Pseud - onymous health data\" is defined in the Personal Health Data Filing System Act (in Norwegian: Helseregister - loven): \"personal health data in which the identity has been encrypted or otherwise concealed, but nonetheless individualized so that it is possible to follow each person through the health system without his identity being revealed\" (3). This means that the identity of patients and prescribers has been encrypted according to Norwegian legislation, but nonetheless individualized, so that it is possible to follow individuals over time and perform record-linkage studies. Data linkage is based on the unique identification number system which is available in all the Nordic countries. Quality checks For quality assurance, a number of queries are carried out monthly or half-yearly to identify possible errors or inconsistencies. NIPH performs different routine checks on the data before they are transferred to the NorPD. In the NorPD, the Nordic article number is linked to the national register of medicinal products with validated aggregerte prescriptionsencryptedPrescriptionswith pseudo-nymised pseudonyms *Trusted third Institute of Public Health NorPD 14 Legemiddelstatistikk 2014:2 Folkehelseinstituttet ATC codes and DDD values (4). This register is updated monthly. NIPH also checks if the data deliveries from each pharmacy are of a reasonable size. The total number of prescription records and the total number of patients and prescribers are checked every month. Statistics for the pharmacies are checked by routine. Unusual variations in size of data files from month to month are identified and any missing data is caught, such as missing special data type deliveries or empty data files caused by technical error at the pharmacy or at the trusted third party. The Personal Identification Number is checked in Statistics Norway against the Central Population Registry. If the Personal Identifica - tion Number is invalid or missing, Statistics Norway creates a special pseudonym, but it is not possible to track these individuals or link them to other data sources. However, the reported total number of ordina - tions and DDDs can be included in the total statistics. 1.2 Prescription statistic in the other Nordic countries During the late 1980s, pharmacies in the Nordic countries gradually computerized their records of dispensed prescriptions which made it possible to collect data efficiently. Although healthcare systems are not organized identically in the Nordic countries, all five countries have a tax-supported public health service with universal coverage. All citizens, inde - pendent of socioeconomic status, have unrestricted access to health services, including partial or complete reimbursement of purchased medicines. National prescription databases, containing data on drugs dispensed at pharmacies (exposure data) to individuals receiving ambulatory care, have been available since 1994 in Finland and Denmark, since 2004 in Norway, since 2005 in Sweden and since 2006 in Iceland. The databases together cover 25 million inhabitants (Denmark: 5.6 million; and Sweden: 9.6 million) and have the potential to link these data to different health outcomes and other data based on the unique personal identity code which all residents in these countries have. The databases serve as a resource for conducting longitudinal and record-linkage studies with health surveys and other registries. They also offer a sound evidence base for national decision-making in the field of drug utilization. An article from 2010 provides an overview of the data collection proce - dures and content of the Nordic countries' prescription databases (5). In addition, the article discusses their unique potential for cross-national record linkage and for analytical pharmacoepidemiological studies.kontroller p\u00e5 data Danmark, 2004 i Norge, siden 2005 i 2014:2 Folkehelseinstituttet 15 1.3 The Norwegian Drug Wholesales Statistics Statistics based on total sales of drugs from whole - salers to pharmacies, hospitals/nursing homes has been available in Norway since the 1970s. The Norwe - gian Drug Wholesales Statistics database includes total sales of drugs from wholesalers to pharmacies, hospitals/nursing homes and non-pharmacy outlets and others with permission to sell medicines. Total sales of prescription and non-prescription human and veterinary medicines are included in the statistics. The statistics give an overview of developments in drug consumption over time, both at county and country level. The statistics, however, contain no information about the individual drug user. Drug Consumption in Norway - published annually Data from the Norwegian Drug Wholesales Statis - tics Database have been published annually in Drug Consumption in Norway (6) since 1977. Each issue includes total sales data for 5 year periods for both prescription- and non-prescription drugs in Norway. The book is available from the website www.drugcon - sumption.no. Further information on the Norwegian Drug Wholesales Statistics database, including how to apply for data, can be found at the Norwegian Institute of Public Health's website www.fhi.no. 1.4 The Anatomical Therapeutic Chemical (ATC) classification system In the ATC system the drug substances are classified into groups at 5 different levels. The drugs are divided into fourteen main groups (1st level), with pharmaco - logical/ therapeutic sub-groups (2nd levels). The 3rd and 4th levels are chemical/pharmacological/ thera - peutic sub-groups and the 5th level is the chemical substance. The ATC code A complete classification of the drug spironolactone (diuretic) with the ATC code C03DA01 illustrates the structure of the ATC system:C Cardiovascular system (1st level, anatomical main group) C03 Diuretics (2nd level, therapeutic plain spironolac - tone (Aldactone\u00ae and Spirix\u00ae) are thus assigned the code C03DA01. The ATC classification system makes it possible to compile drug consumption statistics on 5 different levels, i.e., figures showing total consumption of all preparations classified in main group C - Cardiovas - cular system (1st level), figures for the various sub-groups (2nd, 3rd and 4th levels), and down to figures showing consumption of each active ingredient. The ATC code for all pharmaceuticals on the Norwegian market can be retrieved from the pharmacy medicinal product register and in the monographs of the national drug catalogue \"Felleskatalogen\" . The yellow section of the latter, entitled The Anatomical Therapeutic Chemical Medicines Register, lists all medicinal products belonging to each of the ATC 5th level codes. 1.5 The Defined Daily Dose (DDD) In some tables in part 2 in this book the sales volume of drug consumption is given in number of DDDs. Using DDDs as the unit of measurement allows better comparison between alternative medications, regardless of price differences. The evaluation of drug consumption volumes over time, nationally and internationally, is simplified and improved by the use of DDDs. A DDD is defined as the assumed average maintenance dose per day for a drug used on its main indication in adults. The DDDs are determined on the basis of evaluation of international use of the substance in question, bearing in mind that national therapy traditions (indications, dosages) often differ greatly. Each DDD should there - fore be regarded as a technical measuring unit. Drugs used for more than one indication may cause particular problems which are important to consider when evaluating statistics based on DDDs. With the exception of a very few specially formulated pediatric preparations, adult dosages are used. The DDD for a substance will often be one and the same, irrespective of the route of administration. However, drugs with different bioavailabilities depending on their admin - istration route will have more than one DDD, each of them linked to a specific dosage form. For medications where a booster dose is followed by a smaller main - tenance dosage, the maintenance dose will form the basis for determining the DDD. Whenever possible, the DDD is indicated as the quantity of active substance. Alle spironolakton niv\u00e5), tall for de ulike under - gruppene (2., 3. og 4. niv\u00e5) og ned til tall volum preparater as is the case with combi - nation preparations and some liquid preparations, the DDD is indicated as the number of single doses (number of tablets, capsules, millilitres etc.). The DDDs are not necessarily the most frequently prescribed or used doses. This must be considered when evalu - ating the data. Accordingly it will often be difficult to estimate the number of users by using the DDD as the measuring unit. The sales can be given as the number of DDDs/1000 inhabitants/day, calculated as follows: Total consumption measured in number of DDDs x 1000 365 x number of inhabitants This figure offers an estimation of what proportion of the population that may receive a certain drug treatment. An estimated drug consumption of 10 DDDs/1000 inhabitants/day corresponds to a daily use of this drug by 1% of the population. This estimate is, however, only valid if there is good correlation between the DDD and the actual consumed dose. 1.6 The WHO Collaborating Centre for Drug Statistics Methodology The WHO Collaborating Centre for Drug Statistics Methodology is responsible for the administration and development of the ATC/DDD system. The Centre is located at the Department of Pharmacoepidemiology at the NIPH. Further information about the ATC/DDD system is given in the publication Guidelines for ATC classification and DDD assignment (7). The ATC Index with DDDs which includes a list of all assigned DDDs can be ordered from the Centre (8). Both publications are available in English and Spanish. The website for the Centre is www.whocc.no.ATC and DDD changes are published annually and are made official by the end of the year. ATC/DDD version from January 2014 has been used in the book. The ATC/DDD publications can be ordered from the WHO Collaborating Centre for Drug Statistics Methodology.DDD representer ikke tallet gi som faktisk brukes. 1.6 WHO Collaborating Centre for Drug Statistics Methodology ATC/DDD systemet administreres og videreutvikles av WHO Collaborating Centre for Drug Statistics Methodology. Dette senteret er en del av for ATC classifica - tion and DDD assignment (7). ATC Index with DDDs, som inneholder en liste over alle - nene kan bestilles fra WHO Collaborating Centre for Drug Statistics Methodology. Referanser/References: 1. Forskrift om Filing Lov av 18.mai 2001 4. R\u00f8nning M, Litleskare I, Addis A et al. Recommendations for national registers of medicinal products with validated ATC codes and DDD values. Italian J Public Health 2006;3(1):30-35. 5. Furu K, Wettermark B, Andersen M, Martikainen JE, Almarsdottir AB, S\u00f8rensen HT. The Nordic countries as cohort pharmacoepi-demiological research. Basic Clin Pharmacol Toxicol 2010;106(2):86-94. 6. Sakshaug S Norway 2009-2013. [Legemiddelforbruket i Norge 2009-2013] Oslo: Norwegian Institute of Public Health, 2014. 7. WHO Collaborating Centre for Drug Statistics Methodology, Guidelines for ATC classification and DDD assignment 2014. Oslo, 2013. 8. WHO Collaborating Centre for Drug Statistics Methodology, ATC classification index with DDDs 2009-2013 2.1 Selected key figures from NorPD NorPD contains information from all Norwegian phar - macies of prescriptions to individuals, to a prescriber's own practice and to institutions. In 2013, about 95% of DDDs in NorPD were dispensed to individuals in ambulatory care. Deliveries to institutions (hospitals and nursing homes) amounted to 4.5% of the DDDs and about 0.4% of the DDDs were dispensed for use in the physician's practice. Sales of OTC medicines are not included in NorPD. OTC sales constitute 15% of total sales of pharmaceuticals in Norway in 2013, measured in DDDs (source: Norwegian Drug Wholesale Statistics, Norwegian Institute of Public Health). 2. Reseptregisteret 2009-2013 rundt % av legemidlene i Number of individuals and one-year prevalence (%) of the population who had at least one prescrip - tion dispensed in Norway 2009-2013 Women n (%)Men n (%)Both genders n (%) 2009 1 839 960 (76,1) 1 523 065 (63,2) 3 363 025 (69,6) 2010 1 842 575 (75,4) 1 510 186 (61,8) 3 352 761 (68,6) 2011 1 879 445 (76,0) 1 551 598 (62,6) 3 431 043 (69,3) 2012 1 897 957 (75,9) 1 571 092 (62,4) 3 469 049 2013 1 910 574 5.2 million individuals have been included in NorPD with at least one prescription medication dispensed from a pharmacy. The number of prescriptions dispensed to patients in the same period ( 2004-2013 ) is 373 million. In 2013, 68.6% of the Norwegian population had at least one prescription dispensed, 75.5% of women and 61.7% of men (table 2.1.a). In 2004, the first operational year of NorPD, the proportion of prescriptions having invalid or missing personal identification number was 3.7%. In the period 2005-2007, the proportion was around 2%. The proportion of prescriptions with an invalid personal identification number has declined further to just below 1.4 % in 2008 and 2009. In 2010-2013 the proportion was less than 1% (0.44% in 2013). The age-specific one year prevalence for having a drug dispensed in 2013 was lowest in both genders at about 10-14 years of age (figure 2.1). About 90 % of individuals aged 70 years and older received prescrip - tion medications. Excluding women who received only hormonal contraception for systemic use (ATC code G03A), the prevalence of drug use was reduced by about 10-15 percentage points in women aged 15-29, although the proportion of drug users among women over 15 years of age was still higher than in men.Reseptregisteret ble opprettet 1. januar 2009 har den ligget p\u00e5 i underkant 2.1: One-year prevalence (%) of the population who had at least one prescription dispensed in 2013 in Norway according to age and gender Women MenProportion (%) of the population100 80 60 40 one-year prevalence of the entire population, and among men and women, who received at least one prescription in each of the main ATC groups. The three drug groups most used in both men and women are anti-infectives (ATC group J), drugs affecting the nervous system (ATC group N) and drugs used for respiratory diseases (ATC group R). Table 2.1.c lists the medicines (defined as ATC 5th levels) with most users in Norway in 2013. Phenoxy - methylpenicillin (antibacterial) is used by the highest number of individuals followed by three analgesics (diclofenac, paracetamol, and the combination codeine / paracetamol). Paracetamol and diclofenac are also sold OTC. This use is not covered by NorPD. In general the list comprises mainly the same medi - cines as previous years, but with some changes in the sequence.Tabell 2.1.b 2.1.b: One-year prevalence (%) of the population who had at least one prescription dispensed in Norway in 2013 according to the main ATC groups ATC Women %Men %Both genders % A Alimentary tract and metabolism 18,8 14,1 16,4 B Blood and blood forming 6,1 15,5 H Systemic hormonal preparations, excl. sex hormones and insulins 11,2 5,4 8,3 Drugs with the highest number of users in Norway 2013 ATC code Active ingredient UseNumber of individualsProportion (%) of the population 1 J01CE02 phenoxymethylpenicillin 438 066 303 992 6,0 7 Cholesterol 290 634 382 5,4 9 192 528 3,8 lowering 189 401 3,7 16 eye drops 185 720 Anxiolytic 120 562 2,4 30 A12AX Calcium, combinations with vitamin D and/or other drugs1) Calcium supplement 112 275 2,2 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.Legemiddelstatistikk Prescription categories and re imbursement of medicinal expenses NorPD contains information about the number of individuals having at least one drug dispensed in the various prescription categories. Prescription categories are divided into: Non-reimbursable prescriptions Reimbursement prescriptions Health Trust prescriptions (HELFO) The following is not included: Contribution according to National Insurance Act \u00a7 5.22 in which a contribution may be granted to cover the cost of healthcare when expenses are not otherwise covered by other laws and medicinal support during military service and railway personnel. Non-reimbursable prescriptions These are prescriptions paid in full by the patient. Reimbursement prescriptions (\"Blue Prescription\") The costs under the various reimbursement schemes are combined in the tables (\u00a7\u00a7 2, 3a, 3b, 4, 5). Reimbursement according to \u00a7 2 Drugs listed on the reimbursement list \u00a7 2 will always be reimbursed when prescribed for the diagnoses (indicated by the ICPC and ICD codes) specified in the reimbursement list. The Norwegian Medicines Agency decides which medicines are included in the list and which diagnostic codes/ conditions should be subject to reimbursement prescribing. Reimbursement according to \u00a7 \u00a7 3a and 3b HELFO can decide to reimburse drugs that are not listed in the reimbursement list attached to \u00a7 2, provided that use of the drug is covered by a diagnostic code in the reimbursement list (\u00a7 3a). Decisions are made for the individual patient based on an application from the treating physician. For other expensive drugs for chronic diseases not mentioned in the reimbursement list, in special cases HELFO may grant reimbursement for an individual patient based on the physician's application (\u00a7 3b). NorPD will not contain a complete listing of reimbursement according to \u00a7\u00a7 3a and 3b. Reimbursement according to \u00a7 4 Drugs used for communicable diseases are reimbursed according to \u00a7 4 according to a specified disease list. The reimbursement is granted for antiinfective, immunostimulants and vaccines. 24 Legemiddelstatistikk individer er tatt med i tabellen.This support is provided to all who live in Norway, regardless of citizenship. The physician may prescribe these drugs for use in their own practice without giving the person-identifier of the patient. Such prescriptions will not be available on an individual level in the NorPD. Information regarding self-payment is not available in NorPD. Health Trust Prescription The regional health trusts provide a dedicated funding for certain expensive drugs. These include immune- modulating drugs for the treatment of rheumatic disorders (TNF inhibitors), multiple sclerosis and cancer. Only drugs that are dispensed by prescription to individuals are included in the table. Table 2.2.a Sales of drugs by prescription categories, overview 2013 Number of individuals Proportion (%) of the population Number of DDDs Sales in 1000 NOK Non-reimbursable prescriptions 3 004 244 59,1 589 451 070 2 677 229 Reimbursement prescriptions 2 203 509 43,4 1 622 828 376 9 558 223 Health Trust prescriptions 18 023 0,4 5 332 102 1 466 709 Table 2.2.b: Sales of reimbursed drugs (\u00a7\u00a7 2, 3a, 3b, 4, 5) by ATC main groups 2013 ATC main groups Number of individuals Proportion (%) of the population Number of DDDs Sales in 1000 NOK A Alimentary tract and metabolism 457 966 9,0 179 509 294 1 230 641 B Blood and blood forming organs 285 213 5,6 89 630 902 890 187 C Cardiovascular system 974 074 19,2 724 305 734 1 532 996 D Dermatologicals 247 034 4,9 489 715 122 181 G Genito urinary system and sex hormones 118 860 2,3 37 582 020 271 394 H Systemic hormonal preparations, excl. sex hormones and insulins 332 031 6,5 62 457 368 407 145 J Antiinfectives for systemic use 110 667 2,2 10 313 908 537 271 L Antineoplastic and immunomodulating agents 76 203 1,5 22 354 230 1 184 494 M Musculo-skeletal system 266 847 5,3 53 585 049 200 093 N Nervous system 595 732 11,7 185 342 791 1 660 731 P Antiparasitic products, insecticides and repellents 6 422 0,1 893 219 R Respiratory 759 815 15,0 223 449 555 1 222 738 S Sensory organs 260 115 5,1 32 795 009 215 377 V Various 15 027 0,3 260 913 78 732Legemiddelstatistikk 4, 5) with the highest number of users 2013 ATC code Active ingredient Use Number of individuals Proportion (%) of the population Number of DDDsSales in 1000 NOK 1 C10AA01 simvastatin Cholesterol lowering 288 2 C07AB02 metoprolol cardiac disease267 R06AE07 cetirizine Anti-allergic 236 248 4,7 H03AA01 levothyroxine sodium Thyroxine supplement 191 492 3,8 40 900 239 53 977 5 C10AA05 atorvastatin Cholesterol lowering 188 729 3,7 103 780 967 160 013 6 R03AC02 salbutamol Asthma/COPD 183 418 3,6 18 290 452 7 C08CA01 amlodipine Antihypertensive/ cardiac disease128 353 2,5 57 460 532 54 550 8 N02BE01 paracetamol Analgesic 125 298 2,5 13 819 518 32 R06AX27 desloratadine Anti-allergic mometasone Anti-allergic nose spray 111 844 2,2 13 289 824 39 941 11 N06AB10 escitalopram Antidepressant 108 238 2,1 34 669 614 72 570 12 A10BA02 metformin Diabetes 103 901 2,0 25 488 942 13 A02BC02 pantoprazole Reflux oesofagitis 103 451 2,0 342 620 14 A02BC05 esomeprazole Reflux oesofagitis 96 545 prednisolone Antiinflammatory/ R03AK06 salmeterol and fluticasone Asthma/COPD 92 901 1,8 20 501 17 B01AA03 warfarin Antitrombotic 87 624 1,7 18 C09CA06 candesartan Antihypertensive/ cardiac disease85 509 1,7 40 C03CA01 furosemide Antihypertensive/ cardiac disease83 - nideAsthma/COPD 81 21 S01GX02 levocabastine Anti-allergic, 69 and diuretics Antihypertensive/ cardiac disease67 143 46 554 23 R01AD12 fluticasone furoate Anti-allergic, nose spray 65 24 C09CA01 losartan Antihypertensive/ cardiac disease63 23 C09AA05 ramipril Antihypertensive/ cardiac disease62 503 26 R06AX13 loratadine Anti-allergic 57 685 1,1 11 480 480 15 137 27 D07AC13 mometasone Inflammatory skin disorders / M05BA04 alendronic acid Osteoporosis 52 516 1,0 14 711 498 35 999 * No DDD assigned for this ATC 5th level 26 Legemiddelstatistikk 2014:2 FolkehelseinstituttetTable 2.2.d: Reimbursed drugs (\u00a7\u00a7 2, 3a, 3b, 4, 5) with highest sales in NOK 2013 ATC code Active ingredient Use Number of individuals Proportion (%) of the population Number of DDDsSales in 1000 NOK 1 R03AK06 salmeterol and fluticasone Asthma/COPD 92 901 1,8 776 117 303 501 2 R03AK07 formoterol and budesonideAsthma/COPD 81 476 1,6 15 422 555 224 096 3 B02BD02 coagulation factor VIII Bleeding disorder 176 0,0 66 505 221 029 4 C10AA05 atorvastatin Cholesterol lowering 188 729 3,7 103 780 967 160 013 5 R03BB04 tiotropium bromide COPD 41 186 0,8 A02BC05 esomeprazole Reflux oesofagitis 96 29 413 400 150 468 7 H01AC01 somatropin Growth hormone deficiency 293 8 N06BA04 methylphenidate ADHD 28 0,6 11 934 390 130 124 9 L02BX03 abiraterone Cancer 749 0,0 119 189 127 473 10 C07AB02 metoprolol Antihypertensive/ cardiac disease267 637 5,3 43 681 C10AA01 simvastatin Cholesterol lowering 288 629 5,7 931 12 L01XE01 imatinib Cancer 492 0,0 54 390 100 853 13 A10AC01 insulin (human) Diabetes 32 519 0,6 11 527 383 97 006 14 A10AB05 insulin aspart Diabetes 28 283 0,6 9 023 N02CC01 sumatriptan Migraine L03AA13 pegfilgrastim Cancer 2 341 0,0 170 640 80 127 17 N03AX09 lamotrigine Epilepsy/ bipolar disorders 26 770 0,5 6 889 720 79 996 18 B01AE07 dabigatran etexilate Antitrombotic 13 671 mesalazine Ulcerative colitis / Crohn's disease15 78 523 20 J05AR03 tenofovir disoproxil and emtricitabineHIV infections 1 524 0,0 430 73 653 21 N06AB10 escitalopram Antidepressant 108 238 2,1 34 669 614 72 570 22 C10AX09 ezetimibe Cholesterol lowering 20 725 0,4 5 994 991 70 377 23 N03AX16 pregabalin Neuropathic pain /epilepsy 9 465 24 B01AA03 warfarin Antitrombotic 87 624 18 558 25 R03AC02 salbutamol Asthma/COPD 183 418 3,6 18 290 452 67 26 B01AF01 rivaroxaban Antitrombotic 13 218 0,3 emtricitabine, tenofovir and 663 28 H01CB02 octreotide Cancer candesartan Antihypertensive/ cardiac disease85 509 30 N05AH04 quetiapine Schizophrenia/psychoses 799 0,5 27 og spesielt for 2.3 Description of the main tables The tables in section 2 of this book provide an over - view of the number of individuals who have had prescriptions dispensed from pharmacies in Norway. Anyone who has had at least one prescription dispensed is included and the data are given for each medicinal substance and for groups of medicines. Even if an individual has been given the same medicine several times, he or she is counted as a user only once. Only dispensing data to individuals with a personal identification number are included in the tables. In NorPD the complete personal identification number is missing for 0.44% of the dispensed medicines to individuals in 2013. The tables contain figures for the period 2009-2013. In addition, the following information for 2013 includes: Share of women (%) of the total number of individuals who have had at least one prescription dispensed The number of individuals who have had at least one prescription dispensed in the following age groups: <15, 15-44, 45-69, 70 Sales in million Norwegian kroner (mNOK), i.e. for prescriptions dispensed to individuals with a personal identification number. The amount in NOK corresponds to the actual retail price from the pharmacy. The tables are arranged according to the ATC system (see further description in p. 15). The majority of ATC groups containing drugs on the Norwegian market are included. Medicine use by individuals in hospitals and nursing homes is not included at the individual level in the Norwegian Prescription Database. The total number of medicine users will therefore be higher than the figures in the tables for a number of drugs, particularly for drugs that are frequently used in hospitals or institutions. We have chosen to exclude some ATC groups in this book that are mainly used in hospitals or institutions. The following ATC groups have been omitted: B05 Blood substitutes and perfusion S01J Diagnostic agents S01L Ocular vascular disorder agents V Various (ATC group V01 Allergens is included in the table) 28 Legemiddelstatistikk 2014:2 Folkehelseinstituttetlegemidler, b\u00e5de i Norge (se ogs\u00e5 s. 15). I tabellene i del 2 i denne av minst ett av Non-prescription medicines are sometimes prescribed, but the majority of the OTC medicine sales will not be included in the tables in this book. Sales of OTC medicines are, however, included in the Norwegian Drug Wholesales Statistics database and the figures are published in \"Drug Consumption in Norway\" (see also p. 15). A footnote is used in the tables in part 2 of this book in the various ATC codes where OTC medicines are available in Norway. In 2013, OTC medicines had a share of 15% of total sales measured in DDDs. These shares have remained almost unchanged over time. Most prescribed medicines have an approved marketing authorisation in Norway. However, physicians can prescribe drugs without approved marketing authorisation. They must then apply for a licence from the Norwegian Medicines Agency. There are also some medicines that are part of a so-called \"negative list\" which can only be prescribed by special permission from the Medicines Agency. Drugs that are prescribed on licence or by special permission are included in the tables in the book. The number of individuals who are prescribed these medicines is often low. If the number of individuals is less than five, <5 is used in the tables. Many individuals use more than one medicine. Please be aware that it is not possible to add together the number of users of various drugs or drug groups in the tables to find the total number of users of two or more drugs. Statistics on the aggregate level in the Figure 2.2: The report generator at www.reseptregisteret.no (English version kroner som filbehandling m\u00e5 p\u00e5regnes.tables will, however, include the use of at least one of the drugs in the included drug groups. For example, the figures in the tables show that the total number of users of sleeping pills (ATC group N05C) is lower than the sum of the number of users of the individual medicines that are classified in N05C. This means that some individuals have been given more than one type of sleeping pill during a year, either through the use of more than one simultaneously or by switching from one agent to another. The NorPD website: www.norpd.no The Norwegian Prescription Database has its own website which can be used together with the tables in this report for complementary information. On the website (figure 2.2), one can create reports on the number of users of a particular drug or drug group. This can be done by searching for pre-defined drug groups, through the ATC system or by searching the active substance or product name. The following data on drug use can be extracted from the website: Number of users, split by gender, 5-year age groups, county or health region Number of users per 1 000 population (prevalence per 1 000) Turnover in NOK (pharmacy retail price) Turnover in doses (DDD - defined daily doses) Population base for the statistics, split by gender, age, county or health region Data are available from 2004 with an annual update for the preceding year. The figures in this book may differ slightly from the numbers found on the website. This is because the data extraction for the book was made at another date than the data on the website. Reporting of data from the pharmacy to NorPD is delayed for a minor number of prescriptions. The delay may be a few months, meaning that reports of data from a year can arrive the following year. Besides, individuals without known address are included in the tables in this book but not on the website. Access to data from NorPD It is possible to apply for data from the Norwegian Prescription Database for research or for other purposes which are according to the objectives of NorPD. Application forms are available on the website of NIPH (www.fhi.no) and all applications for access to data from NIPH should be sent to datatilgang@fhi.no. The data is free of charge, but fees for administration and file processing will be required. 30 Legemiddelstatistikk 2014:2 FolkehelseinstituttetBeregning av av \u00e5ret (utleverings\u00e5r minus f\u00f8dsels\u00e5r).Calculation of prevalence per 1000 inhabitants Prevalence is often defined as the number of individuals per 1000 inhabitants who have had at least one prescrip - tion dispensed in a pharmacy during a specific time period. The number of individuals listed in the tables can be used to calculate the prevalence of drug users in the population. Please read the following example: The population in Norway for the years 2009-2013 is shown on p. 105. The population of the four age groups in the tables is also provided. The population as of 1st July each year is used, calculated from the population figures by Statistics Norway from 1st January and 31st December. Age is defined as the age of the individual at the end of the year (year of dispensing minus birth year). Antall individer x 1000 1 040 279 x 1000 Antall innbyggere = 5 080 148 = 204,8 individer som i 2013: 1 040 279 Antall innbyggere i Norge per 1. juli 2013: 5 080 av prevalens (per 1000) for av hjerte-/ karmidler i Norge i 2013: The number of individuals x 1000 1 040 279 x 1000 The number of inhabitants = 5 080 148 = 204.8 individuals per 1000 inhabitantsThe number of individuals who had at least one cardiovascular drug dispensed (ATC group C) in Norway in 2013: 1 040 279 The number of inhabitants in Norway as of 1st July 2013: 5 080 148Calculation of the prevalence (per 1000) of users of cardiovascular drugs in Norway in 2013: Legemiddelstatistikk 2014:2 Folkehelseinstituttet 312.4 ATC main groups ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 A ALIMENTARY TRACT AND METABOLISM 678 403 702 509 742 204 791 540 832 956 57 26 048 194 571 372 083 240 254 1 502 917 B BLOOD AND BLOOD FORMING ORGANS 562 344 581 349 597 921 617 386 629 097 49 3 070 61 114 272 750 292 163 1 045 480 C CARDIOVASCULAR SYSTEM 945 886 975 141 998 461 1 019 237 1 040 279 51 6 903 99 153 542 497 391 726 1 571 794 D DERMATOLOGICALS 587 812 611 440 624 493 632 680 645 684 54 79 769 246 820 216 869 102 226 245 500 G GENITO URINARY SYSTEM AND SEX HORMONES 703 423 721 846 745 367 761 600 785 598 80 3 475 431 263 242 798 108 062 897 948 H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS 375 465 387 821 402 923 414 206 422 537 67 16 419 109 977 183 711 112 430 444 841 J ANTIINFECTIVES FOR SYSTEMIC USE 1 394 508 1 252 392 1 326 405 1 336 787 1 288 914 59 148 972 513 276 429 761 196 905 816 142 L ANTINEOPLASTIC AND IMMU - NOMODULATING AGENTS 72 795 76 656 81 612 86 336 90 729 54 1 264 19 959 43 089 26 417 2 668 185 M MUSCULO-SKELETAL SYSTEM 891 127 901 910 927 355 937 937 925 319 57 14 318 327 053 427 476 156 472 331 706 N NERVOUS SYSTEM 1 230 918 1 248 505 1 279 676 1 304 344 1 327 510 59 30 708 421 950 580 132 294 720 2 600 528 P ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS 86 714 88 743 92 296 95 141 96 547 62 3 632 43 659 38 204 11 052 36 412 R RESPIRATORY SYSTEM 1 183 767 1 183 735 1 223 490 1 239 078 1 220 116 56 159 501 441 102 449 667 169 846 1 363 495 S SENSORY ORGANS 596 290 609 467 617 742 618 314 612 715 57 110 059 175 648 853 132 155 301 674 32 Legemiddelstatistikk 2014:2 Folkehelseinstituttet2.5 ATC group A - Alimentary tract and metabolism 2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 A ALIMENTARY TRACT AND METABOLISM 678 403 702 509 742 204 791 540 832 956 57 26 048 194 571 372 083 240 254 1 502 917 A01 STOMATOLOGICAL PREPARATIONS 11 205 6 463 9 155 15 109 18 958 57 450 7 723 6 281 4 504 3 398 A01A STOMATOLOGICAL PREPARATIONS 11 205 6 463 9 155 15 109 18 958 57 450 7 723 6 281 4 504 3 398 A01AA Caries prophylactic agents 665 776 4 792 10 862 14 642 57 142 5 865 4 796 3 839 2 533 A01AA01 sodium fluoride 1)665 776 4 792 10 862 14 642 57 142 5 865 4 796 3 839 2 533 A01AB Antiinfectives and antisep - tics for local oral treatment 8 998 4 088 2 553 2 415 2 440 52 161 1 025 827 427 247 A01AB02 hydrogen peroxide1)0 <5 <5 0 0 - 0 0 0 0 0 A01AB03 chlorhexidine1)2 293 2 540 2 482 2 360 2 390 52 155 1 010 812 413 220 A01AB04 amphotericin B 6 690 1 529 52 36 25 60 0 8 11 6 19 A01AB09 miconazole 5 <5 5 8 10 60 <5 <5 0 5 6 A01AB11 various1)22 26 <5 <5 <5 <5 2 A01AB17 metronidazole 45 0 0 0 0 - 0 0 0 0 0 A01AC Corticosteroids for local oral treatment 1 026 1 155 1 379 1 409 1 465 64 116 511 599 239 392 A01AC01 triamcinolone 1 026 1 155 1 379 1 398 1 435 64 115 507 577 236 344 A01AC03 hydrocortisone 0 0 0 0 <5 0 0 0 <5 0 6 A01AD Other agents for local oral treatment 598 508 516 532 519 58 32 359 98 30 226 A01AD01 epinephrine 6 9 10 10 14 36 0 <5 6 <5 16 A01AD02 benzydamine 562 475 494 496 477 59 18 346 90 23 207 A01AD11 various 30 24 12 26 28 54 14 9 <5 <5 3 A02 DRUGS FOR ACID RELATED DISORDERS 316 609 338 746 366 465 393 798 417 708 55 7 648 92 424 200 287 117 349 334 466 A02A ANTACIDS 4 537 4 691 4 772 4 442 4 719 43 116 995 1 644 1 964 6 238 A02AA Magnesium compounds 0 0 0 <5 12 58 0 0 8 <5 3 A02AA04 magnesium hydroxide 0 0 0 <5 12 58 0 0 8 <5 3 A02AC Calcium compounds 1 293 1 229 1 085 1 009 928 36 16 144 327 441 627 A02AC01 calcium carbonate 1)1 293 1 229 1 085 1 009 928 36 16 144 327 441 627 A02AD Combinations and complexes of aluminium, calcium and magnesium compounds 1 495 1 485 1 526 1 039 1 179 60 26 576 373 204 169 A02AD01 ordinary salt combinations 1)1 495 1 485 1 526 1 039 1 179 60 26 576 373 204 169 A02AH Antacids with sodium bicarbonate 2 187 2 341 2 471 2 684 2 837 36 41 292 1 037 1 467 5 146 A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPH - AGEAL REFLUX DISEASE (GORD) 314 287 336 339 364 176 391 644 415 383 55 7 566 91 979 199 537 116 301 328 228 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.Legemiddelstatistikk 2014:2 Folkehelseinstituttet 33A02BA H2-receptor antagonists 58 630 57 804 57 052 55 116 53 694 59 1 310 14 602 24 818 12 964 16 190 A02BA01 cimetidine 56 46 34 28 23 74 0 <5 17 <5 27 A02BA02 ranitidine1)55 484 54 984 54 650 53 485 52 431 59 1 303 14 438 24 223 12 467 15 021 A02BA03 famotidine1)2 878 2 547 2 313 1 618 1 312 56 9 174 612 517 1 142 A02BA53 famotidine, combinations1)378 367 221 127 0 0 0 0 0 0 0 A02BB Prostaglandins 248 259 255 360 346 86 <5 228 70 46 188 A02BB01 misoprostol 248 259 255 360 346 86 <5 228 70 46 188 A02BC Proton pump inhibitors 269 754 292 835 321 967 352 025 377 400 54 6 407 81 487 182 681 106 825 311 191 A02BC01 omeprazole 46 873 47 082 48 114 47 472 45 183 55 3 293 9 061 19 890 12 939 46 827 A02BC02 pantoprazole1)85 176 102 237 125 091 148 733 171 451 54 672 39 791 81 449 49 539 63 305 A02BC03 lansoprazole 50 018 48 809 47 348 46 359 43 483 51 419 7 545 22 279 13 240 30 872 A02BC05 esomeprazole 111 446 117 963 125 642 135 124 142 299 55 2 466 31 792 71 031 37 010 170 187 A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) 1 807 1 909 2 143 2 375 2 724 62 263 945 930 586 659 A02BX02 sucralfate 403 366 419 440 470 62 <5 132 191 143 239 A02BX13 alginic acid 1 414 1 549 1 739 1 945 2 239 62 259 803 733 444 401 A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 60 485 62 554 65 509 69 717 72 136 71 1 484 25 258 27 484 17 910 15 329 A03A DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 3 471 3 623 3 150 3 568 4 373 56 229 1 025 1 510 1 609 1 786 A03AA Synthetic anticholinergics, esters with tertiary amino group 28 29 26 27 30 63 0 14 13 <5 34 A03AA04 mebeverine 27 29 26 27 30 63 0 14 13 <5 34 A03AA07 dicycloverine <5 0 0 0 0 - 0 0 0 0 0 A03AB Synthetic anticholinergics, quaternary ammonium compounds 112 132 160 214 497 49 <5 34 182 279 275 A03AB02 glycopyrronium bromide 105 128 155 206 491 50 <5 32 178 279 270 A03AB05 propantheline 7 <5 5 8 6 0 0 <5 <5 0 5 A03AD Papaverine and derivatives 37 59 47 62 39 18 <5 6 22 9 56 A03AD01 papaverine 37 59 47 62 39 18 <5 6 22 9 56 A03AX Other drugs for functional gastrointestinal disorders 3 302 3 405 2 924 3 271 3 815 57 225 972 1 296 1 322 1 422 A03AX13 silicones 3 302 3 405 2 924 3 271 3 815 57 225 972 1 296 1 322 1 422 A03B BELLADONNA AND DERIV - ATIVES, PLAIN 1 382 1 617 1 910 2 134 2 390 59 19 995 988 388 924 A03BA Belladonna alkaloids, tertiary amines 1 098 1 297 1 510 1 670 1 825 58 14 778 720 313 619ATC group A ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 34 Legemiddelstatistikk 2014:2 FolkehelseinstituttetA03BA01 atropine 26 22 23 29 38 61 0 18 13 7 27 A03BA03 hyoscyamine 1 072 1 276 1 487 1 641 1 787 58 14 760 707 306 592 A03BB Belladonna alkaloids, semisynthetic, quaternary ammonium compounds 285 321 406 471 578 60 5 223 274 76 305 A03BB01 butylscopolamine 267 300 386 458 564 60 <5 218 269 73 302 A03BB03 methylscopolamine 18 23 21 13 14 64 <5 5 5 <5 3 A03C ANTISPASMODICS IN COMBINATION WITH PSYCHOLEPTICS 18 19 20 16 14 50 0 0 10 <5 32 A03CA Synthetic anticholinergic agents in combination with psycholeptics 18 19 20 16 14 50 0 0 10 <5 32 A03CA02 clidinium and psycholeptics 18 19 20 16 14 50 0 0 10 <5 32 A03F PROPULSIVES 56 321 58 104 61 221 64 906 66 521 72 1 246 23 493 25 467 16 315 12 587 A03FA Propulsives 56 321 58 104 61 221 64 906 66 521 72 1 246 23 493 25 467 16 315 12 587 A03FA01 metoclopramide 56 214 57 999 61 099 64 774 66 391 72 1 231 23 459 25 412 16 289 12 054 A03FA02 cisapride 93 83 79 83 59 63 7 13 29 10 394 A03FA03 domperidone 44 55 71 62 80 68 8 24 27 21 125 A03FA05 alizapride 0 0 0 11 9 56 0 5 <5 0 15 A04 ANTIEMETICS AND ANTINAUSEANTS 13 055 13 797 14 669 15 274 16 026 59 331 2 893 8 628 4 174 32 758 A04A ANTIEMETICS AND ANTINAUSEANTS 13 055 13 797 14 669 15 274 16 026 59 331 2 893 8 628 4 174 32 758 A04AA Serotonin (5HT 3) antagonists 10 867 11 434 11 986 12 407 12 856 58 250 1 839 7 072 3 695 23 811 A04AA01 ondansetron 10 437 11 150 11 784 12 278 12 840 58 249 1 837 7 063 3 A04AA03 tropisetron 613 440 324 210 26 65 <5 6 13 6 60 A04AA05 palonosetron <5 5 <5 7 16 75 0 5 11 0 46 A04AD Other antiemetics 3 194 3 887 4 658 5 185 5 735 68 82 1 472 3 367 814 8 947 A04AD01 scopolamine 2 112 2 135 2 400 2 318 2 424 58 80 914 1 035 395 893 A04AD10 dronabinol 5 <5 5 5 0 - 0 0 0 0 0 A04AD12 aprepitant 1 078 1 761 2 269 2 873 3 323 76 <5 559 2 342 420 8 054 A05 BILE AND LIVER THERAPY 1 909 2 015 2 303 2 600 2 728 74 95 910 1 258 465 9 873 A05A BILE THERAPY 1 909 2 015 2 303 2 600 2 728 74 95 910 1 258 465 9 873 A05AA Bile acid preparations 1 909 2 015 2 303 2 600 2 728 74 95 910 1 258 465 9 873 A05AA02 ursodeoxycholic acid 1 909 2 015 2 303 2 600 2 728 74 95 910 1 258 465 9 873 A06 DRUGS FOR CONSTIPATION 31 408 44 230 50 571 49 919 55 321 56 7 281 8 512 18 809 20 719 32 451 A06A DRUGS FOR CONSTIPATION 31 408 44 230 50 571 49 919 55 321 56 7 281 8 512 18 809 20 719 32 451 A06AA Softeners, emollients 105 112 208 368 743 52 100 94 237 312 452ATC group A ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 112 194 354 699 53 84 90 230 295 271 A06AB Contact laxatives 13 383 15 058 21 757 22 562 24 463 57 345 2 844 10 211 11 063 7 368 A06AB02 bisacodyl1)3 858 4 056 6 514 6 040 5 666 61 63 766 1 869 2 968 1 884 A06AB06 senna glycosides1)2 020 2 120 4 322 2 820 2 216 56 7 139 665 1 405 1 099 A06AB08 sodium picosulfate1)8 584 10 082 10 948 11 687 12 659 54 275 1 497 4 899 5 988 2 713 A06AB20 contact laxatives in combination1)<5 6 8 A06AB53 dantron, combinations <5 <5 0 0 - 0 0 0 0 0 A06AB56 senna glycosides, combinations 1)17 10 12 11 8 75 <5 5 <5 1 A06AB58 sodium picosulfate, combinations 1)0 31 1 581 3 535 5 410 59 6 572 3 335 1 497 1 669 A06AC Bulk-forming laxatives 1 772 1 996 2 054 2 084 2 266 59 46 645 857 718 629 A06AD Osmotically acting laxatives 18 687 30 442 30 643 29 326 32 340 54 6 764 4 774 9 617 11 185 14 265 A06AD11 lactulose 1)13 507 14 464 14 513 14 603 14 837 51 770 1 979 5 483 6 605 4 022 A06AD12 lactitol 78 59 58 51 39 49 27 8 <5 <5 49 A06AD15 macrogol 0 45 79 135 221 57 209 11 <5 0 207 A06AD17 sodium phosphate1)847 9 665 7 334 2 813 2 015 56 <5 363 1 102 548 412 A06AD65 macrogol, combinations1)4 947 7 273 9 943 12 962 16 618 56 5 921 2 545 3 564 4 588 9 575 A06AG Enemas 4 649 4 892 5 458 5 325 5 466 48 541 1 308 1 838 1 779 7 994 A06AG02 bisacodyl1)1 475 1 410 1 680 1 676 1 699 45 43 474 703 479 754 A06AG04 glycerol1)772 827 905 861 763 47 164 222 199 178 3 875 A06AG10 docusate sodium, incl. combinations 1)1 217 1 394 1 484 1 369 1 412 49 72 333 486 521 1 724 A06AG11 laurilsulfate, incl. combinations 1)1 567 1 647 1 826 1 786 1 920 50 269 347 580 724 1 641 A06AH Peripheral opioid receptor antagonists 164 197 195 181 177 51 0 18 93 66 979 A06AH01 methylnaltrexone bromide 164 197 195 181 177 51 0 18 93 66 979 A06AX Other drugs for constipation 0 0 0 9 474 82 <5 198 196 79 764 A06AX04 linaclotide 0 0 0 0 216 71 <5 97 80 38 201 A06AX05 prucalopride 0 0 0 9 271 91 0 108 122 41 562 A07 ANTIDIARRHEALS, INTESTINAL ANTI-INFLAMMATORY/ANTI-INFECTIVE AGENTS 62 586 69 807 72 492 73 982 76 993 58 7 302 20 917 31 642 17 132 130 269 A07A INTESTINAL ANTIINFECTIVES 25 618 31 199 32 204 32 358 33 905 64 6 772 8 404 11 592 7 137 13 574 A07AA Antibiotics 25 618 31 199 32 204 32 358 33 905 64 6 772 8 404 11 592 7 137 13 574ATC group A ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 36 Legemiddelstatistikk 2014:2 FolkehelseinstituttetA07AA01 neomycin 0 0 0 0 37 73 0 21 14 <5 18 A07AA02 nystatin 25 376 30 730 31 544 31 731 33 307 64 6 747 8 172 11 360 7 028 11 626 A07AA06 paromomycin 81 154 316 257 322 68 21 165 127 9 274 A07AA09 vancomycin 177 182 200 234 238 60 <5 39 90 106 792 A07AA11 rifaximin <5 184 211 189 230 66 6 114 103 7 759 A07AA12 fidaxomicin 0 0 0 <5 <5 <5 104 A07B INTESTINAL ADSORBENTS 95 80 84 102 103 40 21 44 23 15 22 A07BA Charcoal preparations 95 80 84 96 88 40 21 37 17 13 12 A07BA01 medicinal charcoal1)95 80 84 96 88 40 21 37 17 13 12 A07BB Bismuth preparations 0 0 0 6 15 40 0 7 6 <5 10 A07C ELECTROLYTES WITH CARBOHYDRATES 182 259 279 364 449 47 175 142 87 45 1 130 A07CA Oral rehydration salt formulations 1)182 259 279 364 442 48 168 142 87 45 188 A07D ANTIPROPULSIVES 16 106 16 710 17 200 18 029 18 647 56 108 3 598 8 482 6 459 8 167 A07DA Antipropulsives 16 106 16 710 17 200 18 029 18 647 56 108 3 598 8 482 6 459 8 167 A07DA01 diphenoxylate <5 <5 0 13 A07DA02 opium 56 79 86 80 143 65 0 14 84 45 389 A07DA03 loperamide1)15 829 16 464 16 933 17 714 18 322 56 107 3 501 8 337 6 377 7 623 A07DA53 loperamide, combinations1)326 294 283 359 361 53 <5 105 159 96 142 A07E INTESTINAL ANTI-INFLAMMATORY AGENTS 21 914 22 753 23 690 24 490 25 601 52 230 8 879 12 408 4 084 105 133 A07EA Corticosteroids acting locally 5 014 5 212 5 155 5 208 5 537 61 65 1 803 2 605 1 064 15 510 A07EA01 prednisolone 1 011 1 175 1 292 1 222 1 163 50 8 452 554 149 1 175 A07EA02 hydrocortisone 1 233 1 154 408 356 327 69 <5 95 179 52 549 A07EA06 budesonide 2 972 3 190 3 583 3 766 4 153 63 58 1 298 1 923 874 13 786 A07EB Antiallergic agents, excl. corticosteroids 54 53 64 86 5 8 20 <5 494 A07EB01 cromoglicic acid 54 53 64 50 35 86 5 8 20 <5 494 A07EC Aminosalicylic acid and similar agents 19 275 19 918 20 669 21 351 22 091 50 186 7 916 10 748 3 241 89 128 A07EC01 sulfasalazine 6 194 6 104 5 966 5 803 5 666 55 <5 1 335 3 228 1 099 6 665 A07EC02 mesalazine 12 549 13 330 14 229 15 091 16 050 48 181 6 462 7 322 2 085 78 923 A07EC03 olsalazine 488 494 452 406 381 47 <5 97 215 68 1 360 A07EC04 balsalazide 809 750 687 613 589 44 0 198 310 81 2 179 A07F ANTIDIARRHEAL MICROORGANISMS 694 1 252 1 507 1 244 1 228 67 40 605 472 111 2 081 A07FA Antidiarrheal microorganisms 694 1 252 1 507 1 244 1 228 67 40 605 472 111 2 081ATC group A ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.Legemiddelstatistikk 2014:2 Folkehelseinstituttet 37A07FA01 lactic acid producing organ - isms 581 918 912 768 806 70 15 427 335 29 1 618 A07FA02 saccharomyces boulardii 116 283 381 431 505 63 29 220 170 86 348 A07FA51 lactic acid producing organisms, combinations 0 0 0 16 14 57 <5 11 <5 0 35 A07X OTHER ANTIDIARRHEALS 139 99 117 64 43 77 <5 21 18 <5 35 A07XA Other antidiarrheals 139 99 117 64 43 77 <5 21 18 <5 35 A08 ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS 38 343 19 168 10 373 7 674 7 245 77 <5 2 709 3 958 575 12 126 A08A ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS 38 343 19 168 10 373 7 674 7 245 77 <5 2 709 3 958 575 12 126 A08AA Centrally acting antiobesity products 25 710 5 782 0 0 0 - 0 0 0 0 0 A08AA10 sibutramine 25 710 5 782 0 0 0 - 0 0 0 0 0 A08AB Peripherally acting antiobesity products 14 540 14 575 10 373 7 674 7 245 77 <5 2 709 3 958 575 12 126 A08AB01 orlistat 14 540 14 575 10 373 7 674 7 245 77 <5 2 709 3 958 575 12 126 A08AX Other antiobesity drugs <5 <5 0 0 0 - 0 0 0 0 0 A08AX01 rimonabant <5 <5 0 0 0 - 0 0 0 0 0 A09 DIGESTIVES, INCL. ENZYMES 5 126 5 479 5 758 5 740 5 720 57 121 876 2 755 1 968 15 474 A09A DIGESTIVES, INCL. ENZYMES 5 126 5 479 5 758 5 740 5 720 57 121 876 2 755 1 968 15 474 A09AA Enzyme preparations 5 070 5 441 5 699 5 692 5 637 57 121 852 2 722 1 942 15 402 A09AA02 multienzymes (lipase, protease etc.) 5 070 5 441 5 699 5 687 5 628 57 121 848 2 718 1 941 15 382 A09AB Acid preparations 65 50 61 52 63 79 0 10 24 29 26 A09AB01 glutamic acid hydrochloride 1)52 44 54 39 45 76 0 <5 17 25 17 A09AB02 betaine hydrochloride 0 0 <5 <5 <5 8 A09AB03 hydrochloric acid1)<5 6 6 0 <5 5 <5 1 A09AB04 citric acid 10 0 0 0 0 - 0 0 0 0 0 A09AC Enzyme and acid preparations, combinations 0 15 17 9 33 70 0 19 14 0 45 A09AC02 multienzymes and acid preparations 0 15 17 9 33 70 0 19 14 0 45 A10 DRUGS USED IN DIABETES 145 677 152 065 156 542 161 132 165 315 44 1 839 23 380 85 385 54 711 582 040 A10A INSULINS AND ANALOGUES 52 603 54 014 54 994 56 508 58 187 43 1 811 14 207 26 328 15 841 329 145 A10AB Insulins and analogues for injection, fast-acting 33 562 34 874 35 659 36 959 38 386 43 1 804 12 961 16 707 6 914 121 146 A10AB01 insulin (human) 1 823 1 604 1 403 1 294 1 144 40 12 185 627 320 2 332ATC group A ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 38 Legemiddelstatistikk 2014:2 FolkehelseinstituttetA10AB04 insulin lispro 8 615 8 835 9 021 9 118 9 462 42 194 3 930 4 200 1 138 32 647 A10AB05 insulin aspart 23 900 25 159 25 860 27 075 28 325 43 1 664 9 100 12 058 5 503 84 956 A10AB06 insulin glulisine 270 375 404 379 408 47 <5 143 218 45 1 211 A10AC Insulins and analogues for injection, intermediate-acting 33 129 32 520 31 916 32 046 32 559 42 582 5 201 15 605 11 171 97 083 A10AC01 insulin (human) 33 129 32 520 31 916 32 046 32 559 42 582 5 201 15 605 11 171 97 083 A10AD Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting 9 736 9 112 8 304 7 706 7 154 43 <5 458 3 270 3 423 30 446 A10AD01 insulin (human) 17 <5 <5 <5 0 - 0 0 0 0 0 A10AD03 insulin (pork) 0 0 <5 0 0 - 0 0 0 0 0 A10AD04 insulin lispro 672 647 643 609 645 44 <5 117 322 205 2 584 A10AD05 insulin aspart 9 075 8 476 7 672 7 111 6 522 43 <5 341 2 957 3 222 27 862 A10AE Insulins and analogues for injection, long-acting 11 310 13 695 15 222 16 426 17 686 45 793 6 980 7 730 2 183 80 470 A10AE02 insulin (beef) <5 <5 <5 <5 <5 0 12 A10AE04 insulin glargine 6 958 8 433 9 559 10 629 11 727 45 244 4 672 5 289 1 522 49 534 A10AE05 insulin detemir 4 493 5 526 5 927 6 023 6 207 46 569 2 418 2 534 686 30 923 A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS 111 436 117 293 121 207 125 155 128 629 44 30 10 776 71 489 46 334 252 895 A10BA Biguanides 95 537 101 637 103 523 105 196 106 357 44 22 9 537 60 248 36 550 47 497 A10BA02 metformin 95 537 101 637 103 523 105 196 106 357 44 22 9 537 60 248 36 550 47 497 A10BB Sulfonamides, urea derivatives 47 349 46 112 43 116 40 676 38 381 40 10 1 691 19 842 16 838 16 755 A10BB01 glibenclamide 1 738 1 539 1 343 1 190 1 098 42 565 562 A10BB02 chlorpropamide <5 <5 0 0 0 0 A10BB07 glipizide 5 229 4 807 4 281 3 860 3 413 41 0 96 1 431 1 886 1 955 A10BB12 glimepiride 40 684 40 028 37 733 35 800 34 007 40 <5 1 557 18 001 14 445 14 238 A10BD Combinations of oral blood glucose lowering drugs 3 852 8 219 10 974 13 316 15 765 36 0 1 106 10 401 4 258 61 014 A10BD03 metformin and rosiglitazone 2 575 2 284 0 0 0 - 0 0 0 0 0 A10BD04 glimepiride and rosiglitazone <5 0 0 0 0 - 0 0 0 0 0 A10BD05 metformin and pioglitazone 27 32 35 26 30 43 0 <5 21 5 113 A10BD07 metformin and sitagliptin 318 2 187 4 053 5 228 6 295 36 0 443 4 130 1 722 24 095 A10BD08 metformin and vildagliptin 1 068 4 791 7 030 8 175 9 360 37 0 648 6 192 2 520 36 271 A10BD10 metformin and saxagliptin 0 0 0 0 43 23 0 6 29 8 114 A10BD11 metformin and linagliptin 0 0 0 0 166 35 0 16 115 35 421 A10BF Alpha glucosidase inhibitors 922 813 701 640 597 43 0 40 295 262 871ATC group A ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 597 43 0 40 295 262 871 A10BG Thiazolidinediones 5 401 4 672 1 912 1 642 1 579 40 0 77 1 017 485 4 101 A10BG02 rosiglitazone 3 798 3 104 20 <5 0 0 0 0 0 0 0 A10BG03 pioglitazone 1 641 1 779 1 894 1 641 1 579 40 0 77 1 017 485 4 101 A10BH Dipeptidyl peptidase 4 (DPP-4) inhibitors 1 752 6 478 9 436 11 112 13 439 41 0 754 7 732 4 953 49 488 A10BH01 sitagliptin 1 491 4 799 6 711 7 209 7 621 41 0 439 4 597 2 585 29 693 A10BH02 vildagliptin 288 935 1 274 1 755 2 289 45 0 135 1 216 938 6 632 A10BH03 saxagliptin 0 854 1 616 1 767 1 684 39 0 109 1 049 526 6 590 A10BH05 linagliptin 0 0 0 609 2 145 39 0 83 1 013 1 049 6 573 A10BX Other blood glucose lowering drugs, excl. insulins 847 1 335 3 523 5 430 7 805 45 0 973 5 700 1 132 73 168 A10BX02 repaglinide 330 283 252 237 213 34 0 5 117 91 407 A10BX03 nateglinide 13 11 9 10 0 0 0 0 0 0 0 A10BX04 exenatide 491 554 795 874 972 46 0 132 720 120 7 866 A10BX07 liraglutide 19 535 2 605 4 433 5 666 46 0 734 4 186 746 62 351 A10BX09 dapagliflozin 0 0 0 0 1 311 41 0 141 961 209 2 329 A10BX10 lixisenatide 0 0 0 0 73 49 0 11 49 13 215 A11 VITAMINS 91 052 93 046 102 139 119 090 128 838 60 1 249 33 473 49 263 44 853 71 879 A11A MUL TIVITAMINS, COMBINATIONS 0 0 28 96 138 47 68 65 5 0 465 A11AA Multivitamins with minerals 0 0 28 96 138 47 68 65 5 0 465 A11AA03 multivitamins and other minerals, incl. combinations 0 0 28 96 138 47 68 65 5 0 465 A11B MUL TIVITAMINS, PLAIN 78 100 74 69 44 64 25 19 0 0 48 A11BA Multivitamins, plain 78 100 74 69 44 64 25 19 0 0 48 A11C VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO 9 836 11 360 17 026 25 182 34 758 60 699 13 897 13 136 7 026 19 136 A11CA Vitamin A, plain 29 30 42 58 51 59 5 19 25 <5 146 A11CA01 retinol (vit A) 13 14 20 37 35 57 <5 13 18 <5 51 A11CA02 betacarotene 16 16 22 21 16 63 <5 6 7 0 95 A11CC Vitamin D and analogues 9 815 11 337 16 992 25 144 34 722 60 695 13 884 13 118 7 025 18 991 A11CC01 ergocalciferol 3 096 4 250 8 654 13 289 49 67 0 24 20 5 18 A11CC03 alfacalcidol 3 790 3 884 4 123 4 861 4 730 47 140 747 1 854 1 989 6 713 A11CC04 calcitriol 2 297 2 396 2 632 2 947 3 068 46 8 561 1 277 1 222 3 545 A11CC05 colecalciferol 753 939 1 733 4 421 27 121 63 552 12 633 10 079 3 857 8 715ATC group A ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 40 Legemiddelstatistikk 2014:2 FolkehelseinstituttetA11D VITAMIN IN COMBINATION WITH VITAMIN B6 AND B12 1)762 790 749 800 784 38 10 127 457 190 691 A11DA Vitamin B1, plain 745 782 739 788 774 37 10 125 453 186 685 A11DA01 thiamine (vit B1)1)745 782 739 788 774 37 10 125 453 186 685 A11DB Vitamin B1 in combination with vitamin B6 and/or vitamin B12 17 8 10 12 10 70 0 <5 <5 <5 7 A11E VITAMIN B-COMPLEX, INCL. COMBINATIONS 78 387 78 352 82 349 92 535 93 711 60 315 19 496 36 573 37 327 48 503 A11EA Vitamin B-complex, plain 1)77 313 77 144 80 810 91 094 92 410 60 270 19 244 36 097 36 799 47 144 A11EB Vitamin B-complex with vitamin C 114 92 155 231 270 54 <5 101 113 53 71 A11EX Vitamin B-complex, other combinations 1 008 1 155 1 443 1 278 1 083 39 42 157 389 495 1 288 A11G ASCORBIC ACID (VITAMIN C), INCL. COMBINATIONS 3 507 3 677 3 759 3 674 3 502 68 16 390 771 2 325 1 112 A11GA Ascorbic acid (vitamin C), plain 3 507 3 677 3 759 3 674 3 502 68 16 390 771 2 325 1 112 A11GA01 ascorbic acid (vit C) 1)3 507 3 677 3 759 3 674 3 502 68 16 390 771 2 325 1 112 A11H OTHER PLAIN VITAMIN PREPARATIONS 1 462 1 604 1 730 1 589 1 757 63 189 966 452 150 1 385 A11HA Other plain vitamin preparations 1 462 1 604 1 730 1 589 1 757 63 189 966 452 150 1 385 A11HA01 nicotinamide 5 13 11 19 11 9 A11HA02 pyridoxine (vit B6) 1)871 1 072 1 134 1 109 1 374 64 111 836 330 97 574 A11HA03 tocopherol (vit E)1)572 442 412 289 53 69 87 89 44 644 A11HA04 riboflavin (vit B2) 16 12 11 9 21 86 <5 5 12 <5 9 A11HA05 biotin 0 0 0 <5 50 <5 <5 0 0 70 A11HA06 pyridoxal phosphate 0 66 161 131 56 79 <5 32 18 <5 29 A11HA08 tocofersolan 0 0 <5 67 <5 0 0 0 51 A11J OTHER VITAMIN PROD - UCTS, COMBINATIONS 59 61 91 94 79 59 53 16 10 0 236 A11JA Combinations of vitamins 59 48 53 55 62 52 53 9 0 0 226 A11JB Vitamins with minerals 0 13 38 39 17 88 0 7 10 0 10 A12 MINERAL SUPPLEMENTS 91 581 100 943 111 514 125 551 134 766 78 444 11 959 55 174 67 189 90 176 A12A CALCIUM 70 986 80 569 91 211 104 462 113 047 81 249 10 509 47 669 54 620 71 788 A12AA Calcium 1 467 1 417 1 137 1 071 1 005 69 58 184 399 364 1 042 A12AA02 calcium glubionate 8 7 <5 6 0 <5 0 0 0 9 A12AA04 calcium carbonate1)371 412 188 <5 0 0 0 0 0 0 0 A12AA06 calcium lactate gluconate1)1 090 984 928 1 034 984 69 56 181 392 355 1 018 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group A ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 28 24 32 18 50 <5 <5 6 9 13 A12AX Calcium, combinations with vitamin D and/or other drugs 69 722 79 351 90 245 103 588 112 275 82 196 10 364 47 356 54 359 70 746 A12B POTASSIUM 20 533 20 544 20 029 20 998 21 980 64 82 1 172 7 271 13 455 13 969 A12BA Potassium 20 533 20 544 20 029 20 998 21 980 64 82 1 172 7 271 13 455 13 969 A12BA01 potassium chloride 18 968 18 800 18 295 19 060 19 870 64 16 979 6 582 12 293 10 701 A12BA02 potassium citrate 1 828 2 055 2 034 2 268 2 446 63 71 240 802 1 333 3 236 A12BA30 combinations OTHER MINERAL S UPPLEMENTS 3 773 4 004 4 809 5 401 5 736 60 124 608 2 095 2 909 4 177 A12CA Sodium 622 715 878 983 1 182 67 8 53 361 760 724 A12CA01 sodium chloride 1)622 715 878 983 1 182 67 8 53 760 724 A12CB Zinc 865 767 697 769 714 68 50 154 A12CB01 zinc sulfate 865 767 697 769 714 68 50 154 222 288 355 A12CC Magnesium 2 338 2 591 3 300 3 717 3 941 56 67 406 1 559 1 909 3 075 A12CC04 magnesium citrate <5 0 0 0 0 - 0 0 0 0 0 A12CC10 magnesium oxide 13 18 103 174 164 57 <5 16 61 85 140 A12CC30 magnesium (different salts in combination)1)2 328 2 573 3 212 3 563 3 792 56 50 392 1 507 1 843 2 568 A12CX Other mineral products 0 0 0 0 <5 50 <5 0 0 <5 24 A14 ANABOLIC AGENTS FOR SYSTEMIC USE 728 847 866 885 1 008 84 <5 288 627 92 742 A14A ANABOLIC STEROIDS 728 847 <5 288 627 92 742 A14AA Androstan derivatives 645 827 841 847 963 86 <5 267 606 89 533 A14AA07 prasterone 644 827 841 847 963 86 <5 267 606 89 533 A14AA08 oxandrolone <5 0 0 0 0 - 0 0 0 0 0 A14AB Estren derivatives 84 21 25 24 26 12 0 12 12 <5 104 A14AB01 nandrolone 84 21 25 24 26 12 0 12 12 <5 104 A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS 293 548 663 604 507 60 106 227 153 21 171 809 A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS 293 317 335 379 396 55 103 162 114 17 171 698 A16AA Amino acids and derivatives 107 123 131 157 164 54 80 56 24 <5 3 484 A16AA01 levocarnitine 73 87 79 86 99 43 72 20 <5 <5 1 701 A16AA03 glutamine 17 12 19 11 17 82 0 14 <5 0 24 A16AA04 mercaptamine 7 10 8 8 8 38 <5 <5 0 0 741 A16AA06 betaine 11 16 20 22 23 48 6 13 <5 0 1 006 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group A ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 42 Legemiddelstatistikk 2014:2 FolkehelseinstituttetA16AB Enzymes 51 50 56 59 65 38 <5 29 27 5 135 770 A16AB02 imiglucerase 10 7 7 <5 7 57 0 <5 <5 <5 13 904 A16AB03 agalsidase alfa 16 32 33 34 24 38 0 11 9 <5 40 967 A16AB04 agalsidase beta 23 18 7 14 23 35 0 13 10 0 33 830 A16AB05 laronidase 0 <5 <5 0 <5 galsulfase 0 0 0 <5 <5 100 202 A16AB10 velaglucerase alfa 0 0 6 5 5 20 0 <5 <5 0 12 349 A16AX Various alimentary tract and metabolism products 139 149 151 166 170 62 20 78 63 9 32 443 A16AX01 thioctic acid 122 121 109 113 118 67 0 48 61 9 141 A16AX03 sodium phenylbutyrate <5 <5 42 A16AX04 nitisinone 12 13 14 14 16 31 12 <5 0 0 13 420 A16AX05 zinc acetate <5 7 8 11 11 55 <5 2 A16AX07 sapropterin 0 5 15 22 20 70 <5 16 <5 0 16 344 ATC group A ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 15-44 45-69 70 Legemiddelstatistikk 2014:2 BLOOD FORMING ORGANS 562 344 581 349 597 921 617 386 629 097 49 3 070 61 114 272 750 292 163 1 045 480 B01 ANTITHROMBOTIC AGENTS 472 410 485 783 497 174 509 369 519 085 44 434 23 024 225 701 269 926 568 727 B01A ANTITHROMBOTIC AGENTS 472 410 485 783 497 174 509 369 519 085 44 434 23 024 225 701 269 926 568 727 B01AA Vitamin K antagonists 86 427 88 730 92 222 94 810 88 089 40 56 3 016 26 086 58 931 69 966 B01AA01 dicoumarol 93 90 93 81 70 53 0 9 23 38 350 B01AA02 phenindione 27 24 15 <5 <5 67 0 0 <5 <5 62 B01AA03 warfarin 86 322 88 631 92 133 94 729 88 017 40 56 3 007 26 061 58 893 69 554 B01AB Heparin group 32 041 36 949 42 027 46 978 49 253 58 207 10 898 22 420 15 728 109 761 B01AB01 heparin 826 926 943 1 056 1 141 55 125 196 538 282 2 317 B01AB02 antithrombin III <5 <5 0 0 0 - 0 0 0 0 0 B01AB04 dalteparin 15 917 21 249 25 588 28 632 28 495 59 49 6 129 13 463 8 854 63 234 B01AB05 enoxaparin 15 744 15 363 16 078 17 952 20 454 56 37 4 716 8 867 6 834 44 175 B01AB10 tinzaparin 0 0 6 7 10 80 0 35 399 674 400 083 43 183 10 233 183 793 205 874 235 616 B01AC04 clopidogrel 26 429 28 372 29 470 28 352 25 620 37 <5 616 11 985 13 017 28 974 B01AC05 ticlopidine 420 327 273 229 187 48 0 <5 71 115 546 B01AC06 acetylsalicylic acid 370 132 376 011 377 738 379 980 378 066 43 182 9 778 174 501 193 605 98 822 B01AC07 dipyridamole 18 755 19 310 19 501 19 782 19 830 44 0 302 7 562 11 966 22 433 B01AC09 epoprostenol 7 <5 <5 <5 <5 6 <5 2 145 B01AC21 treprostinil 9 9 8 9 15 60 <5 10 <5 0 21 292 B01AC22 prasugrel 31 214 487 1 130 1 711 19 0 110 1 323 278 7 633 B01AC24 ticagrelor 0 0 26 2 341 6 773 26 0 321 4 305 2 147 35 264 B01AC30 combinations 5 557 8 788 11 324 13 223 14 622 43 0 282 6 201 8 139 16 610 B01AC56 acetylsalicylic acid and esomeprazole 0 0 0 80 312 46 0 5 148 159 262 B01AD Enzymes <5 <5 B01AE Direct thrombin inhibitors 9 187 1 168 4 102 13 879 40 0 189 4 853 8 837 81 235 B01AE07 dabigatran etexilate 9 187 1 168 4 102 13 879 40 0 189 4 853 8 837 81 235 B01AF Direct factor Xa inhibitors 45 191 899 1 666 15 590 47 0 753 5 629 9 208 71 534 B01AF01 rivaroxaban 45 191 899 1 332 13 426 45 0 703 4 659 8 064 68 150 B01AF02 apixaban 0 0 0 335 2 261 54 0 51 994 1 216 3 384 B01AX Other antithrombotic agents 16 17 8 5 6 100 0 <5 <5 <5 46 B01AX05 fondaparinux 16 17 0 <5 <5 <5 46 B02 ANTIHEMORRHAGICS 12 439 12 210 12 954 13 337 13 981 92 308 6 869 6 171 633 291 4292.6 ATC group B - Blood and bloodforming organs ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 11 846 12 577 12 908 13 492 94 198 6 702 6 061 531 7 304 B02AA Amino acids 12 033 11 845 12 575 12 906 13 490 94 198 6 700 6 061 531 5 052 B02AA02 tranexamic acid 12 033 11 845 12 575 12 906 13 490 94 198 6 700 6 061 531 252 B02B VITAMIN K AND OTHER HEMOSTATICS 468 419 427 507 564 35 132 189 133 110 284 125 B02BA Vitamin K 275 212 208 224 246 59 50 65 46 85 131 B02BA01 phytomenadione 275 212 208 224 246 59 50 65 46 85 131 B02BB Fibrinogen 0 0 <5 <5 <5 100 0 0 0 <5 <5 100 0 0 <5 0 95 B02BD Blood coagulation factors 187 189 190 241 258 6 82 113 56 7 271 368 B02BD01 coagulation factor IX, II, VII and X in combination <5 <5 <5 <5 <5 B02BD02 coagulation factor VIII 129 134 132 169 176 1 58 77 39 <5 221 029 B02BD03 factor VIII inhibitor bypassing activity <5 <5 13 052 B02BD04 coagulation factor IX 30 28 30 37 42 0 16 17 7 <5 18 399 B02BD06 von Willebrand factor and coagulation factor VIII in combination 15 12 9 14 15 47 <5 7 <5 <5 3 528 B02BD07 coagulation factor 0 <5 100 0 0 <5 0 116 B02BD08 eptacog alfa (activated) 7 7 7 10 12 33 6 <5 <5 0 5 905 B02BD09 0 7 018 B02BX Other systemic hemostatics 6 18 28 41 59 58 0 11 30 18 12 532 B02BX04 romiplostim 6 14 15 17 20 45 0 <5 11 5 6 453 B02BX05 eltrombopag 0 <5 15 25 39 64 0 7 19 13 6 078 B03 ANTIANEMIC PREPARA - TIONS 120 950 129 328 135 640 144 891 146 457 65 2 171 33 801 55 493 54 992 117 709 B03A IRON PREPARATIONS 22 178 24 019 25 072 25 887 27 377 69 1 290 8 306 5 986 11 795 9 405 B03AA Iron bivalent, oral preparations 20 801 22 588 23 597 24 308 25 635 68 1 286 7 351 5 467 11 531 7 305 B03AA01 ferrous glycine sulfate 1)2 892 3 574 4 189 4 998 6 968 72 104 2 504 1 689 2 671 3 437 B03AA02 ferrous fumarate1)1 333 1 320 1 324 1 361 1 466 49 992 256 79 139 237 B03AA03 ferrous gluconate 112 101 52 0 0 0 0 0 0 0 0 B03AA07 ferrous sulfate1)16 693 17 767 18 255 18 290 17 470 68 194 4 654 3 744 8 878 3 631 B03AC Iron, parenteral preparations 1 461 1 524 1 577 1 699 1 869 87 5 1 010 551 303 2 100 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group B ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales FOLIC ACID 100 602 107 727 113 339 122 260 122 663 65 953 27 040 50 141 44 529 34 781 B03BA Vitamin B12 (cyanocobal - amin and analogues) 69 156 76 095 79 008 85 534 83 417 67 210 19 132 31 842 32 233 18 958 B03BA01 cyanocobalamin 6 558 7 389 7 469 8 514 8 210 69 25 2 644 3 186 2 355 1 687 B03BA02 cyanocobalamin tannin complex 36 404 39 772 40 827 44 239 43 570 67 68 10 098 16 498 16 906 9 573 B03BA03 hydroxocobalamin 28 055 31 131 32 969 35 304 33 807 67 112 7 037 12 992 13 666 7 425 B03BA05 mecobalamin 16 38 91 125 211 66 6 103 84 18 271 B03BB Folic acid and derivatives 36 595 36 321 39 074 41 739 44 258 60 754 8 663 20 009 14 832 15 822 B03BB01 folic acid1)36 595 36 321 39 074 41 739 44 258 60 754 8 663 20 009 14 832 15 822 B03X OTHER ANTIANEMIC PREPARATIONS 3 639 3 485 3 456 3 440 3 287 40 26 304 1 112 1 845 73 523 B03XA Other antianemic preparations 3 639 3 485 3 456 3 440 3 287 40 26 304 1 112 1 845 73 523 B03XA01 erythropoietin 470 334 279 280 255 47 <5 25 89 140 5 253 B03XA02 darbepoetin alfa 2 785 2 714 2 704 2 871 2 778 40 26 256 939 1 557 61 438 B03XA03 methoxy polyethylene glycol-epoetin beta 452 475 516 446 291 36 0 27 98 166 6 832 B06 OTHER HEMATOLOGICAL AGENTS 49 54 52 81 84 62 <5 47 30 <5 42 199 B06A OTHER HEMATOLOGICAL AGENTS 49 54 52 81 84 62 <5 47 30 <5 42 199 B06AA Enzymes 8 7 5 <5 <5 streptokinase, combinations <5 5 <5 0 0 - 0 0 0 0 0 B06AB Other hem products 0 0 <5 <5 <5 100 0 0 <5 0 269 B06AC Drugs used in hereditary angioedema 41 47 46 76 80 60 <5 46 27 <5 41 926 B06AC01 c1-inhibitor, plasma derived 39 37 29 44 55 64 <5 33 16 <5 27 019 B06AC02 icatibant 6 14 23 53 57 60 <5 30 23 <5 14 881 B06AC04 conestat alfa 0 0 0 <5 <5 100 0 0 <5 0 26 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group B ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 46 Legemiddelstatistikk 2014:2 FolkehelseinstituttetC CARDIOVASCULAR SYSTEM 945 886 975 141 998 461 1 019 237 1 040 279 51 6 903 99 153 542 497 391 726 1 571 794 C01 CARDIAC THERAPY 124 930 122 995 120 544 119 110 113 974 48 4 966 8 673 38 900 61 435 82 567 C01A CARDIAC GLYCOSIDES 25 820 24 749 23 214 20 106 16 077 49 40 111 2 991 12 935 4 615 C01AA Digitalis glycosides 25 820 24 749 23 214 20 106 16 077 49 40 111 2 991 12 935 4 615 C01AA04 digitoxin 24 736 23 709 22 197 14 057 3 070 53 0 16 385 2 669 624 C01AA05 digoxin 1 123 1 068 1 084 10 662 14 333 48 40 102 2 776 11 415 3 991 C01B ANTIARRHYTHMICS, CLASS I AND III 10 321 11 688 12 400 13 122 13 951 36 89 588 7 335 5 939 28 187 C01BA Antiarrhythmics, class Ia 173 159 131 121 114 53 0 5 47 62 275 C01BA01 quinidine <5 <5 5 <5 6 C01BA03 disopyramide 170 156 126 117 112 52 0 5 47 60 269 C01BB Antiarrhythmics, class Ib 23 17 17 18 17 35 0 5 9 <5 156 C01BB01 lidocaine 0 0 0 <5 0 - 0 0 0 0 0 C01BB02 mexiletine 23 17 17 17 17 35 0 5 9 <5 156 C01BC Antiarrhythmics, class Ic 5 783 6 393 6 735 7 036 7 373 40 82 438 4 521 5 C01BC04 flecainide 5 780 6 390 6 730 7 033 7 371 40 82 438 4 520 2 331 14 607 C01BD Antiarrhythmics, class III 4 475 5 432 5 809 6 269 6 750 31 7 157 2 952 3 634 13 143 C01BD01 amiodarone 4 475 4 853 4 912 5 236 5 593 30 7 119 2 296 3 171 3 899 C01BD07 dronedarone 0 767 1 034 1 166 1 269 36 0 41 729 499 9 244 C01C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES 12 217 14 121 15 618 18 389 19 662 59 4 839 6 913 6 531 1 379 13 112 C01CA Adrenergic and dopaminergic agents 12 217 14 121 15 618 18 389 19 662 59 4 839 6 913 6 531 1 379 13 112 C01CA01 etilefrine 114 95 112 110 100 63 <5 26 40 33 223 C01CA02 isoprenaline 0 0 0 <5 0 - 0 0 0 0 0 C01CA06 phenylephrine 0 0 0 0 <5 - 0 <5 0 0 1 C01CA17 midodrine 14 16 20 20 28 57 0 16 7 5 217 C01CA24 epinephrine 12 082 14 006 15 480 18 251 19 530 59 4 838 6 869 6 482 1 341 12 662 C01CA26 ephedrine 7 6 8 8 6 0 0 <5 <5 0 10 C01D VASODILATORS USED IN CARDIAC DISEASES 83 930 79 479 75 844 73 279 69 136 47 0 1 095 23 221 44 820 36 507 C01DA Organic nitrates 83 930 79 479 75 844 73 279 69 136 47 0 1 095 23 221 44 820 36 507 C01DA02 glyceryl trinitrate 65 061 60 717 58 282 56 629 53 076 46 0 1 031 20 175 31 870 12 272 C01DA08 isosorbide dinitrate 2 787 2 311 1 950 1 705 1 377 52 0 8 177 1 192 1 078 C01DA14 isosorbide mononitrate 35 905 34 145 31 873 30 300 28 711 50 0 129 5 959 22 623 23 156 C01E OTHER CARDIAC PREPARATIONS 138 138 67 11 29 52 0 6 14 9 146 C01EB Other cardiac preparations 138 138 67 11 29 52 0 6 14 9 1462.7 ATC group C - Cardiovascular system ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 126 59 0 0 - 0 0 0 0 0 C01EB15 trimetazidine 9 10 6 7 8 63 0 <5 6 <5 8 C01EB17 ivabradine 0 0 0 <5 15 67 0 5 5 5 111 C01EB18 ranolazine 0 0 0 0 6 0 0 0 <5 <5 27 C02 ANTIHYPERTENSIVES 17 689 17 442 17 597 17 548 17 267 27 20 711 8 063 8 473 68 778 C02A ANTIADRENERGIC AGENTS, CENTRALLY ACTING 6 702 6 469 6 521 6 520 6 532 40 <5 320 3 549 2 661 6 102 C02AB Methyldopa 410 141 107 88 65 69 0 26 24 15 143 C02AB01 methyldopa (levorotatory) 410 141 107 88 65 69 0 26 24 15 143 C02AC Imidazoline receptor agonists 6 347 6 340 6 427 6 440 6 476 40 <5 295 3 532 2 647 5 959 C02AC01 clonidine 78 64 85 80 92 57 <5 34 49 7 132 C02AC05 moxonidine 6 269 6 276 6 342 6 361 6 385 39 0 261 3 484 2 640 5 827 C02C ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING 11 234 11 221 11 285 11 263 10 952 19 0 366 4 705 5 881 13 851 C02CA Alpha-adrenoreceptor antagonists 11 233 11 221 11 285 11 263 10 952 19 0 366 4 705 5 881 13 851 C02CA01 prazosin 0 0 0 0 35 69 0 25 9 <5 54 C02CA04 doxazosin 11 233 11 221 11 285 11 263 10 920 19 0 344 4 696 5 880 13 797 C02CC Guanidine derivatives <5 0 0 0 0 - 0 0 0 0 0 C02CC02 guanethidine <5 0 0 0 0 - 0 0 0 0 0 C02D ARTERIOLAR SMOOTH MUSCLE, AGENTS ACTING ON 319 301 317 318 335 32 <5 12 139 182 351 C02DB Hydrazinophthalazine derivatives 285 270 288 294 316 32 <5 7 127 180 222 C02DB02 hydralazine 285 270 288 294 316 32 <5 7 127 180 222 C02DC Pyrimidine derivatives 34 32 29 23 20 40 0 5 13 <5 129 C02DC01 minoxidil 34 32 29 23 20 40 0 5 13 <5 129 C02DD Nitroferricyanide derivatives 0 0 0 <5 0 - 0 0 0 0 0 C02DD01 nitroprusside 0 0 0 <5 0 - 0 0 0 0 0 C02K OTHER ANTIHYPERTENSIVES 119 142 161 178 193 69 16 56 86 35 48 474 C02KD Serotonin antagonists 18 19 20 14 13 92 0 <5 8 <5 456 C02KD01 ketanserin 18 19 <5 8 <5 456 C02KX Other antihypertensives 102 124 142 166 182 68 16 55 79 32 48 018 C02KX01 bosentan 91 103 114 124 132 67 16 44 50 22 32 073 C02KX02 ambrisentan 12 19 33 46 50 72 0 11 29 10 15 945 C02KX03 sitaxentan 0 <5 0 0 0 - 0 0 0 0 0 C03 DIURETICS 235 555 223 842 208 905 201 895 194 790 60 208 8 149 73 483 112 950 87 211ATC group C ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 216 66 001 53 889 49 049 44 778 61 10 1 804 22 594 20 370 20 026 C03AA Thiazides, plain 45 271 36 364 16 033 14 935 14 014 58 8 649 7 128 6 229 4 026 C03AA01 bendroflumethiazide 31 710 22 807 <5 0 0 0 0 0 0 0 0 C03AA03 hydrochlorothiazide 13 625 16 731 16 032 14 935 14 014 58 8 649 7 128 6 229 4 026 C03AB Thiazides and potassium in combination 30 363 41 642 38 130 34 269 30 853 63 <5 1 165 15 500 14 186 16 000 C03AB01 bendroflumethiazide and potassium 30 363 41 642 38 130 34 269 30 853 63 <5 1 165 15 500 14 186 16 000 C03B LOW-CEILING DIURETICS, EXCL. THIAZIDES 6 5 <5 <5 <5 25 C03BA Sulfonamides, plain 6 5 56 0 <5 <5 <5 25 C03BA04 chlortalidone 6 5 0 <5 <5 17 C03BA08 metolazone 8 C03C HIGH-CEILING DIURETICS 127 997 127 391 125 517 125 342 124 184 60 187 5 150 38 239 80 608 46 447 C03CA Sulfonamides, plain 127 997 127 391 125 517 125 342 124 184 60 187 5 150 38 239 80 608 46 447 C03CA01 furosemide 101 621 99 010 95 661 93 558 90 249 62 183 4 315 29 420 56 331 19 620 C03CA02 bumetanide 31 193 33 444 34 790 36 795 38 766 53 <5 948 9 906 C03D POTASSIUM-SPARING AGENTS 17 602 17 636 17 868 18 231 19 007 47 31 987 7 481 10 508 13 353 C03DA Aldosterone antagonists 17 589 17 623 17 851 18 216 18 990 47 30 984 7 475 10 501 13 216 C03DA01 spironolactone 17 028 17 038 17 160 17 438 18 084 49 30 935 6 929 10 190 7 248 C03DA02 potassium canrenoate 0 <5 <5 0 <5 1 C03DA04 eplerenone 658 678 798 912 1 030 14 0 54 614 362 5 967 C03DB Other potassium-sparing agents 18 18 22 16 19 37 <5 <5 8 7 136 C03DB01 amiloride 18 18 22 16 19 37 <5 <5 8 7 136 C03E DIURETICS AND POTASSIUM- SPARING AGENTS IN COMBINATION 34 026 31 692 28 452 25 731 23 234 66 10 585 10 485 12 154 4 130 C03EA Low-ceiling diuretics and potassium-sparing agents 34 026 31 692 28 452 25 731 23 234 66 10 585 10 485 12 154 4 130 C03EA01 hydrochlorothiazide and potassium-sparing agents 34 026 31 692 28 452 25 731 23 234 66 10 585 10 485 12 154 4 130 C03X OTHER DIURETICS 0 <5 <5 17 35 63 0 <5 20 13 3 230 C03XA Vasopressin antagonists 0 <5 <5 17 35 63 0 20 13 3 230 C03XA01 tolvaptan 0 <5 <5 17 35 63 0 <5 20 13 3 230 C04 PERIPHERAL VASODILA - TORS 1 340 1 165 1 019 928 810 46 <5 21 223 565 837 C04A PERIPHERAL VASODILATORS 1 340 1 165 1 019 928 810 46 <5 21 223 565 837ATC group C ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 0 0 <5 <5 1 C04AB01 phentolamine 0 0 0 0 0 <5 <5 1 C04AD Purine derivatives 1 334 1 160 1 018 927 808 46 <5 21 222 564 836 C04AD03 pentoxifylline 1 334 1 160 1 808 46 <5 21 222 564 836 C04AX Other peripheral vasodilators 6 5 <5 <5 0 0 0 0 0 0 0 C04AX02 phenoxybenzamine 6 5 <5 <5 0 0 0 0 0 0 0 C05 VASOPROTECTIVES 56 622 59 372 62 337 61 786 66 461 57 849 27 702 26 615 11 295 12 323 C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE 51 350 54 315 56 902 56 316 60 385 56 808 26 588 24 023 8 966 10 092 C05AA Corticosteroids 49 667 52 387 54 740 53 845 57 822 56 761 25 315 23 065 8 681 7 208 C05AA01 hydrocortisone 1)9 649 9 749 9 666 11 151 6 121 54 106 2 301 2 641 1 073 1 218 C05AA04 prednisolone1)41 682 44 303 46 731 45 327 53 098 56 666 23 517 21 054 7 861 5 990 C05AE Muscle relaxants 2 137 2 732 2 893 3 174 3 568 53 39 1 805 1 428 296 2 669 C05AE01 glyceryl trinitrate 2 137 2 732 2 893 3 174 3 568 53 39 1 805 1 428 296 2 669 C05AX Other agents for treatment of hemorrhoids and anal fissures for topical use 901 826 852 1 139 841 54 22 392 279 148 215 C05AX03 other preparations, combinations 885 807 832 1 117 819 54 22 380 270 147 147 C05B ANTIVARICOSE THERAPY 5 490 5 250 5 664 5 663 6 294 67 41 1 174 2 682 2 397 2 211 C05BA Heparins or heparinoids for topical use 5 486 5 245 5 654 5 658 6 288 67 41 1 174 2 676 2 397 2 204 C05BA01 organo-heparinoid 1)5 462 5 211 5 627 5 627 6 249 67 41 1 169 2 655 2 384 830 C05BA04 pentosan polysulfate sodium 25 34 27 31 40 88 0 6 21 13 1 374 C05BB Sclerosing agents for local injection <5 5 10 5 6 33 0 0 6 0 7 C05BB02 polidocanol <5 5 10 5 6 33 0 0 6 0 7 C05C CAPILLARY STABILIZING AGENTS 0 0 0 19 8 88 0 0 <5 6 10 C05CA Bioflavonoids 0 0 0 <5 8 88 0 0 <5 6 10 C05CA01 rutoside 0 0 0 <5 8 88 0 0 <5 6 10 C05CX Other capillary stabilizing agents 0 0 0 16 0 - 0 0 0 0 0 C05CX03 Hippocastani semen 0 0 0 16 0 - 0 0 0 0 0 C07 BETA BLOCKING AGENTS 356 313 361 077 364 247 368 506 371 823 49 482 20 906 165 839 184 596 180 367 C07A BETA BLOCKING AGENTS 350 748 355 652 359 141 363 938 367 435 49 482 20 712 163 140 183 101 177 451 C07AA Beta blocking agents, non-selective 25 833 24 967 24 720 24 341 24 423 59 198 5 208 10 605 8 412 11 300 C07AA03 pindolol 28 28 26 20 12 67 0 <5 8 <5 12 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group C ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 15-44 45-69 16 856 17 413 17 656 18 262 63 179 4 992 8 391 4 700 7 110 C07AA06 timolol 636 13 9 7 86 0 32 C07AA07 sotalol 8 818 8 082 7 269 6 706 6 098 46 7 169 2 199 3 723 3 724 C07AA12 nadolol 13 17 29 39 88 63 13 52 23 0 422 C07AB Beta blocking agents, selective 305 475 311 151 315 104 320 868 324 369 48 279 13 556 143 819 166 715 149 838 C07AB02 metoprolol 250 953 256 754 261 252 266 875 270 550 47 256 11 357 120 827 138 110 127 946 C07AB03 atenolol 39 561 36 754 33 974 31 827 29 679 59 22 1 337 12 347 15 973 7 485 C07AB07 bisoprolol 18 388 21 004 23 115 25 416 27 355 46 <5 1 029 11 969 14 355 14 405 C07AB12 nebivolol 0 0 0 0 9 67 0 <5 <5 <5 2 C07AG Alpha and beta blocking agents 24 389 23 887 23 378 22 899 22 479 45 15 2 290 10 462 9 712 16 313 C07AG01 labetalol 2 324 2 392 2 447 2 475 2 442 82 <5 1 563 553 324 2 167 C07AG02 carvedilol 22 092 21 525 20 958 20 442 20 062 41 13 735 9 918 9 396 14 146 C07B BETA BLOCKING AGENTS AND THIAZIDES 6 057 5 815 5 485 5 214 4 816 55 0 208 2 923 1 685 2 916 C07BB Beta blocking agents, selective, and thiazides 6 057 5 815 5 485 5 214 4 816 55 0 208 2 923 1 685 2 916 C07BB07 bisoprolol and thiazides 6 057 5 815 5 485 5 214 4 816 55 0 208 2 923 1 685 2 916 C07BB12 nebivolol and thiazides 0 0 0 0 <5 100 0 <5 0 0 0 C08 CALCIUM CHANNEL BLOCKERS 214 671 221 256 224 233 230 084 235 380 48 86 9 508 112 350 113 436 144 543 C08C SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS 192 742 200 625 205 165 212 139 218 463 48 83 8 721 106 011 103 648 127 861 C08CA Dihydropyridine derivatives 192 742 200 625 205 165 212 139 218 463 48 83 8 721 106 011 103 648 127 861 C08CA01 amlodipine 115 250 119 283 121 607 125 897 129 021 46 62 4 430 62 625 61 904 54 859 C08CA02 felodipine 16 692 16 309 16 008 15 423 14 850 50 0 340 6 396 8 114 10 823 C08CA03 isradipine 664 620 568 518 493 55 <5 198 286 888 C08CA05 nifedipine 29 940 31 649 32 708 34 567 36 991 49 21 2 781 17 924 16 265 40 689 C08CA06 nimodipine 32 44 51 56 39 59 0 11 26 <5 39 C08CA13 lercanidipine 33 491 36 038 37 460 39 048 40 491 50 0 1 332 20 462 18 697 20 562 C08D SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS 23 260 21 851 20 196 19 116 18 080 56 <5 806 6 799 10 472 16 682 C08DA Phenylalkylamine derivatives 17 237 16 444 15 365 14 679 13 847 56 <5 717 5 255 7 872 8 934 C08DA01 verapamil 17 237 16 444 15 365 14 679 13 847 56 <5 717 5 255 7 872 8 934 C08DB Benzothiazepine derivatives 6 091 5 473 4 875 4 472 4 281 55 0 92 1 567 2 622 7 748 C08DB01 diltiazem 6 091 5 473 4 875 4 472 4 281 55 0 92 1 567 2 622 7 748ATC group C ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 15-44 45-69 ON THE RENIN-ANGIOTENSIN SYSTEM 473 388 498 501 517 053 535 479 552 012 48 434 29 254 300 073 222 251 533 396 C09A ACE INHIBITORS, PLAIN 125 439 130 265 132 249 134 815 135 072 41 376 7 246 63 735 63 715 57 995 C09AA ACE inhibitors, plain 125 439 130 265 132 249 134 815 135 072 41 376 7 246 63 735 63 715 57 995 C09AA01 captopril 3 233 2 858 2 509 2 221 1 962 45 178 84 644 1 056 3 893 C09AA02 enalapril 43 095 45 453 45 871 46 498 46 508 46 196 3 066 22 721 20 525 18 461 C09AA03 lisinopril 27 084 26 749 26 060 25 506 24 380 46 <5 1 397 11 903 11 078 10 653 C09AA05 ramipril 52 684 55 804 58 431 61 192 62 787 35 6 2 725 28 703 31 353 24 825 C09AA10 trandolapril 111 92 85 83 77 22 0 6 37 34 162 C09B ACE INHIBITORS, COMBINA - TIONS 35 260 35 985 35 727 35 224 34 166 48 0 1 128 17 383 15 655 25 843 C09BA ACE inhibitors and diuretics 35 023 35 193 34 459 33 721 32 644 48 0 1 047 16 470 15 127 23 915 C09BA02 enalapril and diuretics 20 154 20 520 20 244 20 047 19 540 48 0 677 10 079 8 784 15 018 C09BA03 lisinopril and diuretics 14 889 14 697 14 237 13 715 13 133 49 0 373 6 403 6 357 8 897 C09BB ACE inhibitors and calcium channel blockers 259 820 1 307 1 536 1 546 43 0 83 922 541 1 928 C09BB02 enalapril and lercanidipine 259 820 1 307 1 536 1 546 43 0 83 922 541 1 928 C09C ANGIOTENSIN II ANTAGONISTS, PLAIN 168 742 180 140 187 470 197 324 206 884 51 84 14 729 116 705 75 366 174 588 C09CA Angiotensin II antagonists, plain 168 742 180 140 187 470 197 324 206 884 51 84 14 729 116 705 75 366 174 588 C09CA01 losartan 42 955 51 872 57 364 61 615 63 676 51 42 3 801 35 328 24 505 38 633 C09CA02 eprosartan 2 322 2 063 1 785 1 601 1 443 52 0 43 659 741 2 830 C09CA03 valsartan 20 380 20 748 22 462 25 171 28 100 47 0 1 838 16 359 9 903 27 546 C09CA04 irbesartan 22 328 21 419 20 347 19 745 19 088 49 0 796 10 652 7 640 25 910 C09CA06 candesartan 74 704 78 234 79 742 83 562 88 885 52 40 7 960 50 382 30 503 64 142 C09CA07 telmisartan 5 866 5 988 5 977 5 838 5 822 44 <5 312 3 323 2 186 12 242 C09CA08 olmesartan medoxomil 1 751 1 680 1 642 1 642 1 639 50 <5 132 993 513 3 285 C09D ANGIOTENSIN II ANTAGO - NISTS, COMBINATIONS 184 232 195 551 202 970 210 395 217 369 49 0 8 479 125 318 83 572 274 794 C09DA Angiotensin II antagonists and diuretics 174 848 179 893 180 857 181 947 182 682 51 0 6 301 103 430 72 951 189 040 C09DA01 losartan and diuretics 63 952 66 088 66 981 67 519 67 346 52 0 2 225 36 785 28 336 46 754 C09DA02 eprosartan and diuretics 2 042 1 924 1 774 1 661 1 552 48 0 47 827 678 3 277 C09DA03 valsartan and diuretics 25 424 25 643 25 522 25 941 26 635 49 0 971 15 382 10 282 36 076 C09DA04 irbesartan and diuretics 31 418 30 818 29 807 28 634 27 373 50 0 676 15 090 11 607 41 885 C09DA06 candesartan and diuretics 48 685 51 649 52 876 54 286 55 802 50 0 2 249 32 933 20 620 49 094 C09DA07 telmisartan and diuretics 3 724 3 991 3 940 3 818 3 785 41 0 128 2 268 1 389 9 737 C09DA08 olmesartan medoxomil and diuretics 1 144 1 124 1 146 1 117 1 087 50 0 44 655 388 2 219ATC group C ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 15-44 45-69 70 52 and calcium channel blockers 11 764 16 484 18 665 21 178 23 699 40 0 1 529 14 849 7 321 45 870 C09DB01 valsartan and amlodipine 11 764 16 483 18 494 20 903 23 407 40 0 1 503 14 659 7 245 45 174 C09DB02 olmesartan medoxomil and amlodipine 0 <5 185 0 26 193 78 695 C09DX Angiotensin II antagonists, other combinations 0 4 017 8 368 12 249 16 435 37 0 987 10 399 5 049 39 884 C09DX01 valsartan, amlodipine and hydrochlorothiazide 0 4 017 8 368 12 249 16 435 37 0 987 10 399 5 049 39 884 C09X OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 93 93 84 80 69 41 <5 <5 40 23 177 C09XA Renin-inhibitors 93 93 84 80 69 41 <5 <5 40 23 177 C09XA02 aliskiren 93 92 84 80 69 41 <5 <5 40 23 177 C09XA52 aliskiren and hydrochloro - thiazide 0 <5 0 0 0 - 0 0 0 0 0 C10 LIPID MODIFYING AGENTS 452 790 478 362 495 451 504 104 509 945 46 147 20 352 278 359 211 087 461 771 C10A LIPID MODIFYING AGENTS, PLAIN 452 090 477 639 494 337 501 719 506 662 46 147 20 223 276 226 210 066 447 592 C10AA HMG CoA reductase inhibitors 447 810 472 860 488 704 495 110 499 107 46 133 19 452 271 913 207 609 339 655 C10AA01 simvastatin 356 768 349 782 336 480 314 351 290 634 47 21 8 994 146 138 135 481 119 305 C10AA02 lovastatin 1 424 1 260 1 134 1 050 930 57 0 7 347 576 1 437 C10AA03 pravastatin 22 329 21 340 20 827 20 330 19 842 49 11 465 9 393 9 973 20 039 C10AA04 fluvastatin 7 465 7 510 7 474 7 445 7 372 47 <5 508 4 259 2 604 12 182 C10AA05 atorvastatin 79 686 112 783 140 852 166 650 189 401 44 78 9 406 116 854 63 063 160 886 C10AA07 rosuvastatin 571 2 115 4 420 6 722 9 506 45 26 950 6 406 2 124 25 748 C10AA08 pitavastatin 0 0 0 0 6 33 0 0 5 <5 57 C10AB Fibrates 317 331 317 314 56 215 39 1 715 C10AB02 bezafibrate 64 58 49 50 47 36 <5 <5 34 8 180 C10AB04 gemfibrozil 101 104 103 93 85 31 0 12 58 15 796 C10AB05 fenofibrate 154 170 167 173 184 28 <5 41 124 16 739 C10AC Bile acid sequestrants 2 090 2 238 2 413 2 439 2 530 54 8 468 1 413 641 8 479 C10AC01 colestyramine 1 566 1 686 1 817 1 795 1 864 59 7 401 991 465 2 244 C10AC02 colestipol 308 292 273 280 287 42 <5 20 149 117 817 C10AC04 colesevelam 237 280 351 407 444 37 0 64 317 63 5 417 C10AD Nicotinic acid and derivatives 285 396 391 351 58 24 0 10 38 10 614 C10AD02 nicotinic acid 218 153 107 30 29 28 0 6 16 7 534 C10AD06 acipimox 11 12 9 9 6 50 0 0 <5 <5 46 C10AD52 nicotinic acid, combinations 69 249 301 315 27 15 0 5 21 <5 34ATC group C ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales modifying agents 14 589 16 505 19 315 22 165 24 366 43 6 1 765 16 130 6 465 97 129 C10AX06 omega-3-triglycerides incl. other esters and acids 2 754 3 038 3 591 3 992 4 199 30 <5 602 3 011 584 26 631 C10AX09 ezetimibe 12 126 13 819 16 166 18 711 20 751 45 <5 1 209 13 574 5 964 70 498 C10B LIPID MODIFYING AGENTS, COMBINATIONS 0 81 1 370 2 661 3 215 40 0 160 2 121 934 11 555 C10BA HMG CoA reductase inhibitors in combination with other lipid modifying agents 0 81 1 370 2 661 3 215 40 0 160 2 121 934 11 555 C10BA02 simvastatin and ezetimibe 0 81 1 370 2 661 3 215 40 0 160 2 121 934 11 555ATC group C ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 15-44 611 440 624 493 632 680 645 684 54 79 769 246 820 216 869 102 226 245 500 D01 ANTIFUNGALS FOR DERMATOLOGICAL USE 111 682 116 703 120 515 121 196 128 325 47 12 588 48 465 46 581 20 691 34 037 D01A ANTIFUNGALS FOR TOPICAL USE 96 750 101 082 105 109 105 050 111 180 48 12 335 41 833 38 231 18 781 17 247 D01AA Antibiotics 219 54 52 36 41 88 5 28 6 <5 10 D01AA01 nystatin 219 54 52 36 41 88 5 28 6 <5 10 D01AC Imidazole and triazole derivatives 74 998 79 238 83 294 83 177 87 831 48 10 095 32 361 29 741 15 634 11 120 D01AC01 clotrimazole 1)8 811 9 516 8 746 8 018 8 572 52 1 201 3 272 2 203 1 896 1 261 D01AC02 miconazole1)1 880 2 121 2 193 1 928 2 157 44 321 782 687 367 371 D01AC03 econazole1)2 177 1 119 588 694 732 56 44 172 258 258 93 D01AC08 ketoconazole1)14 992 15 121 16 258 16 243 16 928 41 1 136 7 922 5 861 2 009 2 918 D01AC20 combinations1)50 909 55 208 59 481 59 953 63 529 49 7 826 21 824 22 029 11 850 6 478 D01AE Other antifungals for topical use 24 330 24 671 24 755 24 872 26 681 46 2 563 10 780 9 626 3 712 6 116 D01AE02 methylrosaniline 1)696 694 751 79 D01AE14 ciclopirox1)<5 <5 13 48 841 53 36 277 414 114 305 D01AE15 terbinafine1)16 909 17 514 17 812 18 224 19 247 42 2 062 8 500 6 163 2 522 3 232 D01AE16 amorolfine 7 081 6 829 6 520 6 232 6 333 54 275 2 002 3 074 982 2 500 D01B ANTIFUNGALS FOR SYSTEMIC USE 18 300 19 232 19 020 19 762 21 092 40 433 8 382 9 965 2 312 16 791 D01BA Antifungals for systemic use 18 300 19 232 19 020 19 762 21 092 40 433 8 382 9 965 2 312 16 791 D01BA01 griseofulvin 19 15 19 21 38 42 32 5 <5 0 21 D01BA02 terbinafine 18 285 19 222 19 009 19 744 21 060 40 407 8 377 9 964 2 312 16 769 D02 EMOLLIENTS AND PROTECTIVES 1 841 2 223 2 338 2 528 2 548 54 430 793 866 459 989 D02A EMOLLIENTS AND PROTECTIVES 1 841 2 223 2 338 2 528 2 548 54 430 793 866 459 989 D02AB Zinc products 1)6 10 15 6 9 67 <5 <5 <5 <5 2 D02AE Carbamide products 670 859 971 1 178 1 153 55 159 398 346 250 652 D02AE01 carbamide1)670 859 971 1 178 1 153 55 159 398 346 250 652 D02AF Salicylic acid preparations 1 048 1 229 1 206 1 167 1 179 54 170 341 486 182 206 D02AX Other emollients and protectives 125 148 168 228 244 53 112 65 39 28 128 D03 PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS 91 60 68 80 85 44 0 <5 48 34 29 D03A CICATRIZANTS 91 60 68 80 85 44 0 <5 48 34 29 D03AA Cod-liver oil ointments 7 0 0 0 0 0 0 0 0 0 0 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.2.8 ATC group D - Dermatologicals ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 60 68 80 85 44 0 <5 48 34 29 D03AX03 dexpanthenol 84 60 68 80 85 44 0 <5 48 34 29 D04 ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. 3 676 3 871 4 259 4 334 6 703 66 820 2 744 1 793 1 346 1 086 D04A ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC. 3 676 3 871 4 259 4 334 6 703 66 820 2 744 1 793 1 346 1 086 D04AA Antihistamines for topical use <5 0 <5 8 <5 5 0 <5 0 8 75 <5 <5 5 0 13 D04AB Anesthetics for topical use 2 637 2 798 3 097 3 675 5 410 68 562 2 418 1 475 955 928 D04AB01 lidocaine1)2 637 2 798 3 097 3 675 5 410 68 562 2 418 1 475 955 928 D04AX Other antipruritics 1 052 1 093 1 169 674 1 307 57 261 328 319 399 145 D05 ANTIPSORIATICS 27 497 29 930 31 269 31 759 30 335 45 513 9 091 15 659 5 072 45 746 D05A ANTIPSORIATICS FOR TOPICAL USE 26 165 28 654 29 921 30 308 28 872 45 508 8 802 14 726 4 836 37 380 D05AA Tars 1)980 1 044 1 017 905 960 59 114 290 345 211 227 D05AC Antracen derivatives 11 9 7 <5 10 60 <5 5 <5 2 <5 <5 2 D05AD Psoralens for topical use 6 <5 0 0 0 0 0 0 0 0 0 D05AD01 trioxysalen 6 <5 0 0 0 0 0 0 0 0 0 D05AX Other antipsoriatics for topical use 25 359 27 804 29 076 29 573 28 055 44 398 8 569 14 445 4 643 37 147 D05AX02 calcipotriol 8 744 8 029 5 640 2 226 1 559 41 12 364 845 338 808 D05AX03 calcitriol 1 084 1 127 1 092 1 174 1 170 49 38 348 596 188 785 D05AX52 calcipotriol, combinations 19 312 22 343 25 237 27 797 26 578 44 364 8 206 13 654 4 354 35 555 D05B ANTIPSORIATICS FOR SYSTEMIC USE 1 886 1 880 1 943 2 106 2 106 43 6 463 1 315 322 8 366 D05BA Psoralens for systemic use 34 40 32 26 20 50 0 <5 10 6 15 D05BA02 methoxsalen 33 35 29 26 20 50 0 <5 10 6 15 D05BA03 bergapten <5 5 <5 0 0 0 0 0 0 0 0 D05BB Retinoids for treatment of psoriasis 1 819 1 808 1 866 2 019 2 026 43 6 440 1 271 309 5 647 D05BB02 acitretin 1 819 1 808 1 866 2 019 2 026 43 6 440 1 271 309 5 647 D05BX Other antipsoriatics for systemic use 41 42 50 71 63 35 0 19 37 7 2 704 D05BX51 fumaric acid derivatives, combinations 41 42 50 71 63 35 0 19 37 7 2 704 D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE 105 182 111 213 113 829 110 679 110 706 58 13 150 44 988 35 328 17 240 22 970 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group D ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 56 Legemiddelstatistikk TOPICAL USE 54 026 58 829 61 008 58 567 57 381 55 11 064 18 261 17 904 10 152 5 132 D06AA Tetracycline and derivatives 2 682 2 729 2 878 2 922 3 260 54 392 891 1 279 698 414 D06AA02 chlortetracycline 23 19 28 27 27 52 0 6 14 7 9 D06AA03 oxytetracycline 2 659 2 710 2 850 2 897 3 234 54 392 885 1 266 691 405 D06AX Other antibiotics for topical use 51 499 56 239 58 299 55 806 54 292 55 10 703 17 409 16 676 9 504 4 719 D06AX01 fusidic acid 49 106 53 684 55 137 53 101 51 166 55 9 616 16 441 16 045 9 064 4 283 D06AX05 bacitracin 1 802 1 739 2 378 1 986 2 231 50 698 699 466 368 248 D06AX09 mupirocin 17 14 31 41 90 48 11 41 30 8 20 D06AX13 retapamulin 746 1 008 1 005 875 1 046 56 458 299 178 111 168 D06B CHEMOTHERAPEUTICS FOR TOPICAL USE 53 024 54 414 54 942 54 044 55 283 61 2 216 27 463 18 106 7 498 17 837 D06BA Sulfonamides 3 202 3 373 3 410 3 569 3 482 54 562 1 212 1 067 641 522 D06BA01 silver sulfadiazine 3 202 3 373 3 410 3 569 3 482 54 562 1 212 1 067 641 522 D06BB Antivirals 41 307 41 885 40 813 39 042 38 980 59 1 470 21 524 11 094 4 892 15 119 D06BB03 aciclovir1)20 098 19 696 18 274 16 784 16 801 71 1 015 7 723 6 410 1 653 2 796 D06BB04 podophyllotoxin 13 402 13 567 13 738 12 944 13 095 45 138 11 550 1 333 74 2 854 D06BB06 penciclovir1)4 000 3 349 2 738 1 886 1 560 71 50 628 673 209 303 D06BB10 imiquimod 4 705 6 196 7 040 8 413 8 386 53 274 2 330 2 797 2 985 9 166 D06BB11 docosanol <5 0 0 0 0 - 0 0 0 0 0 D06BX Other chemotherapeutics 8 721 9 426 11 017 11 737 13 197 67 190 4 863 6 102 2 042 2 197 D06BX01 metronidazole 8 721 9 426 11 017 11 737 12 942 68 190 4 862 5 974 1 916 1 913 D06BX02 ingenol mebutate 0 0 0 0 259 48 0 <5 129 129 284 D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS 347 215 359 113 361 203 366 001 368 248 54 51 799 113 605 133 896 68 948 80 627 D07A CORTICOSTEROIDS, PLAIN 286 433 299 004 300 645 311 219 314 150 55 46 435 96 713 112 503 58 499 62 340 D07AA Corticosteroids, weak (group I) 26 763 28 352 28 849 30 901 29 941 55 13 608 8 031 5 179 3 123 3 441 D07AA02 hydrocortisone 1)26 763 28 352 28 849 30 901 29 931 55 13 606 8 028 5 176 3 121 3 434 D07AB Corticosteroids, moder - ately potent (group II) 96 512 102 087 102 552 102 396 105 292 55 24 482 31 854 31 264 17 692 14 202 D07AB02 hydrocortisone butyrate 64 889 67 907 70 580 97 892 85 367 55 20 746 26 143 24 385 14 093 11 492 D07AB08 desonide 33 079 35 702 33 950 5 881 21 365 54 4 146 6 083 7 306 3 830 2 710 D07AC Corticosteroids, potent (group III) 153 609 158 099 157 096 164 821 163 406 54 16 526 52 939 61 300 32 641 32 499 D07AC01 betamethasone 50 086 52 441 54 076 58 253 58 313 54 3 696 18 866 23 367 12 384 7 375 D07AC03 desoximetasone 13 853 13 701 12 998 12 664 11 671 54 479 3 144 5 217 2 831 4 561 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group D ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 6 500 6 008 5 854 5 421 53 181 1 019 2 574 1 647 963 D07AC08 fluocinonide 792 724 670 602 541 51 6 94 282 159 92 D07AC13 mometasone 74 342 78 920 78 528 82 943 83 267 54 10 904 28 207 28 901 15 255 16 652 D07AC17 fluticasone 15 468 13 078 11 896 12 072 11 613 55 1 896 3 963 3 685 2 069 2 856 D07AD Corticosteroids, very potent (group IV) 49 945 52 825 54 584 57 408 60 150 56 1 826 18 115 28 439 11 770 12 198 D07AD01 clobetasol 49 945 52 825 54 584 57 408 60 150 56 1 826 18 115 28 439 11 770 12 198 D07B CORTICOSTEROIDS, COMBINATIONS WITH ANTISEPTICS 37 064 36 056 37 823 29 417 29 528 49 3 310 8 798 11 328 6 092 3 044 D07BB Corticosteroids, moderately potent, combi - nations with antiseptics 17 785 15 445 15 218 194 1 955 46 273 464 810 408 262 D07BB02 desonide and antiseptics 17 619 15 445 15 217 194 1 955 46 273 464 810 408 262 D07BB03 triamcinolone and antiseptics 0 0 <5 0 0 - 0 0 0 0 0 D07BB04 hydrocortisone butyrate and antiseptics 193 0 0 0 0 - 0 0 0 0 0 D07BC Corticosteroids, potent, combinations with antiseptics 20 114 21 373 23 508 29 251 27 796 49 3 073 8 389 10 609 5 725 2 782 D07BC01 betamethasone and antiseptics 17 301 18 864 21 243 26 888 25 387 49 2 889 7 733 9 533 5 232 2 552 D07BC02 fluocinolone acetonide and antiseptics 2 918 2 601 2 358 2 471 2 540 50 196 690 1 125 529 229 D07C CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS 26 357 26 769 26 158 26 354 25 078 54 4 889 7 315 8 374 4 500 3 100 D07CA Corticosteroids, weak, combinations with antibiotics 26 351 26 768 26 158 26 350 25 072 54 4 889 7 310 8 373 4 500 3 098 D07CA01 hydrocortisone and antibiotics 26 351 26 768 26 158 26 350 25 072 54 4 889 7 310 8 373 4 500 3 098 D07CB Corticosteroids, moderately potent, combi - nations with antibiotics 0 0 0 0 <5 67 0 <5 0 0 1 D07CB01 triamcinolone and antibiotics 0 0 0 0 <5 67 0 <5 0 0 1 D07CC Corticosteroids, potent, combinations with antibiotics 6 <5 0 5 <5 67 0 <5 <5 0 betamethasone <5 <5 0 fluocinonide antibiotics 0 0 0 <5 <5 100 0 <5 0 0 1 D07X CORTICOSTEROIDS, OTHER COMBINATIONS 26 626 26 439 25 912 26 280 26 715 50 881 9 022 11 768 5 044 12 143ATC group D ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 15-44 45-69 70 58 Legemiddelstatistikk 2014:2 FolkehelseinstituttetD07XC Corticosteroids, potent, other combinations 26 626 26 439 25 912 26 280 26 715 50 881 9 022 11 768 5 044 12 143 D07XC01 betamethasone 26 626 26 439 25 912 26 280 26 715 50 881 9 022 11 768 5 044 12 143 D08 ANTISEPTICS AND DISINFECTANTS 18 621 19 280 19 088 19 212 20 441 58 3 330 8 336 6 476 2 299 3 002 D08A ANTISEPTICS AND DISINFECTANTS 1)18 621 19 280 19 088 19 212 20 441 58 3 330 8 336 6 476 2 299 3 002 D08AB Aluminium agents 285 278 338 416 429 54 151 119 101 58 76 D08AC Biguanides and amidines 15 171 15 910 15 689 15 791 17 326 59 2 479 7 391 5 657 1 799 2 466 D08AC01 dibrompropamidine1)5 115 5 282 3 802 4 729 5 561 50 1 908 1 763 1 088 802 726 D08AC02 chlorhexidine1)10 315 10 883 12 095 11 282 12 076 63 681 5 742 4 631 1 022 1 740 D08AG Iodine products 54 74 62 85 79 48 9 18 28 24 21 D08AG01 iodine/octylphenoxypoly - glycolether1)5 <5 0 0 0 - 0 0 0 0 0 D08AG02 povidone-iodine 20 31 26 56 50 54 <5 12 21 15 12 D08AG03 iodine1)29 42 36 29 29 38 7 6 7 9 9 D08AJ Quaternary ammonium compounds 135 151 173 134 124 55 19 29 34 42 53 D08AJ03 cetylpyridinium 1)135 151 173 134 124 55 19 29 34 42 53 D08AL Silver compounds 0 <5 <5 <5 Other antiseptics and disinfectants 3 131 3 022 2 970 2 922 2 618 49 717 819 684 398 379 D08AX01 hydrogen peroxide 1)2 059 1 829 1 740 1 669 1 526 52 434 480 393 219 170 D08AX06 potassium permanganate1)1 095 1 207 1 240 1 264 1 103 45 288 341 295 179 209 D09 MEDICATED DRESSINGS 1 937 1 913 1 848 1 767 1 718 57 124 354 574 666 522 D09A MEDICATED DRESSINGS 1 937 1 913 1 848 1 767 1 718 57 124 354 574 666 522 D09AA Medicated dressings with antiinfectives 1 937 1 913 1 848 1 684 1 607 57 119 348 528 612 216 D09AA02 fusidic acid 1 937 1 913 1 848 1 684 1 607 57 119 348 528 612 216 D09AB Zinc bandages 0 0 0 84 112 60 5 6 46 55 305 D09AB01 zinc bandage without supplements 0 0 0 84 112 60 5 6 46 55 305 D10 ANTI-ACNE PREPARATIONS 51 472 54 317 60 886 66 816 70 355 65 4 489 53 369 10 148 2 349 38 718 D10A ANTI-ACNE PREPARATIONS FOR TOPICAL USE 47 904 50 390 56 374 61 689 64 217 67 4 377 47 668 9 841 2 331 20 689 D10AD Retinoids for topical use in acne 24 388 27 056 32 174 36 043 37 161 66 2 966 29 779 3 360 1 056 13 506 D10AD01 tretinoin 9 888 10 547 10 221 10 977 6 861 79 195 3 679 2 196 791 849 D10AD02 retinol 117 170 176 185 63 59 7 16 30 10 16 D10AD03 adapalene 8 449 7 113 6 598 5 960 6 750 67 607 5 265 641 237 1 407 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group D ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 15-44 45-69 70 Legemiddelstatistikk 2014:2 Folkehelseinstituttet level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group D ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 D10AD51 tretinoin, combinations 100 0 <5 0 <5 2 D10AD53 adapalene, combinations 7 081 10 280 16 392 20 141 24 781 63 2 270 21 880 598 33 11 232 D10AE Peroxides 2 245 2 267 2 354 2 633 2 995 58 353 2 495 133 14 566 D10AE01 benzoyl peroxide1)2 245 2 267 2 354 2 633 2 995 58 353 2 495 133 14 566 D10AF Antiinfectives for treatment of acne 16 046 16 076 16 714 17 068 17 498 65 1 269 13 120 2 697 412 3 447 D10AF01 clindamycin 16 009 16 054 16 677 17 029 17 450 65 1 265 13 087 2 686 412 3 424 D10AF02 erythromycin 41 24 38 41 50 72 <5 34 12 0 22 D10AX Other anti-acne preparations for topical use 13 292 13 285 13 815 14 942 15 685 71 710 10 017 4 072 886 3 170 D10AX03 azelaic acid 13 286 13 276 13 810 14 935 15 673 71 710 10 011 4 071 881 3 169 D10AX30 various combinations 7 11 5 7 12 75 0 6 <5 5 2 D10B ANTI-ACNE PREPARATIONS FOR SYSTEMIC USE 5 153 5 748 6 609 7 853 9 255 49 236 8 594 403 22 18 029 D10BA Retinoids for treatment of acne 5 153 5 748 6 609 7 853 9 255 49 236 8 594 403 22 18 029 D10BA01 isotretinoin 5 153 5 748 6 609 7 853 9 255 49 236 8 594 403 22 18 029 D11 OTHER DERMATOLOGICAL PREPARATIONS 15 690 16 780 18 059 18 430 19 627 57 2 997 9 216 5 757 1 657 17 674 D11A OTHER DERMATOLOGICAL PREPARATIONS 15 690 16 780 18 059 18 430 19 627 57 2 997 9 216 5 757 1 657 17 674 D11AC Medicated shampoos 974 1 059 1 205 1 220 1 449 50 132 933 275 109 198 D11AC03 selenium compounds 1)974 1 059 1 205 1 220 1 449 50 132 933 275 109 198 D11AF Wart and anti-corn preparations 1)1 498 1 926 2 068 1 972 2 333 52 1 030 886 315 102 414 D11AH Agents for dermatitis, excluding corticosteroids 10 323 10 818 12 174 12 661 13 169 57 1 825 5 964 4 344 1 036 12 875 D11AH01 tacrolimus 6 804 7 498 8 318 8 696 8 887 57 1 202 4 067 2 919 699 4 128 D11AH02 pimecrolimus 3 712 3 534 3 996 3 952 4 224 59 655 1 917 1 315 337 1 980 D11AH04 alitretinoin 0 0 80 221 317 53 0 105 200 12 6 767 D11AX Other dermatologicals 2 940 3 036 2 677 2 634 2 757 64 14 1 479 847 417 4 187 D11AX01 minoxidil 175 202 161 199 292 71 <5 174 85 29 159 D11AX10 finasteride 797 742 876 D11AX16 eflornithine 0 <5 126 295 380 99 6 228 122 24 276 D11AX18 diclofenac 1 702 1 604 1 132 709 465 49 0 5 161 299 504 60 Legemiddelstatistikk 2014:2 FolkehelseinstituttetG GENITO URINARY SYSTEM AND SEX HORMONES 703 423 721 846 745 367 761 600 785 598 80 3 475 431 263 242 798 108 062 897 948 G01 699 32 068 33 034 33 653 35 989 99 105 25 894 8 335 1 655 7 770 G01A ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS 30 699 32 068 33 034 33 653 35 989 99 105 25 894 8 335 1 655 7 770 G01AA Antibiotics 15 244 20 707 20 475 20 926 22 040 100 48 15 896 5 326 770 5 117 G01AA10 clindamycin 15 244 20 707 20 475 20 926 22 040 100 48 15 896 5 326 770 5 117 G01AD Organic acids 0 0 0 <5 7 57 <5 0 <5 <5 6 G01AD02 acetic acid 0 0 57 <5 0 <5 <5 6 G01AF Imidazole derivatives 16 777 12 788 13 896 14 039 15 467 99 57 11 142 3 322 946 2 632 G01AF01 metronidazole 9 685 5 467 6 546 7 327 7 569 99 8 5 486 1 821 254 1 049 G01AF02 clotrimazole 1)5 326 5 614 5 949 5 667 6 873 99 44 4 954 1 279 596 1 336 G01AF04 miconazole1)768 634 64 0 0 - 0 0 0 0 0 G01AF05 econazole1)1 324 1 335 1 621 1 328 1 322 97 7 939 266 110 247 G01AX Other antiinfectives and antiseptics 6 <5 5 8 9 67 0 <5 7 0 11 G01AX03 policresulen 6 <5 5 8 9 67 0 <5 7 0 11 G02 OTHER GYNECOLOGICALS 44 047 45 250 46 752 47 284 47 703 99 7 41 722 5 794 180 49 757 G02A UTEROTONICS 12 15 11 7 6 100 0 <5 <5 0 1 G02AB Ergot alkaloids 12 15 11 5 100 0 <5 <5 0 1 G02AB01 methylergometrine 12 15 11 7 5 100 0 <5 <5 0 1 G02AD Prostaglandins 0 0 0 0 <5 100 0 0 <5 0 0 G02AD02 dinoprostone 0 0 0 0 <5 100 0 0 <5 0 0 G02B CONTRACEPTIVES FOR TOPICAL USE 41 674 42 960 44 425 45 106 45 532 100 <5 40 437 5 089 <5 46 800 G02BA Intrauterine contraceptives 24 803 24 858 25 084 25 507 25 540 100 <5 20 992 4 544 <5 29 497 G02BA03 plastic IUD with progestogen 24 803 24 858 25 084 25 507 25 540 100 <5 20 992 4 544 <5 29 497 G02BB Intravaginal contraceptives 17 064 18 263 19 552 19 825 20 195 100 <5 19 635 558 <5 17 303 G02BB01 vaginal ring with progestogen and estrogen 17 064 18 263 19 552 19 825 20 195 100 <5 19 635 558 <5 17 303 G02C OTHER GYNECOLOGICALS 2 458 2 367 2 414 2 267 2 270 75 <5 1 383 706 177 2 955 G02CB Prolactine inhibitors 2 458 2 367 2 414 2 267 2 270 75 <5 1 383 706 177 2 955 G02CB01 bromocriptine 1 312 1 226 1 248 1 057 998 90 <5 753 196 48 656 G02CB03 cabergoline 943 921 948 1 004 1 104 63 <5 573 417 111 1 475 G02CB04 quinagolide 302 284 260 245 224 71 0 101 103 20 825 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.2.9 ATC group G - Genito urinary system and sex hormones ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 15-44 OF THE GENITAL SYSTEM 515 229 525 683 538 164 545 211 558 156 98 2 687 370 176 145 086 40 207 417 475 G03A HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE 307 262 315 379 321 843 326 979 336 365 100 1 123 321 156 14 074 12 180 806 G03AA Progestogens and estro - gens, fixed combinations 214 962 221 431 225 448 228 299 233 755 100 929 227 829 4 992 5 129 658 G03AA07 levonorgestrel and ethinylestradiol 87 148 90 257 97 290 113 359 125 595 100 662 122 774 2 157 <5 57 242 G03AA09 desogestrel and ethinylestradiol 55 278 61 035 63 104 56 448 51 914 100 163 50 599 1 151 <5 19 075 G03AA12 drospirenone and ethinylestradiol 74 740 72 600 68 101 59 748 56 408 100 136 54 834 1 437 <5 45 837 G03AA13 norelgestromin and ethinylestradiol 8 924 8 982 9 054 8 962 8 904 100 11 8 646 246 <5 6 514 G03AA14 nomegestrol and estradiol 0 0 0 972 1 194 100 <5 1 148 42 0 990 G03AB Progestogens and estrogens, sequential preparations 18 862 17 640 16 199 14 793 13 478 100 24 12 695 758 <5 5 457 G03AB03 levonorgestrel and ethinylestradiol <5 0 <5 0 0 - 0 0 0 0 0 G03AB04 norethisterone and ethinylestradiol 18 546 16 059 14 345 12 782 11 584 100 19 10 919 645 <5 3 569 G03AB08 dienogest and estradiol 326 1 624 1 895 2 050 1 921 100 5 1 801 115 0 1 888 G03AC Progestogens 89 490 92 562 96 460 100 424 105 909 100 223 97 142 8 538 6 45 632 G03AC01 norethisterone 8 182 7 402 6 657 6 120 5 776 100 <5 4 906 865 <5 1 314 G03AC03 levonorgestrel 141 115 <5 0 0 - 0 0 0 0 0 G03AC06 medroxyprogesterone 19 971 19 607 19 338 18 871 18 870 100 41 15 208 3 618 <5 4 465 G03AC08 etonogestrel 2 807 3 298 4 147 5 381 6 642 100 19 6 456 167 0 7 620 G03AC09 desogestrel 60 277 64 136 68 331 72 227 77 052 100 167 72 932 3 951 <5 32 233 G03AD Emergency contraceptives 100 159 165 134 241 98 <5 230 10 0 59 G03AD01 levonorgestrel 1)99 79 87 82 113 96 <5 106 6 0 23 G03AD02 ulipristal <5 80 78 53 129 99 0 124 5 0 36 G03B ANDROGENS 5 234 5 552 6 300 7 262 8 752 10 64 2 248 5 233 1 207 27 346 G03BA 3-oxoandrosten (4) derivatives 5 231 5 550 6 282 7 254 8 741 10 64 2 239 5 231 1 207 27 337 G03BA03 testosterone 5 231 5 550 6 282 7 254 8 741 10 64 2 239 5 231 1 207 27 337 G03BB 5-androstanon (3) derivatives <5 <5 22 8 11 9 <5 0 9 G03BB01 mesterolone <5 <5 22 8 11 0 0 9 G03C ESTROGENS 112 831 116 574 121 775 123 293 126 359 100 171 5 313 85 519 35 356 81 297 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group G ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 estrogens, plain 104 463 108 549 114 351 116 345 119 654 100 171 5 112 79 746 34 625 71 751 G03CA01 ethinylestradiol 140 127 112 71 48 94 21 18 7 <5 343 G03CA03 estradiol 89 792 95 212 102 308 105 497 109 820 100 41 4 824 76 993 27 962 66 623 G03CA04 estriol 1)16 213 14 807 13 574 12 313 11 302 100 109 303 3 465 7 425 4 783 G03CA53 estradiol, combinations <5 0 0 0 0 - G03CA57 conjugated G03CX Other estrogens 9 183 8 841 8 224 7 705 7 534 100 0 239 6 500 795 9 545 G03CX01 tibolone 9 183 8 841 8 224 7 705 7 534 100 0 239 6 500 795 9 545 G03D PROGESTOGENS 37 790 38 788 39 101 40 073 41 850 100 1 336 30 428 9 883 203 19 566 G03DA Pregnen (4) derivatives 13 106 12 990 13 134 13 808 14 386 100 40 10 401 3 757 188 16 775 G03DA02 medroxyprogesterone 7 215 6 869 6 816 6 651 6 590 100 40 3 620 2 818 112 1 206 G03DA04 progesterone 5 987 6 240 6 465 7 294 7 929 100 0 6 898 954 77 15 569 G03DB Pregnadien derivatives 0 0 12 127 159 100 0 142 17 0 422 G03DB08 dienogest 0 0 12 127 159 100 0 142 17 0 422 G03DC Estren derivatives 25 413 26 536 26 716 26 901 28 086 100 1 296 20 514 6 261 15 2 370 G03DC02 norethisterone 25 413 26 536 26 716 26 901 28 086 100 1 296 20 514 6 261 15 2 370 G03F PROGESTOGENS AND ESTROGENS IN COMBINATION 45 758 44 082 43 373 41 804 41 341 100 <5 2 671 35 273 3 395 31 095 G03FA Progestogens and estro - gens, fixed combinations 36 195 35 051 34 460 33 190 32 658 100 0 815 28 609 3 234 25 342 G03FA01 norethisterone and estrogen 35 628 34 521 33 827 32 517 31 956 100 0 777 27 983 3 196 24 516 G03FA12 medroxyprogesterone and estrogen 527 233 <5 Progestogens and estro - gens, 10 082 9 652 9 671 100 <5 1 940 7 560 169 5 753 G03FB05 norethisterone and estrogen 10 851 10 322 10 082 9 652 9 671 100 <5 1 940 7 560 169 5 753 G03G GONADOTROPINS AND OTHER OVULATION STIMULANTS 11 093 10 343 10 634 10 473 10 334 94 <5 10 051 277 <5 67 928 G03GA Gonadotropins 6 013 6 137 6 273 6 248 6 317 97 <5 6 177 136 <5 66 334 G03GA01 chorionic gonadotrophin 1 277 1 476 1 660 1 317 1 143 83 <5 1 057 82 <5 469 G03GA02 human menopausal gonadotrophin 1 601 1 540 1 842 2 064 2 101 100 0 2 074 27 0 19 752 G03GA04 urofollitropin 0 85 154 200 268 100 0 261 7 0 2 094 G03GA05 follitropin alfa 1 770 1 743 1 799 1 941 1 926 99 0 1 904 22 0 19 183 G03GA06 follitropin beta 2 916 3 016 2 824 2 408 2 335 100 0 2 312 23 0 18 952ATC group G ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.Legemiddelstatistikk 2014:2 Folkehelseinstituttet 63G03GA07 lutropin alfa 65 26 21 17 9 100 0 8 <5 0 46 G03GA08 choriogonadotropin alfa 4 556 4 538 4 600 4 820 5 007 100 0 4 951 56 0 3 114 G03GA09 corifollitropin alfa 0 132 316 283 323 100 0 316 7 0 2 556 G03GA30 combinations 8 <5 <5 16 8 100 0 8 0 0 168 G03GB Ovulation stimulants, synthetic 6 483 5 387 5 646 5 315 5 048 90 0 4 870 176 <5 1 594 G03GB02 clomifene 6 483 5 387 5 646 5 315 5 048 90 0 4 870 176 <5 1 594 G03H ANTIANDROGENS 16 171 16 764 17 326 18 067 17 481 99 93 16 912 390 86 7 182 G03HA Antiandrogens, plain 181 205 199 178 175 7 0 38 53 84 530 G03HA01 cyproterone 181 205 199 178 175 7 0 38 53 84 530 G03HB Antiandrogens and estrogens 15 999 16 565 17 130 17 895 17 309 100 93 16 877 337 <5 6 652 G03HB01 cyproterone and estrogen 15 999 16 565 17 130 17 895 17 309 100 93 16 877 337 <5 6 652 G03X OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 1 298 1 142 979 867 767 95 <5 29 252 485 2 256 G03XA Antigonadotropins and similar agents 50 49 50 51 53 26 <5 18 26 8 168 G03XA01 danazol 50 49 50 51 53 26 <5 18 26 8 168 G03XB Progesterone receptor modulators 0 <5 <5 6 15 100 0 8 7 0 59 G03XB01 mifepristone 0 <5 <5 6 0 - 0 0 0 0 0 G03XB02 ulipristal 0 0 0 0 15 100 0 8 7 0 59 G03XC Selective estrogen receptor modulators 1 248 1 092 927 810 699 100 0 <5 219 477 2 029 G03XC01 raloxifene 1 248 1 092 927 810 699 100 0 <5 219 477 2 029 G04 UROLOGICALS 148 765 156 067 166 514 175 080 185 259 20 690 17 601 94 869 72 099 422 946 G04B UROLOGICALS 109 819 113 502 119 124 123 051 128 784 28 690 15 300 72 960 39 834 345 788 G04BA Acidifiers <5 0 0 0 0 - 0 0 0 0 0 G04BA01 ammonium chloride <5 0 0 0 0 - 0 0 0 0 0 G04BD Drugs for urinary frequency and incontinence 44 578 46 177 49 166 50 206 52 117 68 647 4 099 22 145 25 226 158 270 G04BD04 oxybutynin 1 480 1 504 1 516 1 525 1 468 64 174 429 481 384 8 980 G04BD07 tolterodine 18 355 15 679 14 238 12 763 11 304 72 389 589 4 145 6 181 33 309 G04BD08 solifenacin 17 349 19 877 21 934 22 341 20 910 69 93 1 638 9 117 10 062 62 000 G04BD10 darifenacin 5 630 5 126 4 566 4 059 3 475 74 0 190 1 421 1 864 10 134 G04BD11 fesoterodine 5 380 7 639 10 610 12 962 13 441 67 16 1 067 6 028 6 330 34 631 G04BD12 mirabegron 0 0 0 0 6 735 65 <5 606 3 193 2 933 9 216 G04BE Drugs used in erectile dysfunction 66 640 68 779 71 519 74 530 78 488 0 40 11 309 51 895 15 244 187 480ATC group G ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 64 Legemiddelstatistikk 2014:2 FolkehelseinstituttetATC group ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 G04BE01 alprostadil 2 180 2 543 2 525 2 809 2 893 0 0 122 1 879 892 4 868 G04BE03 sildenafil 34 734 34 385 34 578 34 385 35 222 1 38 4 864 22 723 7 597 79 654 G04BE04 yohimbine 19 15 10 7 11 18 0 <5 5 <5 7 G04BE08 tadalafil 26 821 29 887 32 997 36 673 40 063 0 <5 6 325 27 201 6 535 87 605 G04BE09 vardenafil 10 376 9 934 9 427 9 073 8 785 0 0 1 095 5 978 1 712 14 664 G04BE30 combinations 616 495 539 347 293 0 0 14 205 74 683 G04BX Other urologicals 10 11 11 13 19 47 <5 6 6 <5 38 G04BX01 magnesium hydroxide 10 11 11 13 19 47 <5 6 6 <5 38 G04C DRUGS USED IN BENIGN PROSTATIC HYPERTROPHY 45 440 49 918 55 531 61 004 66 317 1 0 2 511 26 618 37 188 77 157 G04CA Alpha-adrenoreceptor antagonists 34 945 38 363 43 210 48 624 53 898 1 0 1 429 23 388 29 081 56 742 G04CA01 alfuzosin 536 498 13 33 23 G04CA02 tamsulosin 33 877 37 383 41 362 43 587 45 144 2 0 1 323 19 745 24 076 37 853 G04CA03 terazosin 744 649 598 599 601 2 0 99 242 260 495 G04CA52 tamsulosin and dutasteride 0 <5 1 628 6 169 10 799 0 0 15 4 566 6 218 18 370 G04CB Testosterone-5-alpha reductase inhibitors 14 939 16 984 18 676 18 628 18 209 0 0 1 094 5 109 12 006 20 415 G04CB01 finasteride 12 852 15 194 17 122 17 271 17 016 0 0 1 065 4 827 11 124 17 056 G04CB02 dutasteride 2 331 1 939 1 661 1 421 1 258 0 0 37 303 918 3 360Legemiddelstatistikk 2014:2 Folkehelseinstituttet 65H SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS 375 465 387 821 402 923 414 206 422 537 67 16 419 109 977 183 711 112 430 444 841 H01 PITUITARY AND HYPO - THALAMIC HORMONES AND ANALOGUES 24 490 24 833 24 910 24 985 25 586 66 9 288 13 214 1 949 1 135 293 310 H01A ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES 1 577 1 658 1 767 1 866 1 975 44 1 068 534 335 38 156 436 H01AA ACTH <5 <5 0 H01AB Thyrotropin 0 <5 7 10 16 81 0 <5 11 <5 148 H01AB01 thyrotropin alfa 0 <5 7 16 0 <5 148 H01AC Somatropin and somat - ropin agonists 1 555 1 631 1 735 1 825 1 928 43 1 068 520 305 35 147 177 H01AC01 somatropin 1 555 1 631 1 735 1 825 1 928 43 1 068 520 305 35 147 177 H01AX Other anterior pituitary lobe hormones and analogues 21 24 24 31 30 40 0 11 18 <5 9 110 H01AX01 pegvisomant 21 24 24 31 30 40 0 11 18 <5 9 110 H01B POSTERIOR PITUITARY LOBE HORMONES 18 807 18 982 19 167 18 728 19 133 62 8 249 8 817 1 235 832 36 738 H01BA Vasopressin and analogues 11 288 11 248 11 388 11 209 11 257 36 8 213 1 065 1 156 823 35 184 H01BA02 desmopressin 11 288 11 248 11 387 11 209 11 257 36 8 213 1 065 1 156 823 35 184 H01BA04 terlipressin 0 0 <5 0 0 - 0 0 0 0 0 H01BB Oxytocin and analogues 7 522 7 736 7 781 7 522 7 878 99 36 7 754 79 9 1 554 H01BB02 oxytocin 7 522 7 736 7 781 7 522 7 878 99 36 7 754 79 9 1 554 H01C HYPOTHALAMIC HORMONES 4 315 4 430 4 218 4 643 4 737 92 7 4 002 455 273 100 135 H01CA Gonadotropin-releasing hormones 2 829 2 314 2 076 2 362 2 337 100 0 2 307 30 0 5 670 H01CA02 nafarelin 2 829 2 314 2 076 2 362 2 337 100 0 2 307 30 0 5 670 H01CB Somatostatin and analogues 498 593 630 726 751 47 7 74 397 273 89 088 H01CB02 octreotide 398 472 497 569 203 63 079 H01CB03 lanreotide 118 137 148 184 204 46 <5 19 101 80 25 691 H01CB05 pasireotide 0 0 <5 <5 318 H01CC Anti-gonadotropin-releasing hormones 1 246 1 887 1 774 1 814 1 934 100 0 1 902 32 0 5 378 H01CC01 ganirelix 975 1 513 1 397 1 429 1 504 100 0 1 475 29 0 4 153 H01CC02 cetrorelix 298 481 413 406 0 1 225 H02 CORTICOSTEROIDS FOR SYSTEMIC USE 190 388 197 259 208 089 214 495 216 737 56 4 963 60 959 91 689 59 126 54 7642.10 ATC group H - Systemic hormonal preparations, excl. sex hormones and insulins ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 15-44 45-69 70 66 Legemiddelstatistikk 2014:2 FolkehelseinstituttetH02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN 190 244 197 075 207 853 214 275 216 497 56 4 962 60 912 91 547 59 076 54 704 H02AA Mineralocorticoids 1 178 1 223 1 267 1 323 1 367 56 89 429 614 235 369 H02AA02 fludrocortisone 1 178 1 223 1 267 1 323 1 367 56 89 429 614 235 369 H02AB Glucocorticoids 190 110 196 940 207 710 214 119 216 331 56 4 958 60 871 91 484 59 018 54 335 H02AB01 betamethasone 1 700 1 637 1 528 1 495 1 988 42 1 156 296 443 93 638 H02AB02 dexamethasone 2 118 2 552 2 786 3 208 3 485 45 100 346 1 830 1 209 4 152 H02AB04 methylprednisolone 10 745 10 812 11 020 11 094 11 015 54 41 2 524 5 779 2 671 4 003 H02AB06 prednisolone 143 524 152 240 159 525 167 804 168 968 58 3 118 38 314 73 245 54 291 30 480 H02AB07 prednisone <5 82 246 267 347 70 0 55 173 119 858 H02AB08 triamcinolone 34 538 32 179 35 711 33 528 34 019 49 450 20 047 11 698 1 824 4 774 H02AB09 hydrocortisone 437 481 549 597 637 68 67 244 290 36 3 085 H02AB10 cortisone 2 593 2 662 2 750 2 817 2 820 51 135 741 1 361 583 6 241 H02AB13 deflazacort 18 17 25 25 26 42 10 7 7 <5 105 H02B CORTICOSTEROIDS FOR SYSTEMIC USE, COMBINATIONS 332 372 415 409 386 63 <5 65 219 101 60 H02BX Corticosteroids for systemic use, combinations 332 372 415 409 386 63 <5 65 219 101 60 H02BX01 methylprednisolone, combinations 332 372 415 409 386 63 <5 65 219 101 60 H03 THYROID THERAPY 174 354 180 847 185 868 192 035 197 795 82 1 370 37 312 98 828 60 285 62 729 H03A THYROID PREPARATIONS 170 772 177 261 182 151 187 897 193 254 82 1 349 35 988 96 813 59 104 59 438 H03AA Thyroid hormones 170 772 177 261 182 151 187 897 193 254 82 1 349 35 988 96 813 59 104 59 438 H03AA01 levothyroxine sodium 170 484 176 910 181 641 187 229 192 528 82 1 343 35 746 96 396 59 043 54 495 H03AA02 liothyronine sodium 4 095 4 142 4 538 4 698 4 750 90 15 1 402 2 890 443 3 244 H03AA03 combinations of levothy - roxine and liothyronine 429 328 549 701 872 92 <5 350 483 38 1 025 H03AA05 thyroid gland preparations 0 182 187 265 353 90 0 139 203 11 675 H03B ANTITHYROID PREPARATIONS 5 019 5 125 5 432 5 927 6 398 80 35 2 055 2 922 1 386 3 289 H03BA Thiouracils 552 521 651 553 H03BA02 propylthiouracil 552 521 651 582 581 90 0 325 207 49 553 H03BB Sulfur-containing imidazole derivatives 4 590 4 727 5 042 5 510 6 039 79 35 1 856 2 797 1 351 2 736 H03BB01 carbimazole 4 590 4 727 5 042 5 510 6 039 79 35 1 856 2 797 1 351 2 736 H03C IODINE THERAPY 0 0 0 0 <5 50 0 <5 <5 0 2 H03CA Iodine therapy 0 0 0 0 <5 50 0 <5 <5 0 2 H04 PANCREATIC HORMONES 5 336 5 490 5 591 5 586 5 688 47 1 115 2 730 1 489 354 2 328 H04A GLYCOGENOLYTIC HORMONES 5 336 5 490 5 591 5 586 5 688 47 1 115 2 730 1 489 354 2 328ATC group H ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 5 490 5 591 5 586 5 688 47 1 115 2 730 1 489 354 2 328 H04AA01 glucagon 5 336 5 490 5 591 5 586 5 688 47 1 115 2 730 1 489 354 2 328 H05 CALCIUM HOMEOSTASIS 748 803 916 1 090 1 224 59 <5 138 611 474 31 710 H05A PARATHYROID HORMONES AND ANALOGUES 237 263 294 377 468 82 0 52 264 152 13 519 H05AA Parathyroid hormones and analogues 237 263 294 377 468 82 0 52 264 152 13 519 H05AA02 teriparatide 213 253 281 367 467 82 0 52 263 152 13 507 H05AA03 parathyroid hormone 25 12 13 11 <5 100 0 0 <5 0 12 H05B ANTI-PARATHYROID AGENTS 511 541 623 713 756 46 <5 86 347 322 18 191 H05BA Calcitonin preparations 86 80 83 69 21 76 0 <5 <5 16 61 H05BA01 calcitonin (salmon synthetic) 86 80 83 69 21 76 0 <5 <5 16 61 H05BX Other anti-parathyroid agents 425 461 540 644 735 45 <5 84 344 306 18 130 H05BX01 cinacalcet 391 418 474 501 525 49 <5 52 233 239 13 406 H05BX02 paricalcitol 44 59 87 188 284 36 <5 47 144 92 4 724ATC group H ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 15-44 45-69 70 68 Legemiddelstatistikk 2014:2 FolkehelseinstituttetJ ANTIINFECTIVES FOR SYSTEMIC USE 1 394 508 1 252 392 1 326 405 1 336 787 1 288 914 59 148 972 513 276 429 761 196 905 816 142 J01 ANTIBACTERIALS FOR SYSTEMIC USE 1 138 247 1 180 410 1 250 480 1 261 271 1 195 320 59 142 487 468 553 397 925 186 355 300 301 J01A TETRACYCLINES 161 073 167 058 188 189 206 426 187 918 57 2 071 84 508 72 040 29 299 35 708 J01AA Tetracyclines 161 073 167 058 188 189 206 426 187 918 57 2 071 84 508 72 040 29 299 35 708 J01AA02 doxycycline 124 472 129 848 148 596 164 753 145 943 56 800 54 640 62 924 27 579 19 837 J01AA04 lymecycline 13 528 14 771 19 412 22 520 23 686 58 713 17 012 5 044 917 10 646 J01AA06 oxytetracycline 5 244 5 164 2 625 <5 10 60 0 <5 5 <5 2 J01AA07 tetracycline 20 086 19 710 21 378 22 166 20 959 58 615 14 643 4 724 977 4 946 J01AA08 minocycline 16 58 85 145 240 53 <5 267 J01AA12 J01B AMPHENICOLS 0 <5 0 0 0 - 0 0 0 0 0 J01BA Amphenicols 0 <5 0 0 0 - 0 0 0 0 0 J01BA01 chloramphenicol 0 <5 0 0 0 - 0 0 0 0 0 J01C BETA-LACTAM ANTIBACTE - RIALS, PENICILLINS 744 434 776 398 797 519 801 997 774 820 61 106 267 295 965 247 707 124 881 128 672 J01CA Penicillins with extended spectrum 283 578 301 349 309 246 318 249 321 225 74 34 035 103 410 107 225 76 555 55 332 J01CA01 ampicillin 19 39 24 56 57 44 <5 5 15 36 44 J01CA02 pivampicillin 0 0 <5 0 0 - 0 0 0 0 0 J01CA04 amoxicillin 118 112 127 541 131 915 137 759 134 844 55 29 472 32 013 45 798 27 561 18 331 J01CA08 pivmecillinam 176 709 186 059 189 598 193 934 200 464 87 4 911 74 806 66 281 54 466 36 946 J01CA11 sensitive penicillins 444 689 458 149 466 195 458 225 438 658 54 75 654 180 708 133 405 48 891 41 726 J01CE01 benzylpenicillin 58 52 64 85 103 45 <5 13 30 56 136 J01CE02 phenoxymethylpenicillin 444 622 458 036 466 096 458 104 438 508 54 75 651 180 645 133 360 48 852 41 081 J01CE08 benzathine benzylpenicillin 40 99 83 81 112 26 <5 65 39 7 509 J01CF Beta-lactamase resistant penicillins 85 870 92 702 100 307 104 992 87 628 49 4 556 37 435 30 816 14 821 30 941 J01CF01 dicloxacillin 84 083 91 099 98 912 103 764 81 161 49 4 269 34 689 28 506 13 697 27 501 J01CF02 cloxacillin 2 153 1 929 1 714 1 520 8 105 47 296 3 286 2 982 1 541 3 388 J01CF05 flucloxacillin 32 22 17 21 28 36 20 <5 51 J01CR Combinations of penicil - lins, incl. beta-lactamase inhibitors 120 135 114 188 434 57 212 57 85 80 674 J01CR02 amoxicillin and enzyme inhibitor 101 118 94 151 381 60 211 50 60 60 370 J01CR05 piperacillin and enzyme inhibitor 19 17 20 37 53 36 <5 7 25 20 3032.11 ATC group J - Antiinfectives for systemic use ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 24 378 23 566 23 142 21 542 22 070 58 2 780 7 850 7 488 3 952 11 360 J01DB First-generation cephalosporins 23 974 23 116 22 707 20 726 20 949 59 2 716 7 477 7 116 3 640 3 084 J01DB01 cefalexin 23 952 23 099 22 698 20 707 20 940 59 2 716 7 477 7 113 3 634 3 070 J01DB03 cefalotin 23 17 9 20 9 11 0 0 <5 6 14 J01DC Second-generation cephalosporins 63 71 72 103 98 52 <5 6 26 64 81 J01DC02 cefuroxime 63 71 72 103 98 52 <5 6 26 64 81 J01DD Third-generation cephalosporins 346 388 362 705 1 010 46 68 363 332 247 6 278 J01DD01 cefotaxime 122 120 134 447 703 48 5 237 262 199 4 422 J01DD02 ceftazidime 71 80 57 68 73 47 13 36 14 10 1 193 J01DD04 ceftriaxone 155 190 177 195 238 39 51 91 57 39 663 J01DF Monobactams 11 13 8 9 10 50 0 9 0 <5 450 J01DF01 aztreonam 11 13 8 9 10 50 0 9 0 <5 450 J01DH Carbapenems 56 43 53 69 85 54 8 27 28 22 1 466 J01DH02 meropenem 46 39 40 58 62 53 7 23 19 13 993 J01DH03 ertapenem 8 <5 13 10 17 65 0 <5 8 6 403 J01DH04 doripenem 0 0 0 <5 0 - 0 0 AND TRIMETHOPRIM 118 489 117 088 116 661 114 940 116 722 75 13 833 30 594 38 511 33 784 11 262 J01EA Trimethoprim and derivatives 88 503 86 108 84 347 80 744 78 689 85 8 074 21 487 25 244 23 884 6 469 J01EA01 trimethoprim 88 503 86 108 84 347 80 744 78 689 85 8 074 21 487 25 244 23 884 6 469 J01EE Combinations of sulfon-amides and trimethoprim, incl. derivatives 34 027 34 976 36 389 38 556 42 790 57 6 310 9 987 14 728 11 765 4 793 J01EE01 sulfamethoxazole and trimethoprim 34 027 34 976 36 389 38 556 42 790 57 6 310 9 987 14 728 11 765 4 793 J01F MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS 337 301 083 349 643 343 543 296 521 57 36 035 130 094 101 074 29 318 49 680 J01FA Macrolides 244 678 257 943 304 755 295 755 238 975 58 31 273 106 756 79 931 21 015 37 320 J01FA01 erythromycin 123 140 129 188 170 347 152 858 120 963 59 24 475 46 177 38 818 11 493 16 287 J01FA02 spiramycin 3 033 2 794 2 744 2 645 2 018 62 20 684 1 036 278 331 J01FA06 roxithromycin 0 0 0 0 <5 50 0 0 <5 0 1 J01FA09 clarithromycin 36 958 37 830 43 161 48 582 34 941 58 3 047 13 182 14 153 4 559 6 087 J01FA10 azithromycin 90 850 98 413 101 180 105 207 90 289 59 4 514 50 957 29 387 5 431 14 581 J01FA15 telithromycin 0 0 0 <5 6 83 0 5 <5 0 32ATC group J ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 15-44 45-69 70 70 51 154 53 678 56 641 66 378 53 5 559 27 379 24 193 9 247 12 360 J01FF01 clindamycin 45 847 51 154 53 678 56 641 66 378 53 5 559 27 379 24 193 9 247 12 360 J01G AMINOGLYCOSIDE ANTIBACTERIALS 289 273 252 255 242 48 49 115 55 23 10 408 J01GA Streptomycins 0 0 0 0 <5 0 0 0 0 <5 15 J01GA01 streptomycin 0 0 0 0 <5 0 0 0 0 <5 15 J01GB Other aminoglycosides 289 273 252 255 241 49 49 115 55 22 10 393 J01GB01 tobramycin 258 250 219 229 211 49 46 104 44 17 9 413 J01GB03 gentamicin 26 16 19 14 21 33 <5 <5 10 <5 305 J01GB06 amikacin 5 10 14 78 0 7 <5 <5 675 J01M QUINOLONE ANTIBACTERIALS 60 651 64 703 67 271 69 685 68 203 49 608 16 510 29 583 21 502 15 682 J01MA Fluoroquinolones 60 651 64 703 67 271 69 685 68 203 49 608 16 510 29 583 21 502 15 682 J01MA01 ofloxacin 2 717 2 516 2 242 2 057 1 647 41 <5 488 688 468 571 J01MA02 ciprofloxacin 58 298 62 445 65 193 67 734 66 556 49 606 15 803 29 009 21 138 14 268 J01MA12 levofloxacin 15 21 31 20 18 61 0 <5 12 <5 78 J01MA14 moxifloxacin 71 142 205 263 290 56 0 271 16 <5 764 J01X OTHER ANTIBACTERIALS 51 069 54 632 58 484 59 562 61 581 85 1 421 12 317 21 417 26 426 37 530 J01XA Glycopeptide antibacterials 27 23 27 35 29 72 6 6 7 10 316 J01XA01 vancomycin 26 21 24 35 28 75 6 6 7 9 288 J01XA02 teicoplanin <5 <5 <5 <5 28 J01XB Polymyxins 64 55 63 72 79 62 18 35 19 7 2 845 J01XB01 colistin 64 55 63 72 79 62 18 35 19 7 2 845 J01XC Steroid antibacterials 711 757 663 592 646 57 16 234 217 179 408 J01XC01 fusidic acid 711 757 663 592 646 57 16 234 217 179 408 J01XD Imidazole derivatives 23 24 26 25 28 39 0 <5 18 7 71 J01XD01 metronidazole 23 24 26 25 28 39 0 <5 18 7 71 J01XE Nitrofuran derivatives 31 296 33 594 36 784 36 250 36 821 86 1 308 9 330 12 824 13 359 3 922 J01XE01 nitrofurantoin 31 296 33 594 36 784 36 250 36 821 86 1 308 9 330 12 824 13 359 3 922 J01XX Other antibacterials 23 185 24 887 25 921 28 098 29 569 84 113 3 461 10 306 15 689 29 967 J01XX01 fosfomycin 0 <5 <5 <5 12 J01XX05 methenamine 22 969 24 644 25 647 27 852 29 300 84 111 3 412 10 190 15 587 21 579 J01XX08 linezolid 223 252 279 252 273 47 <5 48 119 104 8 368 J01XX09 daptomycin 0 0 0 <5 <5 100 0 0 <5 0 9 J02 ANTIMYCOTICS FOR SYSTEMIC USE 42 646 45 330 46 501 47 777 48 187 86 452 30 539 13 792 3 404 32 205 J02A ANTIMYCOTICS FOR SYSTEMIC USE 42 646 45 330 46 501 47 777 48 187 86 452 30 539 13 792 3 404 32 205 J02AA Antibiotics <5 <5 <5 <5 0 66ATC group J ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 0 66 J02AB Imidazole derivatives 2 262 2 163 2 227 2 264 1 716 45 17 1 137 493 69 502 J02AB02 ketoconazole 2 262 2 163 2 227 2 264 1 716 45 17 1 137 493 69 502 J02AC Triazole derivatives 40 488 43 283 44 379 45 621 46 571 88 437 29 463 13 328 3 343 26 822 J02AC01 fluconazole 40 227 42 967 43 936 45 311 46 203 88 425 29 298 13 170 3 310 15 279 J02AC02 itraconazole 526 471 635 608 576 76 7 344 199 26 953 J02AC03 voriconazole 65 80 80 88 87 37 <5 19 48 16 7 265 J02AC04 posaconazole 9 22 40 55 63 30 <5 18 38 <5 3 324 J02AX Other antimycotics for systemic use 5 - 0 0 0 0 J04 ANTIMYCOBACTERIALS 1 336 1 573 1 645 1 877 1 980 50 144 923 556 357 6 043 J04A DRUGS FOR TREATMENT OF TUBERCULOSIS 931 1 126 1 194 1 454 1 524 53 138 814 354 218 5 676 J04AB Antibiotics 401 444 474 621 563 49 72 132 184 175 1 507 J04AB02 rifampicin 377 422 458 608 555 48 72 128 182 173 1 357 J04AB04 rifabutin 25 24 17 14 9 56 0 5 <5 <5 150 J04AB30 capreomycin 0 0 0 <5 0 - 0 0 0 0 0 J04AC Hydrazides 64 75 88 78 95 59 18 40 29 8 99 J04AC01 isoniazid 64 75 88 78 95 59 18 40 29 8 99 J04AD Thiocarbamide derivatives <5 0 0 0 0 - 0 0 0 0 0 J04AD01 protionamide <5 0 0 0 0 - 0 0 0 0 0 J04AK Other drugs for treatment of tuberculosis 126 203 207 283 318 53 <5 189 88 37 1 141 J04AK01 pyrazinamide 20 28 37 50 68 65 <5 48 13 <5 150 J04AK02 ethambutol 115 198 200 268 304 52 <5 180 86 35 991 J04AM Combinations of drugs for treatment of tuberculosis 493 645 684 808 917 55 67 668 146 36 2 928 J04AM02 rifampicin and isoniazid 433 578 619 752 856 130 35 2 360 J04AM05 rifampicin, pyrazinamide and isoniazid 76 138 111 180 225 0 157 53 15 536 J04AM06 rifampicin, pyrazinamide, ethambutol and isoniazid 58 47 47 0 14 71 0 9 5 0 32 J04B DRUGS FOR TREATMENT OF LEPRA 405 449 454 423 457 42 6 109 203 139 368 J04BA Drugs for treatment of lepra 405 449 454 423 457 42 6 109 203 139 368 J04BA02 dapsone 405 449 454 423 457 42 6 109 203 139 368ATC group J ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 15-44 45-69 70 304 693 31 034 32 722 34 845 39 342 61 996 19 303 14 471 4 572 398 145 J05A DIRECT ACTING ANTIVIRALS 304 693 31 034 32 722 34 845 39 342 61 996 19 303 14 471 4 572 398 145 J05AB Nucleosides and nucleotides 889 27 463 30 034 32 041 65 608 15 781 11 516 4 136 52 486 J05AB01 aciclovir 10 264 11 316 12 172 12 655 12 598 69 399 6 603 4 099 1 497 4 951 J05AB04 ribavirin 770 705 760 900 785 35 <5 14 J05AB06 ganciclovir 0 <5 <5 0 0 0 <5 0 <5 <5 0 0 8 J05AB11 valaciclovir 12 244 13 096 14 811 16 807 18 985 64 205 9 121 7 007 2 652 16 750 J05AB14 valganciclovir 246 283 319 347 365 39 8 96 224 37 15 831 J05AD Phosphonic acid derivatives 0 0 0 <5 <5 100 0 0 <5 0 46 J05AD01 foscarnet 0 0 0 <5 <5 0 0 <5 0 46 J05AE Protease inhibitors 728 860 1 105 1 557 1 551 38 <5 793 730 25 93 830 J05AE01 saquinavir 11 9 7 7 7 29 322 J05AE02 indinavir 6 <5 0 0 0 0 J05AE03 ritonavir 499 604 720 864 963 42 <5 J05AE07 41 J05AE08 atazanavir 660 780 920 1 080 1 140 40 <5 634 483 21 42 501 J05AE09 tipranavir <5 0 0 0 0 - 0 0 0 0 0 J05AE10 darunavir 55 70 91 132 177 33 <5 67 106 <5 9 266 J05AE11 telaprevir 0 0 16 94 85 29 0 35 50 0 17 484 J05AE12 boceprevir 0 0 76 256 161 39 0 63 98 0 20 550 J05AF Nucleoside and nucleotide reverse transcriptase inhibitors 388 399 420 489 587 39 21 275 279 12 21 110 J05AF01 zidovudine 41 34 35 30 36 39 <5 17 14 <5 299 J05AF02 didanosine 53 37 22 17 15 47 0 5 9 <5 247 J05AF04 stavudine 13 13 <5 0 0 - 0 0 0 0 0 J05AF05 lamivudine 117 100 93 92 100 43 18 28 50 <5 1 027 J05AF06 abacavir 48 51 54 60 66 52 15 25 25 <5 1 326 J05AF07 tenofovir disoproxil 158 163 191 228 130 <5 10 006 J05AF08 adefovir dipivoxil 33 22 15 11 10 30 0 <5 8 0 633 J05AF09 emtricitabine 11 11 9 6 8 25 0 <5 6 0 155 J05AF10 entecavir 87 106 126 160 175 36 0 83 89 <5 7 385 J05AF11 telbivudine 8 5 <5 0 <5 0 <5 <5 0 32ATC group J ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 38 10 155 218 15 10 670 J05AG01 nevirapine 186 191 184 176 164 38 <5 61 96 5 4 538 J05AG03 efavirenz 382 321 258 221 192 40 7 79 97 9 4 641 J05AG04 etravirine 12 23 28 28 35 37 <5 11 22 <5 1 197 J05AG05 rilpivirine 0 0 0 <5 12 25 0 7 5 0 294 J05AH Neuraminidase inhibitors 282 095 3 860 2 646 1 808 3 993 53 365 1 820 1 432 376 982 J05AH01 zanamivir 2 542 35 36 34 85 62 <5 47 29 6 22 J05AH02 oseltamivir 279 946 3 829 2 612 1 776 3 911 53 362 1 774 1 404 371 960 J05AR Antivirals for treatment of HIV infections, combinations 1 927 2 184 2 445 2 775 3 043 36 15 1 555 1 414 59 197 516 J05AR01 zidovudine and lamivudine 606 514 421 350 249 44 113 122 13 6 870 J05AR02 lamivudine and abacavir 258 279 290 335 376 31 <5 154 209 11 14 805 J05AR03 tenofovir disoproxil and emtricitabine 890 1 065 1 230 1 433 1 526 41 <5 838 661 25 73 746 J05AR04 zidovudine, lamivudine and abacavir 36 35 31 23 17 0 5 11 <5 725 J05AR06 emtricitabine, tenofovir disoproxil and efavirenz 362 514 650 767 383 395 11 62 687 J05AR08 emtricitabine, tenofovir disoproxil and rilpivirine 0 0 0 143 339 29 0 195 142 <5 26 130 J05AR09 emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat 0 0 0 0 33 33 0 17 16 0 1 238 J05AR10 lopinavir and ritonavir 583 551 510 480 401 49 10 235 151 5 11 316 J05AX Other antivirals 97 179 271 325 379 40 7 156 211 5 21 506 J05AX05 inosine pranobex <5 31 81 61 45 76 <5 27 15 0 188 J05AX07 enfuvirtide <5 0 0 0 0 - 0 0 0 0 0 J05AX08 raltegravir 96 148 190 264 333 35 <5 128 196 5 20 761 J05AX09 maraviroc 5 7 7 7 8 25 0 <5 6 0 556ATC group J ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 AGENTS 72 795 76 656 81 612 86 336 90 729 54 1 264 19 959 43 089 26 417 2 668 185 L02 ENDOCRINE THERAPY 24 457 24 886 25 999 26 144 26 900 52 147 3 181 9 392 14 180 320 416 L02A HORMONES AND RELATED AGENTS 10 788 11 009 11 761 11 175 11 171 22 145 1 965 1 991 7 070 90 600 L02AA Estrogens 25 17 7 <5 <5 0 0 <5 0 0 0 L02AA02 polyestradiol phosphate 25 17 7 <5 <5 0 0 <5 0 0 0 L02AB Progestogens 188 178 202 166 154 81 0 8 66 80 337 L02AB01 megestrol 178 178 202 166 154 81 0 8 66 80 337 L02AB02 medroxyprogesterone 12 0 0 0 0 - 0 0 0 0 0 L02AE Gonadotropin releasing hormone analogues 10 590 10 827 11 558 11 011 11 019 21 145 1 957 1 927 6 990 90 262 L02AE01 buserelin 1 282 1 474 1 898 1 313 1 355 100 0 1 338 17 0 2 230 L02AE02 leuprorelin 3 887 3 891 4 012 3 957 3 736 16 144 411 491 2 690 33 032 L02AE03 goserelin 5 601 5 619 5 783 5 861 6 028 7 <5 239 1 437 4 351 54 724 L02AE04 triptorelin 8 <5 12 13 13 100 0 10 <5 0 46 L02AE05 histrelin 0 0 12 20 20 0 0 0 <5 17 230 L02B HORMONE ANTAGONISTS AND RELATED AGENTS 16 800 17 127 17 878 18 866 19 816 59 <5 1 267 8 511 10 036 229 817 L02BA Anti-estrogens 4 959 4 109 3 861 3 999 4 250 96 <5 695 2 604 949 12 251 L02BA01 tamoxifen 4 716 3 893 3 597 3 766 4 036 96 <5 692 2 488 854 3 847 L02BA03 fulvestrant 267 242 296 267 246 98 0 5 129 112 8 405 L02BB Anti-androgens 6 380 6 641 7 008 6 983 6 964 0 0 <5 1 517 5 445 44 433 L02BB01 flutamide 352 305 253 248 202 1 0 <5 18 182 914 L02BB03 bicalutamide 6 058 6 362 6 775 6 765 6 720 0 0 0 1 479 5 241 38 357 L02BB04 enzalutamide 0 0 0 0 85 0 0 0 29 56 5 162 L02BG Aromatase inhibitors 6 601 7 219 7 378 7 777 8 322 98 0 586 4 499 3 237 34 712 L02BG03 anastrozole 3 276 2 901 2 331 1 857 1 537 93 0 68 810 659 6 608 L02BG04 letrozole 2 360 3 478 4 365 5 300 6 155 100 0 506 3 316 2 333 24 363 L02BG06 exemestane 1 200 1 108 929 809 901 99 0 18 544 339 3 741 L02BX Other hormone anta-gonists and related agents 0 89 377 836 1 182 0 0 0 337 845 138 420 L02BX02 degarelix 0 89 271 380 487 0 0 0 164 323 5 075 L02BX03 abiraterone 0 0 107 484 762 0 0 0 209 553 133 345 L03 IMMUNOSTIMULANTS 5 663 5 883 6 294 6 765 6 747 60 54 2 351 3 715 627 325 389 L03A IMMUNOSTIMULANTS 5 663 5 883 6 294 6 765 6 747 60 54 2 351 3 715 627 325 389 L03AA Colony stimulating factors 2 085 2 222 2 426 2 691 2 831 59 38 481 1 732 580 91 238 L03AA02 filgrastim 362 415 587 599 623 49 32 119 367 105 10 0582.12 ATC group L - Antineoplastic and immunomodulating agents ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 815 1 919 1 958 2 218 2 353 61 6 398 1 458 491 81 180 L03AB Interferons 2 666 2 649 2 756 2 891 2 722 57 16 1 316 1 354 36 152 565 L03AB01 interferon alfa natural 5 11 20 20 14 64 0 8 6 0 1 500 L03AB03 interferon gamma 9 9 9 10 10 60 <5 7 <5 0 937 L03AB04 interferon alfa-2a 14 19 19 23 25 48 0 <5 14 7 934 L03AB05 interferon alfa-2b 62 74 63 49 40 38 0 9 27 <5 1 365 L03AB07 interferon beta-1a 1 348 1 217 1 183 1 178 1 159 70 10 559 585 5 89 662 L03AB08 interferon beta-1b 372 533 637 652 280 <5 27 199 L03AB10 peginterferon alfa-2b 416 310 273 337 260 42 <5 8 9 150 L03AB11 peginterferon alfa-2a 468 503 594 687 8 21 817 L03AC Interleukins 0 0 <5 0 0 - 0 0 0 0 0 L03AC01 aldesleukin 0 0 <5 0 0 - 0 0 0 0 0 L03AX Other immunostimulants 1 023 1 148 1 266 1 358 1 322 72 <5 624 685 11 81 586 L03AX03 BCG vaccine 7 13 12 10 12 17 0 <5 <5 7 73 L03AX13 glatiramer acetate 1 016 1 135 1 254 1 348 1 310 72 <5 623 681 <5 81 513 L04 IMMUNOSUPPRESSANTS 37 221 39 932 42 913 46 379 49 521 55 926 13 743 25 996 8 856 1 592 934 L04A IMMUNOSUPPRESSANTS 37 221 39 932 42 913 46 379 49 521 55 926 13 743 25 996 8 856 1 592 934 L04AA Selective immunosuppressants 4 619 4 910 5 466 6 255 7 280 51 89 1 892 4 149 1 150 248 941 L04AA06 mycophenolic acid 2 965 3 266 3 591 3 926 4 207 37 78 993 2 485 651 38 945 L04AA10 sirolimus 70 101 130 150 189 35 5 23 142 19 5 688 L04AA13 leflunomide 1 362 1 458 1 539 1 662 1 785 69 0 221 1 113 451 10 094 L04AA18 everolimus 263 294 336 402 449 29 7 59 283 100 26 820 L04AA21 efalizumab 118 0 0 0 0 - 0 0 0 0 0 L04AA23 natalizumab 58 49 0 0 0 - 0 0 0 0 0 L04AA24 abatacept <5 <5 0 0 72 75 0 11 42 19 3 598 L04AA25 eculizumab <5 <5 5 8 <5 30 993 L04AA27 fingolimod 0 0 186 487 896 74 <5 562 333 0 129 879 L04AA31 teriflunomide 0 0 0 0 140 77 0 83 56 <5 2 925 L04AB Tumor necrosis factor alpha (TNF-) inhibitors 8 409 9 649 11 057 12 629 13 980 53 184 5 185 7 409 1 202 1 097 987 L04AB01 etanercept 5 162 5 078 6 122 6 948 6 521 54 110 2 053 3 679 679 448 004 L04AB02 infliximab 83 <5 0 0 <5 0 5 L04AB04 adalimumab 3 519 3 993 4 121 4 589 4 962 50 79 2 259 2 325 299 457 394 L04AB05 certolizumab pegol 0 135 314 606 1 232 72 <5 310 742 179 54 835 L04AB06 golimumab 0 1 038 1 208 1 219 2 145 50 <5 915 1 140 89 137 748 L04AC Interleukin inhibitors 69 127 180 293 436 42 16 185 206 29 41 098ATC group L ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 76 Legemiddelstatistikk 2014:2 FolkehelseinstituttetATC group ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 L04AC03 anakinra 68 75 85 121 125 48 12 46 54 13 7 955 L04AC05 ustekinumab <5 50 92 166 304 40 <5 136 151 16 27 440 L04AC07 tocilizumab 0 0 0 0 <5 33 0 <5 <5 0 52 L04AC08 canakinumab 0 <5 6 7 17 <5 <5 0 0 5 651 L04AD Calcineurin inhibitors 4 578 4 799 5 027 5 288 5 524 39 166 1 458 3 114 786 113 734 L04AD01 ciclosporin 3 289 3 307 3 332 3 274 3 199 38 71 707 1 818 603 58 604 L04AD02 tacrolimus 1 349 1 570 1 770 2 092 2 381 39 96 770 1 328 187 55 130 L04AX Other immunosuppressants 26 860 28 382 29 767 31 228 32 173 58 635 7 756 16 835 6 947 91 174 L04AX01 azathioprine 6 197 6 390 6 714 7 087 7 362 52 219 3 400 3 037 706 6 543 L04AX02 thalidomide 330 348 320 330 295 47 <5 5 100 187 9 208 L04AX03 methotrexate 20 347 21 622 22 692 23 702 24 355 61 416 4 385 13 597 5 957 10 973 L04AX04 lenalidomide 106 157 171 236 257 46 0 <5 140 116 54 740 L04AX05 pirfenidone 0 0 0 21 50 30 0 0 37 13 9 709Legemiddelstatistikk 2014:2 Folkehelseinstituttet 77M MUSCULO-SKELETAL SYSTEM 891 127 901 910 927 355 937 937 925 319 57 14 318 327 053 427 476 156 472 331 706 M01 ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS 815 420 824 208 833 848 838 542 821 122 57 12 426 317 311 389 001 102 384 207 077 M01A ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS 815 299 824 121 833 776 838 491 821 087 57 12 426 317 303 388 989 102 369 206 330 M01AB Acetic acid derivatives and related substances 491 574 505 424 508 808 485 786 439 563 55 6 513 184 377 205 498 43 175 52 567 M01AB01 indometacin 11 675 2 710 1 116 1 153 1 129 61 17 410 560 142 925 M01AB02 sulindac 386 16 0 0 0 - 0 0 0 0 0 M01AB05 diclofenac 1)464 462 481 108 483 169 461 621 417 775 54 6 473 179 796 193 678 37 828 41 400 M01AB15 ketorolac 11 27 23 9 12 67 0 6 5 <5 3 M01AB55 diclofenac, combinations 23 266 29 244 31 576 29 001 25 182 63 31 5 475 13 812 5 864 10 238 M01AC Oxicams 81 319 76 309 69 293 59 451 52 902 54 228 17 095 28 296 7 283 13 486 M01AC01 piroxicam 55 461 51 627 47 991 43 612 39 641 52 202 14 318 21 151 3 970 9 900 M01AC06 meloxicam 26 731 25 438 21 952 16 207 13 527 61 27 2 862 7 288 3 350 3 586 M01AE Propionic acid derivatives 273 810 276 001 294 401 332 774 343 199 61 5 879 131 480 162 628 43 212 84 727 M01AE01 ibuprofen1)211 641 215 745 226 838 225 258 217 264 61 4 957 91 560 98 875 21 872 30 058 M01AE02 naproxen1)59 487 58 354 62 549 65 207 72 012 57 901 26 134 33 945 11 032 21 188 M01AE03 ketoprofen 7 912 7 478 7 396 6 735 5 438 60 15 1 109 3 139 1 175 2 623 M01AE14 dexibuprofen 1 417 1 025 881 707 637 62 <5 270 279 86 153 M01AE17 dexketoprofen 0 0 0 0 <5 67 0 <5 <5 0 0 M01AE52 naproxen and esomeprazole 0 0 5 217 50 859 64 416 63 57 18 326 34 985 11 048 30 705 M01AG Fenamates 669 106 7 293 M01AG02 tolfenamic acid 669 131 7 293 M01AH Coxibs 35 851 35 999 36 515 43 619 72 688 56 95 22 510 38 463 11 620 38 045 M01AH01 celecoxib 8 030 7 851 7 720 9 983 16 437 62 32 4 650 8 643 3 112 10 706 M01AH04 parecoxib <5 0 0 29 M01AH05 etoricoxib 28 047 28 365 29 013 34 034 57 270 55 63 18 140 30 396 8 671 27 310 M01AX Other antiinflammatory and antirheumatic agents, non-steroids 51 313 48 137 41 749 37 374 34 782 66 5 2 372 19 684 12 721 17 212 M01AX01 nabumetone 9 107 7 343 6 378 4 799 3 773 67 <5 709 2 143 920 1 880 M01AX05 glucosamine 1)41 918 40 410 34 884 31 959 30 393 66 <5 1 598 17 213 11 579 13 933 M01C SPECIFIC ANTIRHEUMATIC AGENTS 285 242 208 133 99 73 0 14 53 32 747 M01CB Gold preparations 241 199 171 100 71 82 0 8 40 23 243 M01CB01 sodium aurothiomalate 74 36 30 26 19 63 0 <5 6 10 58 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.2.13 ATC group M - Musculo-skeletal system ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 15-44 45-69 70 78 Legemiddelstatistikk 2014:2 FolkehelseinstituttetM01CB03 auranofin 167 163 141 74 52 88 0 5 34 13 185 M01CC Penicillamine and similar agents 12 14 13 12 12 33 0 <5 7 <5 74 M01CC01 penicillamine 12 14 13 12 12 33 0 <5 7 <5 74 M01CX Other specific antirheumatic agents 32 30 24 21 16 63 0 <5 6 8 430 M02 TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN 27 101 24 394 53 477 59 206 60 159 60 2 258 18 757 24 818 14 326 5 738 M02A TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN 27 101 24 394 53 477 59 206 60 157 60 2 258 18 756 24 817 14 326 5 738 M02AA Antiinflammatory preparations, non-steroids for topical use 27 032 24 200 53 269 59 087 60 050 60 2 256 18 707 24 792 14 295 5 725 M02AA10 ketoprofen 1)23 095 20 122 47 409 51 291 51 649 60 1 871 16 056 21 638 12 084 4 175 M02AA13 ibuprofen1)3 853 3 998 4 923 5 837 5 818 60 294 1 806 2 142 1 576 982 M02AA15 diclofenac 160 167 1 322 2 402 2 890 58 98 918 1 117 757 568 M02AB Capsaicin and similar agents 5 6 6 8 5 60 0 0 <5 <5 1 M02AB01 capsaicin 5 6 6 8 5 60 0 0 <5 <5 1 M02AC Preparations with salicylic acid derivatives 69 189 207 124 119 49 <5 60 32 25 11 M02AX Other topical products for joint and muscular pain 11 13 9 5 8 100 0 0 0 8 2 M02AX10 various 11 13 9 5 8 100 0 0 0 8 2 M03 MUSCLE RELAXANTS 5 592 5 918 6 009 5 939 6 104 57 100 1 642 3 525 837 12 862 M03B MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS 5 388 5 657 5 654 5 586 5 630 55 99 1 373 3 333 825 9 377 M03BA Carbamic acid esters 1 087 1 097 1 030 911 745 68 0 165 525 55 2 000 M03BA02 carisoprodol 1 087 1 097 1 030 911 745 68 0 165 525 55 2 000 M03BA52 carisoprodol, combinations excl. psycholeptics <5 0 0 0 0 - 0 0 0 0 0 M03BB Oxazol, thiazine, and triazine derivatives 0 0 <5 0 7 0 chemically close to antihistamines <5 <5 0 0 0 - 0 0 0 0 0 M03BC51 orphenadrine, combinations <5 <5 0 0 0 - 0 0 0 0 0 M03BX Other centrally acting agents 4 318 4 583 4 652 4 696 4 901 53 99 1 212 2 818 772 7 370 M03BX01 baclofen 4 277 4 544 4 608 4 650 4 850 53 99 1 201 2 783 767 6 965 M03BX02 tizanidine 59 59 71 75 78 37 0 19 54 5 406ATC group M ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.Legemiddelstatistikk 2014:2 Folkehelseinstituttet 79M03C MUSCLE RELAXANTS, DIRECTLY ACTING AGENTS 0 0 <5 0 0 - 0 0 0 0 0 M03CA Dantrolene and derivatives 0 0 <5 0 0 - 0 0 0 0 0 M03CA01 dantrolene 0 0 <5 0 0 - 0 0 0 0 0 M04 ANTIGOUT PREPARATIONS 39 433 40 882 43 057 45 482 47 763 28 20 2 942 20 661 24 140 22 086 M04A ANTIGOUT PREPARATIONS 39 433 40 882 43 057 45 482 47 763 28 20 2 942 20 661 24 140 22 086 M04AA Preparations inhibiting uric acid production 36 397 37 670 39 470 41 688 43 558 28 6 2 505 18 839 22 208 17 641 M04AA01 allopurinol 36 397 37 661 39 441 41 625 43 473 28 6 2 492 18 798 22 177 14 747 M04AA03 febuxostat 0 9 33 75 105 24 0 15 49 41 2 894 M04AB Preparations increasing uric acid excretion 2 123 2 062 2 072 2 041 1 970 31 <5 117 880 972 2 267 M04AB01 probenecid 2 123 2 062 2 072 2 041 1 970 31 <5 117 880 972 2 267 M04AC Preparations with no effect on uric acid metabolism 2 597 3 070 3 688 4 213 5 085 23 13 576 2 318 2 178 2 178 M04AC01 colchicine 2 597 3 070 3 688 4 213 5 085 23 13 576 2 318 2 178 2 178 M05 DRUGS FOR TREATMENT OF BONE DISEASES 56 744 57 597 58 371 59 962 61 037 88 <5 686 22 624 37 725 83 135 M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION 56 744 57 597 58 371 59 962 61 037 88 <5 686 22 624 37 725 83 135 M05BA Bisphosphonates 54 669 55 785 56 550 57 193 58 056 88 <5 635 21 747 35 672 52 164 M05BA01 etidronic acid 297 240 205 151 22 82 0 0 6 16 13 M05BA02 clodronic acid 44 48 48 41 34 59 0 0 12 22 418 M05BA03 pamidronic acid 13 21 19 16 18 56 0 0 12 6 85 M05BA04 alendronic acid 52 053 52 702 52 893 53 133 53 858 88 <5 544 19 770 33 542 37 102 M05BA06 ibandronic acid 704 696 668 653 271 391 2 034 M05BA07 risedronic acid 1 214 1 097 948 832 639 94 0 <5 227 408 1 538 M05BA08 zoledronic acid 835 1 584 2 329 2 908 3 378 89 0 91 1 745 1 542 10 974 M05BB Bisphosphonates, combinations 2 267 1 950 1 659 1 434 668 94 0 <5 132 535 533 M05BB01 etidronic acid and calcium, sequential 2 267 1 950 1 659 1 434 668 94 0 <5 132 535 533 M05BX Other drugs affecting bone structure and mineralization 0 27 398 1 851 3 212 79 0 55 941 2 216 30 437 M05BX04 denosumab 0 27 398 1 851 3 212 79 0 55 941 2 216 30 437 M09 OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM <5 0 0 31 76 24 0 <5 55 19 809ATC group M ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 80 Legemiddelstatistikk 2014:2 FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM <5 0 0 31 76 24 0 <5 55 19 809 M09AB Enzymes 0 0 0 31 76 24 0 <5 55 19 809 M09AB02 collagenase clostridium histolyticum 0 0 0 31 76 24 0 <5 55 19 809 M09AX Other drugs for disorders of the musculo-skeletal system <5 0 0 0 0 - 0 0 0 0 0 M09AX01 hyaluronic acid <5 0 0 0 0 - 0 0 0 0 0ATC group M ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 15-44 45-69 70 Legemiddelstatistikk 2014:2 Folkehelseinstituttet 81N NERVOUS 1 230 918 1 248 505 1 279 676 1 304 344 1 327 510 59 30 708 421 950 580 132 294 720 2 600 528 N02 61 9 388 253 955 353 797 173 619 657 256 N02A OPIOIDS 487 517 491 941 500 644 514 434 528 298 56 4 736 174 143 236 612 112 807 384 344 N02AA Natural opium alkaloids 405 617 401 941 403 516 404 550 404 507 56 4 513 139 206 180 704 80 084 236 283 N02AA01 morphine 7 048 7 000 6 790 6 820 6 852 49 13 931 3 262 2 646 13 709 N02AA03 hydromorphone 41 40 48 68 95 48 <5 17 60 17 4 094 N02AA05 oxycodone 16 910 19 067 20 444 22 975 26 884 54 19 4 560 12 252 10 053 62 873 N02AA08 dihydrocodeine 49 47 52 47 53 81 0 12 37 <5 323 N02AA55 oxycodone, combinations 228 1 001 1 831 2 874 4 069 56 0 405 1 701 1 963 11 978 N02AA59 codeine, combinations excl. psycholeptics 392 734 387 038 383 925 56 4 494 136 369 171 522 71 540 143 306 N02AB Phenylpiperidine derivatives 10 453 11 167 11 306 11 506 12 148 59 7 2 085 5 181 4 875 44 304 N02AB01 ketobemidone 3 731 3 994 3 972 3 993 4 143 55 <5 1 204 2 076 861 5 505 N02AB02 pethidine 1 340 1 343 1 243 1 201 1 281 60 0 380 715 186 1 868 N02AB03 fentanyl 5 857 6 331 6 583 6 785 7 173 62 5 583 2 649 3 936 36 930 N02AC Diphenylpropylamine derivatives 7 442 4 700 30 15 12 75 0 <5 6 <5 68 N02AC04 dextropropoxyphene 0 0 9 15 12 75 <5 <5 68 N02AC54 dextropropoxyphene, combinations excl. psycholeptics 7 442 4 700 22 0 0 - 0 0 0 0 0 N02AD Benzomorphan derivatives 45 41 35 30 24 42 0 <5 14 8 367 N02AD01 pentazocine 45 41 35 30 24 42 0 <5 14 8 367 N02AE Oripavine derivatives 12 080 13 189 14 009 15 272 15 863 71 6 1 270 4 215 10 372 47 087 N02AE01 buprenorphine 12 080 13 189 14 009 15 272 15 863 71 6 1 270 4 215 10 372 47 087 N02AG Opioids in combination with antispasmodics 1 729 1 840 1 776 1 959 1 895 57 <5 484 936 474 1 653 N02AG01 morphine and antispasmodics 218 263 310 384 314 0 10 79 225 58 N02AG02 ketobemidone and antispasmodics 1 515 1 584 1 470 1 577 1 586 58 <5 474 858 253 1 595 N02AX Other opioids 114 947 127 986 138 495 155 617 172 547 58 268 50 812 80 230 41 237 54 583 N02AX02 tramadol 114 947 127 986 138 478 155 326 172 161 58 267 50 718 80 035 41 141 52 057 N02AX06 tapentadol 0 0 31 495 615 57 <5 161 315 138 2 526 N02B OTHER ANALGESICS AND ANTIPYRETICS 281 468 305 897 337 952 363 609 386 155 64 3 328 90 709 174 676 117 442 79 050 N02BA Salicylic acid and derivatives 806 840 883 797 938 60 242 301 249 146 323 N02BA01 acetylsalicylic acid 802 836 879 791 931 60 <5 122.14 ATC group N - Nervous system ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 15-44 Pyrazolones 885 887 891 970 1 051 68 5 501 361 184 283 N02BB02 metamizole sodium 22 12 5 13 18 44 <5 <5 8 7 9 N02BB51 phenazone, combinations excl. psycholeptics 863 875 886 957 1 033 69 <5 499 353 177 274 N02BE Anilides 280 253 304 673 336 641 362 291 384 456 64 3 085 082 669 N02BE01 304 336 641 362 291 384 388 64 3 084 90 012 174 064 117 228 71 647 N02BE51 paracetamol, combinations excl. psycholeptics 1)0 0 0 0 134 63 <5 52 48 33 21 N02BG Other analgesics and antipyretics <5 0 <5 68 404 48 0 94 284 26 6 775 N02BG07 flupirtine <5 0 0 2 N02BG08 ziconotide 0 0 <5 0 0 - 0 0 0 0 0 N02BG10 cannabinoids 0 0 <5 67 402 48 0 93 283 26 6 774 N02C ANTIMIGRAINE PREPARATIONS 87 608 88 921 91 693 94 417 97 251 80 1 991 46 229 45 158 3 873 193 862 N02CA Ergot alkaloids 3 477 3 072 2 918 2 496 877 83 <5 95 536 245 519 N02CA04 methysergide 6 6 6 N02CA52 ergotamine, combinations psycholeptics 13 15 15 12 21 76 0 <5 10 8 24 N02CA72 ergotamine, combinations with psycholeptics 3 458 3 053 2 895 2 477 856 83 <5 92 527 236 488 N02CC Selective serotonin (5HT 1) agonists 81 971 83 476 85 970 89 144 93 214 80 1 911 45 329 42 539 3 435 190 971 N02CC01 sumatriptan 40 472 41 843 43 349 45 284 47 946 78 1 681 25 466 19 104 1 695 85 021 N02CC02 naratriptan 1 497 1 501 1 581 1 651 1 707 87 8 738 882 79 5 052 N02CC03 zolmitriptan 14 223 14 230 14 481 14 789 15 150 82 129 6 757 7 651 613 27 801 N02CC04 rizatriptan 22 306 22 398 23 373 24 259 25 269 82 219 12 792 11 405 853 31 718 N02CC05 almotriptan 3 286 3 053 2 936 2 939 2 988 83 9 1 488 1 403 88 6 050 N02CC06 eletriptan 11 192 11 289 11 403 11 471 11 735 83 38 5 180 6 198 319 35 308 N02CC07 frovatriptan 19 6 5 7 8 88 0 5 <5 0 21 N02CX Other antimigraine preparations 3 163 3 418 3 920 3 949 4 271 79 89 1 109 2 779 294 2 372 N02CX01 pizotifen 53 61 60 78 72 85 <5 29 35 7 234 N02CX02 clonidine 3 111 3 357 3 861 3 874 4 199 79 88 1 080 2 744 287 2 138 N03 ANTIEPILEPTICS 100 382 103 954 108 555 113 451 116 903 56 3 557 36 383 54 679 22 284 375 234 N03A ANTIEPILEPTICS 100 382 103 954 108 555 113 451 116 903 56 3 557 36 383 54 679 22 284 375 234 N03AA Barbiturates and derivatives 2 844 2 700 2 544 2 430 2 361 52 29 242 1 262 828 1 856 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group N ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 2 426 2 270 2 149 2 064 52 28 206 1 124 706 1 325 N03AA03 primidone 284 288 287 293 309 48 <5 36 142 130 531 N03AB Hydantoin derivatives 2 218 2 051 1 938 1 798 1 704 43 18 187 952 547 800 N03AB02 phenytoin 2 217 2 051 1 937 1 798 1 704 43 18 187 952 547 800 N03AB05 fosphenytoin <5 0 <5 0 0 - 0 0 0 0 0 N03AD Succinimide derivatives 139 149 173 183 206 64 99 83 21 <5 1 852 N03AD01 ethosuximide 139 149 173 183 206 64 99 83 21 <5 1 852 N03AE Benzodiazepine derivatives 13 713 13 528 13 006 12 558 11 748 54 136 3 104 6 134 2 374 5 720 N03AE01 clonazepam 13 713 13 528 13 006 12 558 11 748 54 136 3 104 6 134 2 374 5 720 N03AF Carboxamide derivatives 20 004 19 238 18 449 17 652 16 961 47 761 4 549 8 474 3 177 31 839 N03AF01 carbamazepine 17 750 16 830 15 931 15 023 14 205 47 290 3 513 7 539 2 863 13 337 N03AF02 oxcarbazepine 2 236 2 298 2 375 2 426 2 526 45 468 894 857 307 9 962 N03AF03 rufinamide 96 96 97 99 100 36 24 67 8 <5 2 118 N03AF04 eslicarbazepine <5 205 213 233 <5 150 21 6 421 N03AG Fatty acid derivatives 13 867 14 184 14 347 14 693 15 127 45 1 643 5 986 6 165 1 333 33 653 N03AG01 valproic acid 13 786 14 111 14 279 14 623 15 047 45 1 621 5 958 6 138 1 330 32 749 N03AG03 aminobutyric acid 0 0 0 7 16 88 0 11 <5 <5 10 N03AG04 vigabatrin 114 100 88 90 94 56 45 24 21 <5 615 N03AG06 tiagabine 12 11 13 10 10 50 0 <5 7 0 280 N03AX Other antiepileptics 61 469 66 054 71 880 77 827 82 517 59 1 914 27 105 37 846 15 652 299 514 N03AX03 sultiame 64 98 130 161 206 45 172 32 <5 0 1 274 N03AX09 lamotrigine 22 368 23 711 24 878 26 197 27 013 60 1 000 13 283 10 379 2 351 80 475 N03AX10 felbamate 25 23 21 21 20 30 0 17 <5 0 441 N03AX11 topiramate 3 039 3 060 3 047 3 127 3 230 71 232 1 772 1 120 106 10 188 N03AX12 gabapentin 20 412 24 447 26 611 28 936 30 998 60 58 6 664 16 168 8 108 47 147 N03AX14 levetiracetam 4 977 5 539 6 101 6 784 7 307 48 614 2 735 2 666 1 292 43 313 N03AX15 zonisamide 444 457 473 520 611 54 86 324 171 30 7 922 N03AX16 pregabalin 17 120 15 264 16 892 18 332 19 654 59 12 4 670 10 230 4 742 99 469 N03AX17 stiripentol 19 33 30 24 21 33 14 7 0 0 1 291 N03AX18 lacosamide 122 262 341 411 445 52 13 247 161 24 5 529 N03AX21 retigabine 0 0 18 138 103 59 <5 70 29 <5 846 N03AX22 perampanel 0 0 0 0 149 48 <5 97 47 <5 1 620 N04 ANTI-PARKINSON DRUGS 17 238 17 787 18 178 18 653 19 088 51 19 1 581 8 209 9 279 129 739 N04A ANTICHOLINERGIC AGENTS 3 034 2 915 2 808 2 667 2 481 50 6 519 1 548 408 1 521 N04AA Tertiary amines 2 991 2 880 2 773 2 635 2 448 50 6 517 1 526 399 1 443 N04AA01 trihexyphenidyl 15 22 23 20 27 56 5 9 11 <5 196 N04AA02 biperiden 2 971 2 854 2 747 2 611 2 418 50 <5 508 1 514 395 1 239ATC group N ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 Ethers chemically close to antihistamines 48 40 38 37 34 65 0 <5 23 9 77 N04AB02 orphenadrine (chloride) 48 40 38 37 34 65 0 <5 23 9 77 N04B DOPAMINERGIC AGENTS 14 267 14 940 15 436 16 047 16 673 51 13 1 071 6 698 8 891 128 218 N04BA Dopa and dopa derivatives 7 716 7 906 8 015 8 279 8 579 43 12 149 2 575 5 843 70 223 N04BA02 levodopa and decarboxylase inhibitor 7 051 7 180 7 277 7 562 7 860 44 12 143 2 279 5 426 52 617 N04BA03 levodopa, decarboxylase inhibitor and COMT inhibitor 1 358 1 448 1 395 1 415 1 399 37 0 15 596 788 17 606 N04BB Adamantane derivatives 114 114 123 142 161 58 <5 53 85 22 500 N04BB01 amantadine 114 114 123 142 161 58 <5 53 85 22 500 N04BC Dopamine agonists 8 784 9 442 9 976 10 381 10 874 54 0 904 5 438 4 532 38 000 N04BC01 bromocriptine <5 <5 12 N04BC04 ropinirole 2 316 2 665 2 667 2 676 2 729 45 0 157 1 481 1 091 14 194 N04BC05 pramipexole 6 258 6 501 6 946 7 350 7 750 57 0 747 3 793 3 210 15 971 N04BC06 cabergoline 322 209 177 142 121 50 0 8 36 77 410 N04BC07 apomorphine 19 18 21 19 18 56 0 0 10 8 1 036 N04BC09 rotigotine 427 517 541 528 573 45 0 23 279 271 6 379 N04BD Monoamine oxidase B inhibitors 2 862 3 184 3 339 3 519 3 652 37 0 48 1 789 1 815 18 432 N04BD01 selegiline 2 116 2 126 2 087 2 138 2 183 37 0 29 1 080 1 074 3 028 N04BD02 rasagiline 864 1 183 1 329 1 460 1 530 37 0 21 748 761 15 404 N04BX Other dopaminergic agents 230 192 152 160 119 50 0 0 52 67 1 062 N04BX01 tolcapone 13 11 11 9 8 38 0 0 5 <5 60 N04BX02 entacapone 218 181 141 151 111 50 0 0 47 64 1 001 N05 PSYCHOLEPTICS 616 964 614 376 618 313 616 277 619 567 63 9 295 141 729 281 090 187 453 584 464 N05A ANTIPSYCHOTICS 104 082 104 077 104 361 106 114 106 651 55 902 37 444 48 021 20 284 299 592 N05AA Phenothiazines with aliphatic side-chain 25 877 24 617 23 180 21 794 20 118 57 21 5 236 10 692 4 169 7 788 N05AA01 chlorpromazine 492 439 389 280 222 59 0 92 96 34 789 N05AA02 levomepromazine 25 435 24 212 22 826 21 541 19 912 57 21 5 150 10 605 4 136 6 999 N05AB Phenothiazines with piperazine structure 19 829 18 276 17 128 15 768 13 470 68 18 2 733 5 861 4 858 5 995 N05AB01 dixyrazine 54 32 <5 0 0 - 0 0 0 0 0 N05AB02 fluphenazine 27 22 20 15 14 50 0 0 6 8 30 N05AB03 perphenazine 5 736 5 423 5 084 4 728 3 506 59 0 581 2 167 758 4 023 N05AB04 prochlorperazine 14 075 12 860 12 078 11 063 10 061 71 18 2 162 3 757 4 124 1 937 N05AB06 trifluoperazine <5 5ATC group N ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 70 62 61 50 54 57 0 <5 21 186 N05AC01 3 N05AC02 thioridazine 66 58 57 47 49 55 0 144 N05AC04 N05AD Butyrophenone derivatives 4 473 4 277 4 089 4 023 3 966 54 <5 390 1 526 2 048 1 322 N05AD01 haloperidol 4 466 4 270 4 082 4 014 3 959 54 <5 388 1 523 2 046 1 314 N05AD03 melperone 7 6 6 6 7 0 0 N05AE Indole derivatives 1 302 1 164 1 033 957 902 61 <5 419 447 34 11 472 N05AE03 sertindole 186 161 138 127 125 58 0 75 46 <5 1 336 N05AE04 ziprasidone 1 118 1 006 897 831 778 61 <5 345 401 30 10 136 N05AF Thioxanthene derivatives 24 245 23 752 22 935 22 560 22 303 55 30 7 546 11 231 3 496 12 153 N05AF01 flupentixol 5 006 4 918 4 621 4 478 4 351 66 <5 1 118 2 230 1 002 2 420 N05AF03 chlorprothixene 17 012 16 658 16 269 16 097 15 541 53 28 5 903 7 581 2 029 6 682 N05AF05 zuclopenthixol 2 908 2 822 2 661 2 581 3 044 51 <5 766 1 752 525 3 051 N05AG Diphenylbutylpiperidine derivatives 142 135 139 128 117 36 <5 65 38 10 286 N05AG02 pimozide 116 118 117 111 115 37 <5 64 37 10 284 N05AG03 penfluridol 27 17 22 17 <5 2 and oxepines 28 510 31 688 35 237 39 939 44 837 52 110 20 833 19 247 4 647 131 169 N05AH02 clozapine 2 299 2 362 2 398 2 459 2 533 37 0 1 196 1 264 73 9 636 N05AH03 olanzapine 16 068 15 799 15 754 16 072 16 385 47 29 6 503 7 660 2 193 55 961 N05AH04 quetiapine 11 509 15 094 18 864 23 376 28 125 56 85 14 330 11 202 2 508 64 599 N05AH05 asenapine 0 0 0 117 87 62 0 42 44 <5 973 N05AL Benzamides 580 548 527 566 569 46 <5 281 262 25 3 709 N05AL03 tiapride 5 7 7 7 5 60 <5 <5 <5 0 44 N05AL05 amisulpride 575 541 520 559 564 46 0 278 261 25 3 665 N05AN Lithium 7 995 7 877 7 727 7 792 7 682 57 <5 2 242 4 295 1 143 13 520 N05AN01 lithium 7 995 7 877 7 727 7 792 7 682 57 <5 2 242 4 295 1 143 13 520 N05AX Other antipsychotics 11 446 12 299 12 804 13 193 13 752 49 762 6 122 4 799 2 069 111 993 N05AX07 prothipendyl 0 0 <5 0 1 N05AX08 risperidone 8 150 8 255 8 366 8 303 8 392 47 651 2 956 2 915 1 870 34 957 N05AX12 aripiprazole 3 625 4 379 4 744 4 916 5 143 52 150 3 040 1 749 204 55 928 N05AX13 paliperidone 0 0 37 512 782 43 0 461 302 19 21 106 N05B ANXIOLYTICS 282 070 277 880 273 985 273 911 270 647 64 3 336 62 510 127 039 77 762 103 939 N05BA Benzodiazepine derivatives 261 074 255 446 250 055 249 597 245 061 65 2 923 52 738 117 007 72 393 90 020ATC group N ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 86 Legemiddelstatistikk 2014:2 282 132 588 128 283 125 831 120 562 63 2 716 25 624 57 908 3 N05BA04 oxazepam 134 703 133 963 131 939 134 353 134 612 67 70 29 659 63 754 41 129 39 881 N05BA06 lorazepam 20 21 30 31 48 58 <5 16 17 12 71 N05BA08 bromazepam 7 5 6 7 8 75 0 0 <5 <5 28 N05BA09 clobazam 558 615 645 706 340 126 8 1 996 N05BA12 alprazolam 4 521 4 340 4 024 4 133 3 851 47 0 1 556 1 885 410 4 934 N05BB Diphenylmethane derivatives 28 280 30 163 31 960 32 347 33 868 62 417 12 239 13 920 7 292 9 533 N05BB01 hydroxyzine 28 280 30 163 31 960 32 347 33 868 62 417 12 239 13 920 7 292 9 533 N05BC Carbamates 10 6 7 6 <5 75 0 0 0 <5 4 N05BC01 meprobamate 10 6 7 6 <5 75 0 0 0 <5 4 N05BE Azaspirodecanedione derivatives 2 394 2 345 2 371 2 580 2 403 59 <5 880 1 184 335 4 381 N05BE01 buspirone 2 394 2 345 2 371 2 580 2 403 59 <5 880 1 184 335 4 381 N05C HYPNOTICS AND SEDATIVES 405 810 406 162 411 062 407 120 410 808 65 6 023 79 044 185 450 140 291 180 934 N05CA Barbiturates, plain <5 <5 <5 0 0 0 0 N05CA04 barbital <5 <5 <5 0 0 - 0 0 0 0 0 N05CC Aldehydes and derivatives 0 0 0 0 5 40 <5 <5 0 0 9 N05CC01 chloral hydrate 0 0 0 0 5 40 <5 <5 0 0 9 N05CD Benzodiazepine derivatives 44 520 41 807 39 255 34 101 28 367 58 1 192 5 465 11 539 10 171 18 439 N05CD01 flurazepam 20 17 16 16 16 50 0 0 7 9 53 N05CD02 nitrazepam 35 856 33 406 31 315 27 880 24 446 60 316 4 332 10 394 9 404 8 317 N05CD03 flunitrazepam 8 479 7 690 6 971 5 780 1 185 49 0 241 635 309 2 631 N05CD04 estazolam <5 0 0 0 0 - 0 0 0 0 0 N05CD05 triazolam 105 115 98 107 91 56 0 27 36 28 90 N05CD08 midazolam 1 071 1 493 1 759 2 255 3 117 47 995 1 016 625 481 7 348 N05CF Benzodiazepine related drugs 351 044 349 542 352 287 355 331 355 049 66 63 58 651 166 861 129 474 124 617 N05CF01 zopiclone 308 363 305 048 306 107 306 438 303 992 66 49 46 150 141 911 115 882 105 568 N05CF02 zolpidem 53 835 55 244 56 956 61 114 62 261 66 14 15 397 29 902 16 948 19 049 N05CF03 zaleplon 7 <5 0 0 0 - 0 0 0 0 0 N05CH Melatonin receptor agonists 38 868 42 795 48 436 53 571 56 177 60 5 015 22 745 20 937 7 480 35 515 N05CH01 melatonin 38 868 42 795 48 436 53 571 56 177 60 5 015 22 745 20 937 7 480 35 515 N05CM Other hypnotics and sedatives 1 944 2 109 2 131 2 141 2 087 47 0 161 550 1 376 2 354 N05CM02 clomethiazole 1 870 2 048 2 057 2 007 1 986 47 0 140 509 1 337 2 198 N05CM05 scopolamine 77 65 75 89 65 54 0 <5 23 40 105ATC group N ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 0 18 19 <5 51 N05CM09 Valerianae radix 0 0 0 33 <5 0 0 0 0 0 N05CM11 bromides 0 0 <5 <5 0 - 0 0 0 0 0 N06 PSYCHOANALEPTICS 325 942 333 134 341 017 349 413 353 980 63 11 105 119 649 147 825 75 401 558 153 N06A ANTIDEPRESSANTS 292 396 297 124 303 747 310 242 313 336 66 644 102 509 144 598 65 585 288 610 N06AA Non-selective monoamine reuptake inhibitors 60 237 61 908 63 098 64 758 65 888 72 87 16 665 35 298 13 838 27 129 N06AA02 imipramine 34 26 22 19 21 62 <5 <5 8 9 58 N06AA04 clomipramine 3 276 3 080 2 907 2 714 2 602 70 12 414 1 504 672 2 080 N06AA05 opipramol 5 6 6 9 5 40 0 0 <5 <5 11 N06AA06 trimipramine 11 930 11 431 10 943 10 553 9 890 70 <5 1 923 5 056 2 907 6 306 N06AA07 lofepramine 15 13 12 11 9 56 0 <5 5 <5 51 N06AA09 amitriptyline 40 585 43 086 45 318 47 831 49 857 73 67 13 811 27 248 8 731 16 347 N06AA10 nortriptyline 1 837 2 104 1 983 1 980 1 996 68 <5 589 938 468 690 N06AA12 doxepin 3 348 3 017 2 749 2 496 2 280 69 0 161 935 1 184 1 585 N06AA21 maprotiline <5 <5 <5 <5 0 0 0 N06AB Selective serotonin reuptake inhibitors 178 930 180 612 184 013 186 449 185 672 66 534 66 420 81 396 37 322 150 351 N06AB03 fluoxetine 9 010 9 289 9 634 10 578 10 750 76 175 6 295 3 593 687 15 485 N06AB04 citalopram 32 885 30 680 29 143 27 158 25 200 69 6 5 753 12 505 6 936 16 582 N06AB05 paroxetine 17 508 16 895 16 172 15 536 14 828 69 <5 3 073 8 090 3 663 14 268 N06AB06 sertraline 26 427 26 384 27 181 28 814 29 740 66 348 12 044 12 171 5 177 29 506 N06AB08 fluvoxamine 620 603 586 552 559 55 0 222 265 72 1 011 N06AB10 escitalopram 98 493 102 626 107 172 109 487 109 896 65 26 41 455 46 709 21 706 73 500 N06AF Monoamine oxidase inhibitors, non-selective 111 111 102 95 97 62 0 27 51 19 1 099 N06AF03 phenelzine 102 102 94 88 91 60 0 25 48 18 574 N06AF04 tranylcypromine 9 9 9 7 <5 <5 525 N06AG Monoamine oxidase A inhibitors 965 880 853 758 738 64 <5 171 412 154 1 649 N06AG02 moclobemide 965 880 853 758 738 64 <5 412 154 1 649 N06AX Other antidepressants 90 568 92 850 95 460 98 898 101 299 60 38 31 666 46 252 23 343 108 382 N06AX01 oxitriptan 244 261 308 293 276 79 7 160 98 11 325 N06AX02 tryptophan 5 <5 <5 12 N06AX03 mianserin 31 289 30 307 29 477 28 143 27 133 61 11 6 127 13 004 7 991 10 305 N06AX05 trazodone <5 <5 <5 0 12 N06AX06 nefazodone 43 42 36 36 30 47 0 <5 27 <5 293 N06AX11 mirtazapine 30 394 31 458 33 331 35 820 36 953 57 8 10 228 15 424 11 293 29 086 N06AX12 bupropion 5 978 7 641 8 808 10 205 11 330 59 <5 5 616 4 863 850 21 402ATC group N ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 69 N06AX16 venlafaxine 28 734 28 791 29 240 30 295 31 108 62 11 11 414 15 108 4 575 34 549 N06AX18 reboxetine 530 512 424 413 383 66 0 168 182 33 792 N06AX21 duloxetine 2 419 2 804 3 021 3 203 3 503 67 0 1 064 1 913 526 11 361 N06AX22 agomelatine 0 28 22 15 18 61 0 <5 14 <5 175 N06AX25 Hyperici herba 0 0 0 <5 0 - 0 0 0 0 0 N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS 27 837 30 080 31 221 33 009 34 763 38 10 621 20 661 3 321 160 200 254 N06BA Centrally acting sympathomimetics 27 490 29 711 30 821 32 609 34 369 38 10 616 20 453 3 186 114 199 614 N06BA01 amfetamine 269 303 336 383 402 44 28 260 99 15 7 336 N06BA02 dexamfetamine 1 024 1 167 1 285 1 473 1 691 45 61 1 150 456 24 22 248 N06BA04 methylphenidate 24 240 26 471 27 302 28 993 30 397 38 9 953 17 893 2 492 59 136 353 N06BA07 modafinil 291 329 349 366 436 60 22 268 127 19 4 882 N06BA09 atomoxetine 3 213 3 055 3 108 3 036 3 282 35 1 199 1 909 172 <5 28 578 N06BA12 lisdexamfetamine 0 0 0 <5 26 54 <5 18 <5 0 217 N06BC Xanthine derivatives 281 285 326 322 309 51 <5 171 103 34 168 N06BC01 caffeine 281 285 326 322 309 51 <5 171 103 34 168 N06BX Other psychostimulants and nootropics 75 102 86 88 95 45 <5 44 35 12 472 N06BX03 piracetam 65 77 70 77 84 44 <5 35 35 12 284 N06BX13 idebenone 10 8 10 11 11 55 <5 9 0 0 188 N06BX17 adrafinil 0 18 6 0 0 - 0 0 0 0 0 N06C PSYCHOLEPTICS AND PSYCHOANALEPTICS IN COMBINATION 0 0 0 <5 0 - 0 0 0 0 0 N06CA Antidepressants in combination with psycholeptics 0 0 0 <5 0 - 0 0 0 0 0 N06CA02 melitracen and psycholeptics 0 0 0 <5 0 - 0 0 0 0 0 N06D ANTI-DEMENTIA DRUGS 13 344 14 174 14 759 15 519 15 483 62 <5 32 1 505 13 944 69 290 N06DA Anticholinesterases 12 372 12 920 12 850 13 047 12 995 62 0 6 1 297 11 692 50 614 N06DA02 donepezil 9 243 8 920 8 530 8 320 7 960 64 0 5 762 7 193 22 334 N06DA03 rivastigmine 2 975 3 935 4 303 4 776 5 146 60 0 <5 556 4 589 25 873 N06DA04 galantamine 558 502 395 347 301 56 0 0 37 264 2 407 N06DX Other anti-dementia drugs 1 538 1 969 3 030 3 598 3 682 60 <5 26 422 3 232 18 676 N06DX01 memantine 1 538 1 816 2 837 3 467 3 645 60 0 <5 411 3 231 18 664 N06DX02 Ginkgo folium 0 153 193 131 37 76 <5 23 11 <5 12ATC group N ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 15-44 45-69 70 SYSTEM DRUGS 46 042 47 182 48 455 45 131 50 686 52 55 17 204 29 951 3 476 283 947 N07A PARASYMPATHOMIMETICS 721 660 684 733 747 65 <5 117 359 267 2 553 N07AA Anticholinesterases 493 509 523 568 591 60 <5 104 256 227 1 245 N07AA01 neostigmine 0 0 0 0 <5 0 <5 0 0 0 15 N07AA02 pyridostigmine 492 505 519 566 588 60 0 <5 <5 - 0 0 0 0 0 N07AB Choline esters 112 22 33 30 29 66 0 <5 19 8 38 N07AB01 carbachol 112 22 33 30 29 66 0 <5 19 8 38 N07AX Other parasympathomimetics 123 130 131 138 131 91 0 11 88 32 1 269 N07AX01 pilocarpine 123 130 131 138 131 91 0 11 88 32 1 269 N07B DRUGS USED IN ADDICTIVE DISORDERS 44 554 45 745 46 701 41 867 47 793 52 38 16 748 28 141 2 866 207 996 N07BA Drugs used in nicotine dependence 34 174 34 822 35 032 29 885 23 082 55 <5 7 219 14 431 1 431 34 441 N07BA01 nicotine 1)769 906 1 000 916 928 49 0 111 552 265 572 N07BA03 varenicline 33 475 34 002 34 123 29 045 22 201 55 <5 7 113 13 916 1 171 33 869 N07BB Drugs used in alcohol dependence 4 984 4 866 4 953 4 948 17 479 58 35 5 397 10 654 1 393 13 034 N07BB01 disulfiram 4 533 4 450 4 541 4 523 4 315 29 0 1 384 2 678 253 2 966 N07BB03 acamprosate 550 526 543 588 580 32 0 170 378 32 862 N07BB04 naltrexone 26 19 17 14 11 314 73 35 3 535 6 711 1 033 7 797 N07BB05 nalmefene 0 0 0 0 1 722 30 <5 458 1 170 93 1 410 N07BC Drugs used in opioid dependence 5 704 6 368 7 048 7 353 7 736 31 <5 4 311 3 367 56 160 521 N07BC01 buprenorphine 2)1 981 2 133 2 270 2 465 2 650 30 0 1 632 1 015 <5 48 680 N07BC02 methadone2)3 140 3 337 3 636 3 631 3 718 34 <5 1 710 1 954 52 83 032 N07BC51 buprenorphine, combinations 2)1 194 1 562 1 759 1 925 2 012 25 0 1 419 592 <5 28 809 N07C ANTIVERTIGO PREPARATIONS 421 424 454 531 66 325 Antivertigo preparations 421 424 454 531 555 66 305 138 1 325 N07CA01 betahistine 410 413 438 512 535 66 <5 100 296 138 1 298 N07CA03 flunarizine 11 11 16 19 20 70 <5 10 9 0 27 N07X OTHER NERVOUS SYSTEM DRUGS 361 366 644 2 061 2 114 60 12 300 1 556 246 72 072 N07XX Other nervous system drugs 361 366 644 2 061 2 114 60 12 300 1 556 246 72 072ATC group N ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only. 2) The figures only include methadone dispensed according to prescription from the pharmacies. Patients may also receive this drug dispensed according to special arrangements in the health regions. 90 Legemiddelstatistikk 2014:2 FolkehelseinstituttetN07XX02 riluzole 286 278 294 297 285 37 0 17 161 107 4 141 N07XX04 sodium oxybate 33 49 58 63 84 57 10 54 17 <5 6 387 N07XX05 amifampridine 0 0 0 <5 0 2 766 N07XX06 tetrabenazine 42 37 35 41 43 49 <5 11 24 7 791 N07XX07 fampridine 0 <5 257 1 659 1 692 1 351 129 57 313 N07XX09 dimethyl fumarate 0 0 0 0 8 63 0 7 <5 0 674ATC group N ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 88 743 92 296 95 141 96 547 62 3 632 43 659 38 204 11 052 36 412 P01 ANTIPROTOZOALS 83 638 85 626 88 926 91 618 92 720 63 2 396 41 873 37 582 10 869 34 292 P01A AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES 54 583 55 588 57 290 58 106 58 337 65 676 24 828 24 363 8 470 6 694 P01AB Nitroimidazole derivatives 54 576 55 587 57 289 58 103 58 335 65 675 24 827 24 363 8 470 6 673 P01AB01 metronidazole 54 571 55 540 57 236 58 039 58 227 65 670 24 770 24 317 8 470 6 218 P01AB02 tinidazole 7 6 9 124 149 68 6 79 62 <5 452 P01AB03 ornidazole 0 46 73 9 0 - 0 0 0 0 0 P01AB06 nimorazole 0 0 0 <5 <5 0 0 0 <5 0 2 P01AC Dichloroacetamide derivatives 13 <5 11 12 9 56 <5 5 <5 0 21 P01AC01 diloxanide 13 <5 11 12 9 56 <5 5 <5 0 21 P01AX Other agents against amoebiasis and other protozoal diseases <5 <5 0 0 0 - 0 0 0 0 0 P01AX11 nitazoxanide <5 <5 0 0 0 - 0 0 0 0 0 P01B ANTIMALARIALS 29 645 30 716 32 446 34 304 35 069 59 1 727 17 369 13 530 2 443 27 595 P01BA Aminoquinolines 5 421 5 684 5 912 6 128 6 131 82 37 1 619 3 411 1 064 3 583 P01BA01 chloroquine 40 21 17 22 14 79 0 <5 8 <5 15 P01BA02 hydroxychloroquine 5 371 5 661 5 897 6 107 6 112 82 37 1 612 3 402 1 061 3 553 P01BA03 primaquine 12 <5 0 6 14 P01BB Biguanides 19 494 20 468 21 918 23 899 24 803 54 1 196 13 559 9 002 1 046 22 150 P01BB01 proguanil 22 11 7 <5 <5 100 0 <5 <5 0 2 P01BB51 proguanil, combinations 19 476 20 459 21 913 23 898 24 799 54 1 196 13 557 9 000 1 046 22 148 P01BC Methanolquinolines 5 044 4 802 4 841 4 473 4 312 58 498 2 296 1 178 340 1 857 P01BC01 quinine 629 569 473 439 396 65 0 14 161 221 264 P01BC02 mefloquine 4 415 4 235 4 368 4 035 3 917 57 498 2 282 1 017 120 1 594 P01BD Diaminopyrimidines 5 <5 0 0 0 - 0 0 0 0 0 P01BD01 pyrimethamine 5 <5 0 0 0 - 0 0 0 0 0 P01BE Artemisinin and derivatives, plain 0 0 0 <5 <5 0 0 <5 0 0 2 P01BE03 artesunate 0 0 0 <5 <5 0 0 0 2 AND 100 <5 0 32.15 ATC group P - Antiparasitic products, insecticides and repellents ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK <15 15-44 45-69 70 3 P02 ANTHELMINTICS 2 047 2 107 2 224 2 315 2 388 57 1 057 857 378 96 1 235 P02B ANTITREMATODALS 19 26 41 50 55 51 <5 39 13 <5 161 P02BA Quinoline derivatives and related substances 19 26 41 50 55 51 <5 39 13 <5 161 P02BA01 praziquantel 19 26 41 50 55 51 <5 39 13 <5 161 P02C ANTINEMATODAL AGENTS 2 016 2 068 2 171 2 262 2 330 57 1 054 814 367 95 1 060 P02CA Benzimidazole derivatives 1 870 1 900 2 004 2 070 2 127 56 1 000 704 341 82 952 P02CA01 mebendazole 1 847 1 877 1 960 2 006 1 993 55 978 638 299 78 386 P02CA03 albendazole 24 23 45 70 140 68 25 68 43 <5 566 P02CF Avermectines 47 62 58 80 86 60 7 56 18 5 90 P02CF01 ivermectin 47 62 58 80 86 60 7 56 18 5 90 P02CX Other antinematodals 114 120 119 128 139 71 56 63 10 10 19 P02CX01 pyrvinium 114 120 119 128 139 71 56 63 10 10 19 P02D ANTICESTODALS 18 18 26 13 16 44 <5 12 <5 0 14 P02DA Salicylic acid derivatives 18 18 26 13 16 44 <5 12 <5 0 14 P02DA01 niclosamide 18 18 26 13 16 <5 12 0 14 P03 ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS 1 157 1 176 1 297 1 374 1 688 50 205 1 062 322 99 885 P03A ECTOPARASITICIDES, INCL. SCABICIDES 1 157 1 176 1 297 1 374 1 688 50 205 1 062 322 99 885 P03AC Pyrethrines, incl. synthetic compounds 1 085 1 093 1 222 1 298 1 618 49 192 1 029 300 97 861 P03AC04 permethrin 1)1 085 1 093 1 222 1 298 1 618 49 192 1 029 300 97 861 P03AX Other ectoparasiticides, incl. scabicides 77 86 82 84 80 14 41 23 <5 24 P03AX01 benzyl benzoate 1)18 24 28 21 34 59 6 21 6 <5 11 P03AX03 malathion1)59 62 54 63 47 60 9 20 17 <5 13 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group P ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 15-44 45-69 70 Legemiddelstatistikk 2014:2 Folkehelseinstituttet 93R RESPIRATORY SYSTEM 1 183 767 1 183 735 1 223 490 1 239 078 1 220 116 56 159 501 441 102 449 667 169 846 1 363 495 R01 NASAL PREPARATIONS 348 415 353 908 364 669 376 523 376 766 57 30 790 174 044 139 735 32 197 105 797 R01A DECONGESTANTS AND OTHER NASAL PREPARA - TIONS FOR TOPICAL USE 294 861 297 143 307 141 316 067 316 889 56 29 575 141 622 116 543 29 149 99 550 R01AA Sympathomimetics, plain 3 803 4 017 3 672 3 650 3 520 52 1 127 1 181 865 347 266 R01AA05 oxymetazoline1)1 550 1 802 1 781 1 847 1 824 54 854 539 307 124 121 R01AA07 xylometazoline1)2 264 2 233 1 899 1 812 1 700 51 273 643 561 223 1)514 602 603 468 387 68 R01AC Antiallergic agents, excl. corticosteroids 44 853 39 407 40 956 39 433 38 277 56 9 782 18 085 8 870 1 540 10 213 R01AC01 cromoglicic acid 1)10 197 8 772 8 705 7 943 7 646 59 1 674 3 489 2 121 362 2 014 R01AC02 levocabastine1)34 686 30 659 32 377 31 556 30 702 55 8 165 14 614 6 751 1 172 8 164 R01AC03 azelastine1)227 198 127 151 132 58 15 67 39 11 36 R01AD Corticosteroids 252 559 259 097 267 954 278 421 279 941 56 19 624 124 856 108 195 27 266 88 406 R01AD01 beclometasone 1 943 11 <5 0 0 - 0 0 0 0 0 R01AD04 flunisolide 2 634 11 9 10 10 60 0 0 6 <5 18 R01AD05 budesonide 39 753 34 996 32 644 31 215 28 699 57 1 459 10 673 13 064 3 503 10 406 R01AD08 fluticasone 27 939 24 352 22 518 21 931 21 129 55 919 7 645 9 829 2 736 9 386 R01AD09 mometasone 143 465 141 114 144 414 151 022 152 995 56 9 341 67 572 60 361 15 721 47 677 R01AD11 triamcinolone 11 025 9 687 8 713 7 889 6 924 57 293 2 747 3 072 812 2 821 R01AD12 fluticasone furoate 38 322 60 417 70 241 77 348 79 316 56 8 001 40 135 25 800 5 380 17 569 R01AD58 fluticasone, combinations 0 0 0 0 1 551 54 75 822 517 137 527 R01AX Other nasal preparations 572 630 728 836 1 000 52 64 283 311 342 597 R01AX03 ipratropium bromide 302 355 422 469 534 51 185 293 440 R01AX06 mupirocin 270 276 306 367 466 53 63 228 126 49 157 R01B NASAL DECONGESTANTS FOR SYSTEMIC USE 75 490 81 771 83 161 88 700 89 209 67 1 640 48 028 34 998 4 543 6 246 R01BA Sympathomimetics 75 490 81 771 83 161 88 700 89 209 67 1 640 48 028 34 998 4 543 6 246 R01BA01 phenylpropanolamine 75 490 81 771 83 161 88 700 89 207 67 1 640 48 028 34 996 4 543 6 235 R01BA52 pseudoephedrine, combinations 0 0 0 0 <5 50 0 0 <5 0 12 R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 419 368 423 205 418 109 420 887 418 306 54 81 746 107 422 152 534 76 604 1 013 119 R03A ADRENERGICS, INHALANTS 328 514 335 492 347 921 354 853 357 307 54 57 184 97 977 136 035 66 111 680 822 R03AA Alpha- and beta- adrenoreceptor agonists 181 209 246 188 9 <5 0 171 R03AA01 epinephrine 181 209 246 251 201 35 188 9 <5 0 171 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.2.16 ATC group R - Respiratory system ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 NOK 244 327 249 080 258 858 265 033 266 976 54 54 565 75 258 93 661 43 492 137 211 R03AC02 salbutamol 190 769 198 277 208 540 216 082 219 571 54 53 185 62 233 72 287 31 866 71 249 R03AC03 terbutaline 38 318 35 556 34 151 32 149 29 979 57 1 323 11 197 12 701 4 758 10 860 R03AC04 fenoterol 17 17 16 12 14 36 0 <5 11 <5 29 R03AC12 salmeterol 10 555 10 563 9 699 9 202 8 885 56 207 1 011 4 173 3 494 15 100 R03AC13 formoterol 16 879 16 627 15 456 14 434 13 601 56 277 2 775 6 686 3 863 17 892 R03AC18 indacaterol 0 713 4 814 7 450 9 343 46 0 195 4 938 4 210 22 081 R03AK Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics 164 535 168 449 175 117 178 269 180 135 56 9 205 47 246 81 459 42 225 543 440 R03AK06 salmeterol and fluticasone 90 149 90 997 94 190 95 885 94 551 55 7 557 22 444 40 708 23 842 306 202 R03AK07 formoterol and budesonide 76 239 79 114 82 417 83 238 83 758 56 1 605 23 847 39 846 18 460 226 346 R03AK08 formoterol and beclometasone 1 522 1 783 1 942 2 795 4 443 58 35 1 496 2 194 718 7 459 R03AK11 formoterol and fluticasone 0 0 0 0 2 239 58 97 741 1 051 350 3 433 R03AL Adrenergics in combination with anticholinergics <5 <5 0 0 0 - 0 0 0 R03AL02 salbutamol and ipratropium bromide <5 <5 0 0 0 - 0 0 0 0 0 R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS 140 443 146 450 149 797 152 867 153 128 51 41 257 21 544 51 923 38 404 257 374 R03BA Glucocorticoids 88 434 91 633 92 760 94 053 91 993 51 40 963 18 515 22 691 9 824 76 144 R03BA01 beclometasone 4 729 4 380 4 075 4 021 3 713 55 750 908 1 375 680 3 091 R03BA02 budesonide 25 860 25 066 23 194 21 290 19 625 57 2 355 5 063 8 027 4 180 24 177 R03BA05 fluticasone 59 302 62 013 64 095 63 972 61 703 47 38 208 9 994 9 683 3 818 39 025 R03BA07 mometasone <5 <5 0 546 703 53 66 289 273 75 917 R03BA08 ciclesonide 0 1 874 3 476 6 104 8 080 58 550 2 589 3 728 1 213 8 934 R03BB Anticholinergics 57 032 60 133 62 625 64 442 66 894 52 689 3 722 31 806 30 180 997 R03BB01 ipratropium bromide 39 555 38 289 35 884 32 181 28 751 57 688 3 114 12 772 12 177 21 875 R03BB04 tiotropium bromide 22 767 27 429 32 809 39 704 41 458 48 <5 622 20 363 20 470 153 377 R03BB05 aclidinium bromide 0 0 0 0 1 794 683 2 557 R03BB06 glycopyrronium bromide 0 0 0 0 1 899 49 0 49 1 032 818 3 187 R03BC Antiallergic agents, excl. corticosteroids 521 454 430 39 233 R03BC01 cromoglicic acid 521 454 430 383 345 66 24 114 168 39 233 R03C ADRENERGICS FOR SYSTEMIC USE 68 733 63 272 40 582 33 966 27 069 49 19 921 2 690 3 291 1 167 3 651 R03CA Alpha- and beta- adrenoreceptor agonists 55 608 49 364 23 993 17 522 12 615 50 8 216 1 785 2 017 597 2 064 R03CA02 ephedrine 55 608 49 364 23 993 17 522 12 615 50 8 216 1 785 2 017 597 2 064ATC group R ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 16 104 16 917 17 886 17 339 14 953 48 12 177 917 1 285 574 1 587 R03CC02 salbutamol 4 877 4 731 4 844 4 351 3 497 47 2 840 236 281 140 262 R03CC03 terbutaline 11 149 12 109 12 968 12 926 11 371 48 9 449 661 905 356 1 097 R03CC12 bambuterol 238 245 210 219 206 55 0 21 107 78 228 R03D OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 40 012 41 123 42 178 42 327 41 450 56 8 029 10 347 16 308 6 766 71 273 R03DA Xanthines 5 287 4 785 4 300 3 856 3 431 60 5 196 1 685 1 545 2 475 R03DA02 choline theophyllinate 8 10 6 8 7 100 0 <5 6 0 31 R03DA04 theophylline 5 272 4 768 4 288 3 844 3 417 60 5 192 1 676 1 544 2 374 R03DA05 aminophylline 26 19 19 14 17 65 0 <5 11 <5 69 R03DC Leukotriene receptor antagonists 35 710 37 220 38 267 38 587 37 874 56 8 017 10 146 14 661 5 050 40 039 R03DC01 zafirlukast 25 22 22 21 19 63 0 <5 10 8 202 R03DC03 montelukast 35 686 37 199 38 245 38 567 37 857 56 8 017 10 145 14 652 5 043 39 837 R03DX Other systemic drugs for obstructive airway diseases 53 145 751 1 058 1 303 49 18 155 637 493 28 758 R03DX05 omalizumab 53 84 133 175 256 59 18 139 94 5 25 264 R03DX07 roflumilast 0 61 620 885 1 049 47 0 16 545 488 3 494 R05 COUGH AND COLD PREPARATIONS 385 148 382 371 422 433 413 274 375 144 59 25 725 119 313 158 652 71 454 67 953 R05C EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS 133 512 135 840 147 156 135 972 113 567 57 5 525 23 052 48 326 36 664 29 677 R05CA Expectorants 3 334 3 671 4 351 3 935 3 977 55 1 726 872 864 515 288 R05CA10 combinations 1)3 334 3 671 4 351 3 935 3 977 55 1 726 872 864 515 288 R05CB Mucolytics 130 752 132 821 143 557 132 685 110 178 57 3 870 22 309 47 688 36 311 29 389 R05CB01 acetylcysteine1)126 968 128 953 139 329 128 839 106 696 57 2 486 21 649 46 895 35 666 22 149 R05CB02 bromhexine1)4 561 4 658 4 974 4 549 4 134 54 1 383 760 1 059 932 679 R05CB12 tiopronin 5 5 alfa (desoxyribonu - clease) 109 118 128 130 129 50 41 76 11 <5 6 537 R05D COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS 258 842 254 586 283 928 281 002 259 319 60 18 354 91 366 111 630 37 969 33 797 R05DA Opium alkaloids and derivatives 258 842 254 586 283 928 281 002 259 319 60 18 354 91 366 111 630 37 969 33 797 R05DA01 ethylmorphine 249 476 245 677 274 413 271 657 250 796 60 18 005 88 676 107 603 36 512 30 954 R05DA03 hydrocodone 581 592 592 543 514 62 <5 84 281 147 187 R05DA04 codeine 7 715 7 203 7 752 7 704 6 904 64 77 2 437 3 309 1 081 1 762 R05DA07 noscapine 1)1 763 1 880 1 952 1 664 1 636 60 298 476 593 269 152 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group R ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 1 R05DA20 combinations 3 036 2 836 2 918 2 979 2 631 62 16 709 1 445 461 742 R05F COUGH SUPPRESSANTS AND EXPECTORANTS, COMBINATIONS 41 525 41 844 48 192 49 235 46 193 62 2 840 16 573 19 768 7 012 4 479 R05FA Opium derivatives and expectorants 41 525 41 844 48 192 49 235 46 193 62 2 840 16 573 19 768 7 012 4 479 R05FA02 opium derivatives and expectorants 41 525 41 844 48 192 49 235 46 193 62 2 840 16 573 19 768 7 012 4 479 R06 ANTIHISTAMINES FOR SYSTEMIC USE 519 116 511 537 529 217 544 575 555 485 59 72 192 228 452 198 865 55 976 161 378 R06A ANTIHISTAMINES FOR SYSTEMIC USE 519 116 511 537 529 217 544 575 555 485 59 72 192 228 452 198 865 55 976 161 378 R06AA Aminoalkyl ethers 18 15 14 23 29 66 <5 10 9 8 36 R06AA02 diphenhydramine <5 <5 0 11 55 0 7 <5 <5 6 R06AA04 clemastine 14 14 14 17 18 72 <5 <5 7 6 29 R06AB Substituted alkylamines 35 818 25 263 22 719 20 363 19 417 67 4 377 7 068 5 420 2 552 5 641 R06AB02 dexchlorpheniramine 35 818 25 263 22 719 20 363 19 417 67 4 377 7 068 5 420 2 552 5 641 R06AD Phenothiazine derivatives 62 798 64 453 65 875 66 127 66 678 62 3 639 23 906 29 361 9 772 34 934 R06AD01 alimemazine 56 465 57 913 59 728 60 223 60 961 62 3 587 21 603 26 924 8 847 32 253 R06AD02 promethazine 6 991 7 154 6 719 6 464 6 242 68 54 2 527 2 689 972 2 671 R06AD03 thiethylperazine <5 5 11 R06AE Piperazine derivatives 294 720 285 404 293 955 285 833 277 991 59 37 525 109 473 100 565 30 428 56 389 R06AE03 cyclizine 1)655 737 759 731 774 71 15 219 349 191 389 R06AE05 meclozine1)1 956 2 031 2 165 2 271 2 613 88 89 1 943 373 208 246 R06AE07 cetirizine1)291 604 282 294 290 730 282 583 274 382 58 37 420 107 239 99 718 30 005 55 259 R06AE09 levocetirizine 844 703 661 611 572 63 12 262 245 53 495 R06AX Other antihistamines for systemic use 164 938 169 564 178 145 206 281 223 948 59 30 493 101 709 75 409 16 337 64 378 R06AX02 cyproheptadine 59 40 17 24 31 58 6 <5 12 9 20 R06AX13 loratadine 1)92 307 83 864 82 823 71 385 61 729 61 3 188 27 904 24 245 6 392 15 676 R06AX17 ketotifen <5 7 <5 10 R06AX22 ebastine1)11 035 10 315 10 432 9 816 9 205 66 120 3 930 4 274 881 7 189 R06AX26 fexofenadine 24 496 27 017 30 412 29 345 29 771 62 708 15 293 11 259 2 511 10 075 R06AX27 desloratadine 48 971 55 048 60 505 103 482 129 266 57 26 786 57 704 37 816 6 960 31 407 R07 OTHER RESPIRATORY SYSTEM PRODUCTS 0 0 0 <5 12 50 <5 8 0 0 15 248 R07A OTHER RESPIRATORY SYSTEM PRODUCTS 0 0 0 <5 12 50 <5 8 0 0 15 248 R07AX Other respiratory system products 0 0 0 <5 9 33 <5 7 0 0 15 231 R07AX02 ivacaftor 0 0 0 <5 9 33 <5 7 0 0 15 231 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group R ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 618 314 612 715 57 110 059 175 648 155 301 674 S01 OPHTHALMOLOGICALS 526 629 538 818 549 815 547 600 540 362 58 96 802 152 891 167 700 122 969 286 482 S01A ANTIINFECTIVES 250 367 269 034 266 933 262 214 249 591 55 69 067 72 654 72 004 35 866 43 884 S01AA Antibiotics 247 638 266 185 264 028 259 211 246 579 55 68 931 71 627 70 766 35 255 42 446 S01AA01 chloramphenicol 182 292 197 212 200 731 197 307 185 720 55 44 299 56 530 56 960 27 931 35 016 S01AA02 chlortetracycline <5 <5 <5 <5 0 0 S01AA11 gentamicin 1 763 1 702 1 597 1 252 111 53 7 41 37 26 15 S01AA12 tobramycin 2 332 2 302 2 322 2 028 1 783 56 212 548 613 410 171 S01AA13 fusidic acid 75 838 82 810 75 325 71 484 64 306 57 27 388 15 436 13 903 7 579 5 626 S01AA26 azithromycin 0 0 0 2 795 8 981 60 2 917 2 615 2 400 1 049 949 S01AA30 combinations of different antibiotics 4 936 5 105 5 269 4 340 4 797 58 271 1 065 1 855 1 606 668 S01AD Antivirals 3 249 3 266 3 171 3 399 3 230 56 120 911 1 372 827 810 S01AD01 idoxuridine <5 0 0 0 0 - 0 0 0 0 0 S01AD03 aciclovir 3 248 3 266 3 171 3 399 3 230 56 120 911 1 372 827 810 S01AE Fluoroquinolones 1 982 2 138 2 327 2 468 2 613 55 150 1 002 988 473 616 S01AE03 ciprofloxacin 1 982 2 138 2 327 2 468 2 613 55 150 1 002 988 473 616 S01AX Other 0 0 0 0 <5 100 0 0 0 3 S01AX15 propamidine 0 0 <5 0 0 <5 0 0 S01B ANTIINFLAMMATORY AGENTS 44 119 45 945 46 769 49 872 51 179 58 1 750 9 100 18 909 21 420 15 850 S01BA Corticosteroids, plain 30 111 30 638 31 478 33 551 33 532 58 1 709 8 087 13 529 10 207 10 495 S01BA01 dexamethasone 18 319 18 993 20 148 20 502 20 553 55 529 4 500 8 877 6 647 7 161 S01BA04 prednisolone 12 418 11 840 10 925 13 613 13 742 59 1 129 4 280 5 361 2 972 2 167 S01BA07 fluorometholone 17 16 12 12 7 57 0 0 5 <5 10 S01BA09 clobetasone 18 16 13 16 15 53 <5 <5 7 <5 42 S01BA13 rimexolone 4 177 4 351 4 414 4 285 4 162 58 194 1 024 1 591 1 353 1 115 S01BB Corticosteroids Antiinflammatory agents, non-steroids 15 618 17 141 17 568 18 734 20 187 58 47 1 441 6 325 12 374 5 354 S01BC03 diclofenac 15 618 15 814 11 689 7 413 6 137 56 37 969 2 182 2 949 1 315 S01BC10 nepafenac 0 1 528 6 095 10 294 9 113 58 8 219 2 694 6 192 2 869 S01BC11 bromfenac 0 0 0 1 372 5 325 58 <5 266 1 582 3 473 1 171 S01C ANTIINFLAMMATORY AGENTS AND ANTIINFEC - TIVES IN COMBINATION 56 226 56 906 57 674 57 855 57 314 58 1 082 8 618 20 464 27 150 10 9412.17 ATC group S - Sensory organs ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 in combination 56 226 56 906 57 674 57 855 57 314 58 1 082 8 618 20 464 27 150 10 941 S01CA01 dexamethasone and anti-infectives 56 226 56 906 57 674 57 855 57 314 58 1 082 8 618 20 464 27 150 10 941 S01E ANTIGLAUCOMA PREPARATIONS AND MIOTICS 68 940 70 039 70 786 71 402 72 192 56 215 2 134 21 767 48 076 129 995 S01EA Sympathomimetics in glaucoma therapy 3 992 4 077 4 222 4 446 4 920 53 5 182 1 344 3 389 4 346 S01EA01 epinephrine dipivefrine 122 9 <5 0 0 - 0 0 0 0 0 S01EA03 apraclonidine 97 115 122 145 155 58 0 15 54 86 79 S01EA05 brimonidine 3 838 3 983 4 122 4 351 4 805 53 5 170 1 303 3 327 4 265 S01EB Parasympathomimetics 1 433 1 291 1 254 1 179 1 012 60 <5 52 271 686 1 031 S01EB01 pilocarpine 1 431 1 289 1 253 1 178 1 012 60 <5 52 S01EC Carbonic anhydrase inhibitors 9 634 10 040 10 322 10 647 10 892 57 123 698 2 823 7 248 12 683 S01EC01 acetazolamide 1 531 1 699 1 828 1 926 1 840 55 42 542 635 621 1 025 S01EC03 dorzolamide 2 660 2 503 2 393 2 342 2 357 58 15 51 571 1 720 2 853 S01EC04 brinzolamide 5 811 6 195 6 452 6 759 7 109 56 71 120 1 743 5 175 8 805 S01ED Beta blocking agents 48 377 48 841 49 028 49 468 49 878 56 148 1 219 15 018 33 493 63 972 S01ED01 timolol 22 977 22 326 21 731 21 600 21 606 57 131 568 7 286 13 621 22 525 S01ED02 betaxolol 2 012 1 778 1 587 1 433 1 247 65 <5 19 275 950 811 S01ED51 timolol, combinations 25 922 27 060 27 984 28 616 29 164 55 27 701 8 163 20 273 40 636 S01EE Prostaglandin analogues 36 048 36 697 37 171 37 056 37 446 57 26 671 10 560 26 189 47 962 S01EE01 latanoprost 28 946 27 890 26 156 24 231 23 338 57 10 355 6 112 16 861 18 837 S01EE03 bimatoprost 1 807 1 867 1 871 2 061 2 247 57 <5 59 677 1 509 3 339 S01EE04 travoprost 4 844 5 035 6 464 7 197 7 095 55 <5 117 2 037 4 938 11 036 S01EE05 tafluprost 1 654 3 068 4 029 4 999 5 994 63 13 160 2 120 3 701 14 748 S01F MYDRIATICS AND CYCLOPLEGICS 4 899 5 066 5 041 5 318 5 318 47 405 1 251 2 383 1 279 976 S01FA Anticholinergics 4 891 5 062 5 038 5 312 5 311 47 405 1 247 2 380 1 279 971 S01FA01 atropine 2 670 2 549 2 323 2 323 2 185 46 322 464 890 509 436 S01FA04 cyclopentolate 2 277 2 546 2 746 3 069 3 177 47 78 813 1 510 776 500 S01FA06 tropicamide 157 189 164 140 139 55 8 54 54 23 33 S01FA54 cyclopentolate, combinations 0 0 0 0 <5 50 0 0 <5 0 2 S01FB Sympathomimetics excl. antiglaucoma preparations 39 29 35 33 28 46 0 10 17 <5 5 S01FB01 phenylephrine 39 29 35 33 28 46 0 10 17 <5 5ATC group S ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 158 625 167 530 163 501 163 518 59 28 200 72 741 50 377 12 200 46 566 S01GA Sympathomimetics used as decongestants 23 098 20 728 21 288 20 300 19 136 61 2 106 8 630 6 728 1 672 5 673 S01GA51 naphazoline, combinations 11 <5 6 <5 0 - 0 0 0 0 0 S01GA52 tetryzoline, combinations 23 089 20 725 21 283 20 297 19 136 61 2 106 8 630 6 728 1 672 5 673 S01GX Other antiallergics 152 775 141 091 149 662 146 552 147 512 59 26 664 65 487 44 635 10 726 40 893 S01GX01 cromoglicic acid 1)25 305 22 551 23 401 22 545 21 636 62 3 067 9 114 7 612 1 843 5 350 S01GX02 levocabastine1)77 301 70 567 75 499 73 827 75 061 58 14 591 33 521 21 890 5 059 18 489 S01GX04 nedocromil 2 018 1 777 1 702 1 442 1 395 59 148 712 452 83 288 S01GX05 lodoxamide1)35 0 0 0 0 - 0 0 0 0 0 S01GX06 emedastine 490 379 384 376 345 63 58 141 111 35 113 S01GX07 azelastine 691 580 553 531 508 58 62 223 161 62 143 S01GX08 ketotifen1)17 926 16 305 17 279 16 686 17 238 60 2 956 7 596 5 378 1 308 6 906 S01GX09 olopatadine 34 046 32 856 35 349 35 456 35 267 57 6 726 15 684 10 196 2 661 9 605 S01X OTHER OPHTHALMOLOGICALS 18 266 26 371 34 504 40 602 45 774 76 360 4 506 19 555 21 353 38 222 S01XA Other ophthalmologicals 18 266 26 371 34 504 40 602 45 774 76 360 4 506 19 555 21 353 38 222 S01XA03 sodium chloride, hypertonic 20 15 17 10 15 53 0 0 <5 11 25 S01XA18 ciclosporin 41 70 112 252 474 72 17 107 256 94 6 418 S01XA20 artificial tears and other indifferent preparations 1)18 234 26 329 34 451 40 510 45 650 76 346 4 476 19 500 21 328 31 780 S02 OTOLOGICALS 14 496 14 933 20 226 18 711 20 091 54 3 260 5 369 8 146 3 316 3 887 S02A ANTIINFECTIVES 7 037 7 346 10 565 9 590 8 282 47 2 810 2 367 2 283 822 1 469 S02AA Antiinfectives 7 037 7 346 10 565 9 590 8 282 47 2 810 2 367 2 283 822 1 469 S02AA01 chloramphenicol 123 75 75 17 11 55 <5 <5 <5 <5 13 S02AA03 boric acid 14 0 <5 <5 <5 3 S02AA15 ciprofloxacin 6 937 7 290 10 501 9 576 8 264 47 2 808 2 361 2 277 818 1 453 S02B CORTICOSTEROIDS 7 724 7 847 10 185 9 549 10 784 60 245 2 725 5 506 2 308 2 135 S02BA Corticosteroids 7 724 7 847 10 185 9 549 10 784 60 245 2 725 5 506 2 308 2 135 S02BA07 betamethasone 7 724 7 847 10 185 9 549 10 784 60 245 2 725 5 506 2 308 2 135 S02C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION 70 66 104 91 1 764 50 288 520 678 278 283 S02CA Corticosteroids and anti-infectives in combination 70 66 104 91 1 764 50 288 520 678 278 283 S02CA02 flumetasone and anti infectives 70 66 104 91 64 58 <5 19 30 13 10 S02CA05 fluocinolone acetonide and antiinfectives 0 0 0 0 1 702 50 286 501 649 266 272 1) The ATC level comprises OTC medicinal products. The number of individuals is registered for prescription sales only.ATC group S ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 PREPARATIONS 75 322 77 041 68 909 73 479 73 853 54 14 028 22 537 26 694 10 594 11 304 S03C CORTICOSTEROIDS AND ANTIINFECTIVES IN COMBINATION 75 322 77 041 68 909 73 479 73 853 54 14 028 22 537 26 694 10 594 11 304 S03CA Corticosteroids and anti-infectives in combination 75 322 77 041 68 909 73 479 73 853 54 14 028 22 537 26 694 10 594 11 304 S03CA01 dexamethasone and anti-infectives 15 356 14 416 24 937 11 256 12 789 55 1 528 3 664 5 329 2 268 1 608 S03CA04 hydrocortisone and anti-infectives 62 503 65 038 47 812 64 616 63 093 53 12 755 19 502 22 173 8 663 9 696ATC group S ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales 15-44 45-69 70 Legemiddelstatistikk 2014:2 Folkehelseinstituttet 101V VARIOUS 13 317 15 898 18 601 21 869 23 890 50 3 147 7 984 8 096 4 663 83 699 V01 ALLERGENS 6 170 7 289 8 273 8 927 9 462 47 1 701 6 078 1 646 37 46 410 V01A ALLERGENS 6 170 7 289 8 273 8 927 9 462 47 1 701 6 078 1 646 37 46 410 V01AA Allergen extracts 6 170 7 289 8 273 8 927 9 462 47 1 701 6 078 1 646 37 46 410 V01AA02 grass pollen 4 021 5 033 5 758 6 330 6 829 44 1 097 4 714 1 008 10 27 195 V01AA03 house dust mites 301 349 426 488 539 46 114 341 81 <5 3 126 V01AA05 tree pollen 3 705 4 150 4 670 4 874 4 896 50 901 3 060 914 21 10 980 V01AA07 insects 185 183 181 156 160 55 17 49 84 10 762 V01AA10 flowers 90 108 141 149 149 60 13 85 51 0 736 V01AA11 animals 217 288 382 425 494 54 100 296 97 <5 3 6102.18 ATC group V - Various ATC level2009 2010 2011 2012 2013 2013 2013 Number of individualsShare of women (%)Number of individuals per age group Sales in 1000 Kjemisk (klassifikasjonssystem for Chemical (classification medicines) DDD Definert d\u00f8gndose Defined Daily Doses samarbeid FHI Folkehelseinstituttet GP General Practitioner ICD -10 International Classification of Diseases version 10 ICPC International Classification of Primary Care MA Markedsf\u00f8ringstillatelse Marketing Authorisation NIPH Norwegian Institute of Public Health NMD Norsk Medisinaldepot Norwegian Medicinal Depot (wholesaler) NOK Norske kroner NorPD Reseptregisteret Anti-Inflammatory Drug OTC Reseptfritt Over The Counter, non prescription drugs SPC Summary of Product Characteristics SSB Statistisk sentralbyr\u00e5 Statistics definerte befolkningsutvalget. Definitions PrevalenceUsers (individuals) are defined as persons who had at least one prescription dispensed at pharmacies in the period. Prevalence is defined as the number of users per 100 inhabitants (%) in the defined population sample. Incidence (new users) Incidence is the number of users of a particular drug or drug group in a defined time period who were not users in a previous, defined time period. Incidence can be expressed as a percentage relative to the number of potential users in the defined population sample. Legemiddelstatistikk 2014:2 Folkehelseinstituttet 103Folkemengde i Norge 2009-2013 (per 1. juli)/ Population in Norway 2009-2013 (as of 1st July) Y ear 2009 2010 2011 2012 2013 Population 4 829 800 4 888 946 4 953 217 5 018 415 5 080 148 Folkemengde etter alder i 2013 (per 1. juli)/ Population by age in 2013 (as of 1st July) Age groups <15 15-44 45-69 70 Population 897 813 2 055 878 1 571 928 554 530 Kilde: Statistisk sentralbyr\u00e5 / basert p\u00e5 data fra Reseptregisteret per mars 2014 / List of publications based on data from the Norwegian Prescription Database (NorPD) as of March 2014 2014: Andersen JB, Heldal AT, Engeland A, Gilhus NE. Myasthenia gravis epidemiology Romundstad P , Borchgrevink PC. Chronic pain and use of opioids: a popula- tion based pharmacoepidemiological study from the Norwegian prescription database and the Nord-Tr\u00f8ndelag health study (HUNT). Pain 2014 Mar 15. [Epub print] Grytli HH, Fagerland of b-Blockers and Prostate Cancer-Specific Survival: A Cohort Study of 3561 Prostate Cancer Patients with High-Risk or Metastatic Disease. European Urology 2014;65:635-641. Karlstad \u00d8, Furu Drugs for Attention-Deficit Hyperactivity Disorder in Opioid Maintenance Treatment Patients in Norway. Eur Addict Res 2014;20:59-65. Langballe EM, Engdahl B, Nordeng H, Ballard C, Aarsland D, Selbaek G. Short- and Long-Term Mortality Risk Associated with the Use of Antipsychotics Among 26,940 Dementia Outpatients: A Population-Based Study. Co-morbidity in persistent opioid users with chronic non-malignant pain in Norway. Eur J Pain. 2014 Jan 20. [Epub ahead of print] Nordfj\u00e6rn T, Bjerkeset psychological - tors of and Stene LC, Drivvoll AK, Strom H, Joner G. Incidence of type 1 diabetes in Norway among children aged 0-14 years between 1989 and 2012: has the incidence stopped rising? Results from the Norwegian Childhood Diabetes Registry. Diabetologia 2014;57:57-62. K, Fredheim S, Ruths S. Increased risk of hip fracture among older people using antidepressant drugs: data from the Norwegian Prescription Database and the Norwegian Hip Fracture Registry. Age Ageing 2013 Jul;42:514-20. Berge LI, Riise T, KJ, Midthjell K, et al. Does diabetes have a protective effect on migraine? Epidemiology 2013;24:129-34. Bjorner T, Tvete IF, Aursnes I, Skomedal T. [Dispensing benzodiazepines and S, et al. Antidepressants to cancer patients during the last year of life--a population-based study. Psychooncology Falch JA, Furu K, Meyer HE. Hip fracture and other predictors of anti-osteoporosis drug use in Norway. Osteoporos Int 2013 Engeland Bj\u00f8rge T, Daltveit AK, Skurtveit S, Vangen S, Vollset SE, et al. Effects of preconceptional paternal drug expo - sure on birth outcomes: Cohort study of 340000 pregnancies using Norwegian population-based databases. British Journal of Gjelstad S, Dalen children the burden of broad-spectrum antibi- otics in general practice? Prescription pattern for paediatric outpatients with respiratory tract infections in Norway. BMJ Open 2013;3:e002285. Fredheim OM, Borchgrevink PC, Mahic M, Skurtveit S. A pharmacoepidemiological cohort study of subjects starting strong opioids for nonmalignant pain: a study from the Norwegian Prescription Database. Pain 2013 Nov;154:2487-93. Hold\u00f8 I, Handal M, Skurtveit S, Bramness JG. Association between prescribing hypnotics for parents and children in Norway. Arch Dis Child 2013 ;98:732-6.Legemiddelstatistikk 2014:2 Folkehelseinstituttet 105Jonasson C, Tvete IF, proton pump inhibitor utilization in gastroesophageal reflux disease and the effect of restrictions on reimbursement: a nationwide prescription database study. Scand J Gastroenterol 2013 Klovstad H, Natas O, Tverdal A, Aavitsland P . Systematic screening with information and home sampling for genital Chlamydia trachomatis infections in young men and women in Norway: a randomized controlled trial. BMC Infectious Diseases 2013;13:30. Kravdal O. The poorer cancer survival among the unmarried in Norway: Is much explained by comorbidities? Social Science and Medicine 2013;81:42-52. Kvaale MK, Grave K, Kristoffersen AB, Norstrom M. The prescription rate of antibacterial agents in dogs in Norway - geographical patterns and trends during the period 2004-2008. J Vet Pharmacol Ther MC, Fossa SD. A national study of adverse effects and global quality of life among candidates for curative treatment for prostate cancer. BJU Int 2013 Feb;111:221-32. Lillefjell M, Haugan T, Martinussen P , Halvorsen T. Treatment outcomes among individuals in a musculoskeletal pain rehabilitation program related to the prevalence and trends in the dispensing of prescribed medications. Journal of Musculoskeletal Pain 2013;21:311-319. Log T, Skurtveit S, Selmer R, Tverdal A, Furu K, Hartz I. The association between prescribed opioid use for mothers and children: a record-linkage study. Eur J Clin Pharmacol Engeland A, Furu K, Ravndal E, Handal M. Prescription drug use among pregnant women in opioid Maintenance Treatment. Addiction 2013;108:367-76. Mauseth SA, Skurtveit S, Spigset O. Adherence, persistence and switch rates for anticholinergic drugs used for overac - tive bladder in women: data from the Database. Acta Obstet Gynecol Scand 2013;92:1208-1215.Neutel CI, Skurtveit S, Berg C, S. Trends in prescription of strong opioids for 41-80 year old Norwegians, 2005-2010. Eur J Pain 2013;18:438-446. Neutel CI, Skurtveit S, Berg C, Sakshaug S. Multiple prescribers in older safety during pregnancy: a Norwegian population registry study. Eur J Epidemiol 2013;28:759-69. Nordeng H, Lupattelli A, Rom\u00f8ren M, after gestational exposure to nitrofurantoin. Obstet - rics and Gynecology S, Berk M, Grawe RW. Clusters of personality traits and psychological symptoms asso - ciated with later benzodiazepine prescriptions in the general population: The HUNT Cohort Study. Addict Behav 2013 Oct;38:2575-80. Nordfjaern T. Prospective associations between benzodiazepine use and later life satisfaction, somatic pain and psycho - logical health among the elderly. Hum Psychopharmacol 2013 May;28:248-57.Persheim MS, severe pain]. Tidsskrift for den Norske M, Tornhage CJ, Lokk J. National surveys: a way to manage treatment strategies in Parkinson's disease? Pharmaceutical prescribing patterns and patient experiences of symptom control and their impact on disease. J Multidiscip Healthc PC. Laxative prescriptions to cancer outpatients receiving opioids: A study from the Norwegian prescription database. Supportive Care in Cancer 2013;21:67-73. Skurtveit S, Selmer R, Tverdal A, Furu K, Nystad W, Handal M. Drug exposure: inclusion of dispensed drugs before preg- nancy may lead to underestimation of risk associations. J Clin Epidemiol 2013 Jacobsen GW, Dyb G, Tverdal A, Schei B. Intimate partner violence and cardiovascular risk in women: A population-based cohort study. Journal of Women's Health 2013;22:250-8. Stephansson O, Kieler H, Haglund B, Artama Furu K, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of stillbirth and infant mortality. JAMA 2013;309:48-54. 106 Legemiddelstatistikk Sakshaug S, Jugessur A, Graff-Iversen S, et al. Resting heart rate and physical activity as risk factors for lone atrial fibrillation: a prospective study of 309,540 men and women. Heart 2013 Dec;99:1755-60. Tvete IF, Bjorner T, Aursnes IA, Skomedal T. A 3-year survey quantifying the risk of dose escalation of benzodiazepines and congeners to identify risk factors to aid doctors to more rationale prescribing. BMJ Open 2013;3:e003296. Westin AA, Bramness JG, Chalabianloo F, Rygnestad T, Slordal L. [Pregabalin should be moved to the prescription group B]. Tidsskr Nor Laegeforen 2013 Mar 19;133:615-6. Lund A, Oedegaard KJ, Hundal O. Risk of depression in diabetes is highest for young persons using oral anti-diabetic agents. Diabet Med. May]. Tidsskr Nor Laegeforen. 2012 ;132:1084-8. In Forskrivning legemidler 1975-2010. [Patterns in Norway, 1975 - 2010] Tidsskr Nor Laegeforen In Norwegian. Bramness JG, Furu Skurtveit S, Engeland A. Effect of withdrawal of carisoprodol on use of other prescribed drugs with abuse potential. Clin Pharmacol Therap 2012;91:438-41. Bramness JG, Skurtveit S, M\u00f8rland J, Engeland A. An increased risk of motor vehicle accidents after prescription of methadone. Addiction. 2012;107:967-72. Devold H, Furu K, Skurtveit S, Tverdal A, Falck JA, S\u00f8g\u00e5rd AJ. Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway. Pharmacoepidemiol Drug Saf. 2012;21:297-304. Devold HM, S\u00f8gaard AJ, Tverdal A, Falch JA, Furu K, Meyer HE. Hip fracture and other predictors of anti-osteoporosis drug use in Norway. Osteoporosis International 2012;24:1225-33. Fasmer OB, switching to methadone: A pharmacoepidemiological study from a national prescription database. Palliative Medicine 2012;26:804-12. Fredheim OM, Moksnes K, Opoid switching to methadone: a pharmacoepidemiological study from a national prescription database. Palliat Med 2012;26;804-812. Gedde-Dahl A, Devold HM, Molden E. Statin medication in patients treated with antiepileptic drugs in Norway. Pharma- coepidemiology and Drug Safety 2012;21:881-5. Gjelsvik B, Heyerdahl F, Hawton K. Prescribed medication availability and deliberate self-poisoning: a longitudinal study. J Clin Psychiatry. 2012;73:e548-54. Bratlid T, Handal M, Skurtveit S. Hypnotic drug use among 0-17 year olds during 2004-2011: A nation- wide prescription database study. Scandinavian Journal of Public Health 2012;40:704-11. Hjellvik V, Mahic M, Tverdal A. Utdanning S, Comorbidities in an asthma population 8-29 years old: A study from the Norwegian Prescription Database. Pharmacoepidemiology and Drug Safety 2012;21:1045-52. Kieler H, Artama M, Engeland A, Ericsson O, Furu Gissler M, N\u00f8rgaard M, Nielsen RB, Stephansson O, Valdimarsdottir U, Zoega H, Haglund B. Selective serotonin-reuptake inhibitors during pregnancy and risks of persistent pulmonary hyper - tension of the newborn: population based cohort study from the five Nordic countries BMJ. 2012 Jan 12;344:d8012. doi: of addictive anxiolytics and hypnotics in a national cohort of incident users in Norway. Eur J Clin Pharmacol 2012;68: 311-9. Kvaale MK, Grave M. The prescription rate of antibacterial agents in dogs in Norway - geographical patterns and trends during the period 2004-2008. Journal of Veterinary Pharmacology and Holmen J. The HUNT study: Participation is associated with survival and depends on socioeconomic status, diseases and symptoms. BMC Medical Research Methodology 2012;12:143. Lillemoen S, Fredheim OMS. Concomitant medication among persistent pain. Acta Anaesthesiologica Scandinavica 2012;56:1267-76. Neutel CI, Skurtveit is the point of guidelines? Benzodiazepine and z-hypnotic use by an elderly popula- tion. Medicine 2012;13:893-7. Neutel I, Skurtveit S, Berg C. Polypharmacy of potentially addictive medication in the older persons - quantifying usage. Pharmacoepidemiol Drug Saf 2012;21:199-206 Neutel CI, Skurtveit S, Berg C. Benzodiazepine and transdermal buprenorphine - long-term use drugs. Acta Anaesthesiol Scand. 2012;56:88-94. Nordfj\u00e6rn T. A population-based cohort study of anxiety, depression, sleep and alcohol outcomes among benzodiaz- epine and z-hypnotic users. Addictive Behaviors 2012;37:1151-7. Nyborg G, Straand J, Brekke M. Inappropriate prescribing for the elderly - A modern epidemic? European Journal of Clinical Pharmacology 2012;68:1085-94. Pedersen L, Hansen AB, Svendsen K, Skurtveit S, Fredheim M, Lindbaek M, Nordeng H. Pregnancy outcome after gestational exposure to erythromycin - a population- based register study from Norway. British Journal of Clinical Pharmacology 2012;74:1053-62. R\u00f8nning PA, Helseth E, Meling TR, population-based study on the effect of temozolomide in the treat - ment of glioblastoma multiforme. Neuro-Oncology 2012;14:1178-84.Selmer R, Blix HS, Landmark K, Reikvam \u00c5. Choice of initial antihypertensive drugs and persistence of drug use--a 4-year follow-up Nordstr\u00f6m Hartz I. Mental distress and subsequent use of psycho - tropic drugs among adolescents - a prospective register linkage study. J Adolescent Health 2012;50:578-87 Steffenak AKM, Wilde-Larsson G, Skurtveit S, Hartz I. Increase in psychotropic drug use between 2006 and 2010 among adolescents in Norway: A nationwide prescription database study. Clinical Epidemiology 2012;4:225-31. Stene LE, Dyb G, Tverdal A, Jacobsen GW, Schei B. Intimate partner violence and prescription of potentially addictive drugs: prospective cohort study of women in the Oslo Health Study. BMJ Open. 2012 Apr 5;2(2):e000614. Svendal G, Fasmer OB, Engeland A, Berk M, Lund A. Co-prescription of medication for bipolar disorder and diabetes mellitus: A nationwide population-based study with focus on gender differences. BMC Medicine 2012;10:148. K, Skurtveit S, Romundstad Differential patterns of opioid use: defining persistent opioid use in a prescription database. Eur J Pain 2012;16:359-69. Viktil KK, Engeland A, Furu K. Outcomes after antirheumatic drug use before and during pregnancy - a cohort study among 150 000 pregnant women and expectant fathers. Scand J Rheum 2012;41:196-201. Von Soest T, Bramness JG, Pedersen W, Wichstr\u00f8m L. The relationship between socio-economic status and antidepressant prescription: A longitudinal survey and register study of young adults. Epidemiology and Psychiatric Sciences 2012;21:87-95. 108 Legemiddelstatistikk TSH within the reference range as a predictor of future hypothyroidism and hyperthyroidism: 11-year follow-up of the 2012;97:93-9. M, Tverdal A. Cigarette smoking and risk of subsequent use of antibacterials: a follow-up of 365 117 men and women. J Antimicrob Chemother 2011;66:2159-67. Bramness JG, Sexton JA. M, Straand J. Does present use of cardiovascular medication reflect elevated cardiovascular risk scores estimated ten years ago? A population based longitudinal observation study. BMC Public Health. 2011;11:144. Dalen DM, Furu K, Locatelli M, Str\u00f8m S. Generic substitution: micro evidence from register data in Norway. Eur J Health Econ 2011;12:49-59. Engeland A, Bj\u00f8rge S, Vollset SE, Furu K. Risk of diabetes after gestational diabetes and preeclampsia. A registry-based study of 230.000 women in Norway. Eur J Epidemiol 2011;26:157-63. Espnes MG, Bj\u00f8rge T, Engeland A. Comparison of recorded medication use in the Medical Birth Registry of Norway with prescribed medicines registered in the Norwegian Prescription Database. Pharmacoepidemiol Drug Saf 2011;20:243-8. Fasmer OB, Riise in opioid mainte - nance therapy: of mother-reported use of antiasth- matics among children: a comparison 2011;64:878-84. Nor Laegeforen 2011;131:461-3. In Godman B, Sakshaug Berg C, Wettermark B, Haycox A. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Expert Rev Pharmacoecon Outcomes Res. 2011;11:121-9. Godman B, Shrank W, Andersen M, Berg C, Bishop I, Burkhardt T, Garuoliene K, Herholz H, Joppi prescribing in findings and future implications. Frontiers Pharmacology 2011 Gjelstad S, Straand J, Dalen I, Fetveit A, Str\u00f8m H, Lindb\u00e6k M. Do general practitioners' consultation rates influence their prescribing patterns of antibiotics for acute respiratory tract infections? J Antimicrob Chemother 2011;66:2425-33. Hancock P , Nystad W, London SJ. Oral contraceptive pill use before preg- nancy and respiratory outcomes in early childhood. Pediatr Allergy Immunol 2011;22:528-36. Handal M, Engeland A, of prescribed opioid analgesics and co-medication with benzodiazepines in women before, during and after pregnancy. A population based cohort study. Eur J Clin Pharmacol 2011;67:953-60 Harman C, Reid M, Thomas KV.In situ calibration of a passive sampling device for selected illicit drugs and their metabolites in wastewater, and subsequent year-long assessment of community drug usage. Environ Sci Technol. 2011;45:5676-82. Hartz I, Bramness JG, Skurtveit S. Prescription of antidepressants to patients on opioid maintenance - Str\u00f8m H. Boiled coffee intake and subsequent risk for Type 2 Diabetes. Epidemiology 2011;22:418-21. Hofvind S, Sakshaug S, Ursin G, Graff-Iversen S. Breast cancer incidence trends in Norway -explained by hormone therapy or mammographic screening? International Journal S, Nafstad P , Furu K. A prospective study of asthma and subsequent use of hypnotics in young adults. Pharmacoepidemiol Drug Saf 2011;20:370-7 Kjosavik SR, Hunskaar S, Aarsland D, Ruths S. Initial of antipsychotics and antidepressants in general prac - tice Rytter E, Johannessen SI. Prescription patterns of antiepileptic drugs in patients with epilepsy in a nation-wide population. Epilepsy Res. 2011;95:51-9. Langballe EM, Engdahl B, Selbaek G, Nordeng H. Concomitant of anti-dementia drugs with psychotropic drugs in Norway--a population-based study. Pharmacoepidemiol Saf. Handal M, Tverdal A, Furu K, Skurtveit S. The association between smoking and subsequent repeated use of prescribed opioids among adolescents and young adults - a population-based cohort study. Pharmacoepidemiol Drug Saf 2011;20:90-8. Log T, Skurtveit S, Tverdal A, Furu K, Hartz I. Dispensing of prescribed analgesics in Norway among young people with foreign- or Norwegian-born parents. Scand J Pain 2011;2:36-44. Mahic M, Skurtveit S, Selmer R, R\u00f8nning M, Furu K. Prevalence, incidence and persistence of etanercept and adalimimab in Norway 2005-2009. Pharmacoepidemiol Drug Saf. 2011;20:457-63. Neubert A, Hsia Y, de Jong-van den Berg LT, Janhsen K, Glaeske G, Furu K, Kieler H, N\u00f8rgaard M, Clavenna A, Wong IC. Comparison of anti-diabetic drug prescribing in children and adolescents in seven European countries. Br J Clin Phar - macol. P , Fredheim O. To what extent does a cohort of new users of weak opioids develop persistent or probable problematic opioid use? Pain ADHD OB. Are migraine and bipolar disorders comorbid phenomena?: findings from a pharmacoepidemiological study using the J Clin Psychopharmacol. \u00d8degaard \u00d8. A pharmaco-epidemiological study of migraine and antidepressant medications: Complete one year data from the Norwegian population. J Affective Disorders 2011;129:198-204. 2010: Amundsen MO, Engdahl B, Berg C, Nordeng H. Cardiovascular co-medication among users of antiobesity drugs: a population-based study. Pharm World Sci. 2010;32:752-8. Amundsen MO, Engdahl B, Berg C, Nordeng H. Use of psychotropic drugs and analgesics among users of antiobesity drugs--a population based study. Pharmacoepidemiol Saf 2010;19:273-9. A, Owe JF, Gilhus NE. requiring pyridostigmine treatment in a national popu- lation cohort. Eur J analgetika [Use of need for other pain-relieving drugs]. Tidsskr Nor Laegeforen 2010;130:1463-6. In Norwegian. Bramness JG, Rossow I. Can the total consumption of a medicinal drug be used as an indicator of excessive use? The case of carisoprodol. Drugs: Education, Prevention, and (Lyrica) help patients reduce their use of benzodi- azepines? A comparison with gabapentin using the Norwegian Clin Devold HE, Falch JA, S\u00f8gaard AJ. Prescription of anti-osteoporosis drugs during 2004-2007 - a nationwide register study in Norway. Eur J Clin Pharmacol 2010;66:299-306. Fredheim OM, Skurtveit . Increasing use of opoids from 2004 to 2007 - Pharmacoepidemio - logical data from a complete national prescription database in Norway. Eur J Pain 2010;14:289-294.Fredheim OM, Log T, Olsen W, Skurtveit S, Sagen \u00d8, Borchgrevink P . Prescription of opioids to children and adolescents; a study from a national prescription database in Norway. Pediatric Anesthesia 2010;20:537-544. Furu K, Skurtveit Almarsdottir AB, S\u00f8rensen HT. The Nordic Countries as of antipsychotic medication: a Skille E, Skurtveit S. Disability pension as a predictor of later use of benzodiazepines among benzodi- azepines users. Soc Sci Med 2010;70:921-5. Hausken AM, Furu K, Tverdal A, Skurtveit S. Mental distress and subsequent use of anxiolytic drugs - a prospective population-based cohort study of 16 000 individuals. Scand J Public Health 2010;38:465-73. Hjellvik V, Tverdal A, Furu K. Body mass index as predictor for asthma: a cohort study of 118 723 males and females. Eur Resp J 2010;35:1235-42. Hunskaar S, E, Lur\u00e5s H. Competition in general practice: prescriptions to the elderly in a list patient system. J Health Econ. 2010;29:751-64 K. Prevalence, incidence and persistence of anti-asthma medication use in 2- to 29-year-olds: a nationwide prescription study. Eur J Clin Pharmacol M, CJ. Psychiatric comorbidity in patients Sandberg S. The prevalence of self-monitoring of blood glucose and costs of glucometer strips in a nationwide cohort. Diabetes Technol Ther 2010;12:701-5. Korn\u00f8r H, Pedersen W, In Skurtveit K, Bramness J, Selmer R, Tverdal A. Benzodiazepines predict use of opioids- a follow-up study of 17 074 men and women. Pain Med 2010;11:805-14. Skurtveit S, Furu K, Selmer R, Handal M, Tverdal A. Nicotine dependence predicts repeated use of prescribed opioids. Prospective population-based cohort study. Ann Epidemiol drugs: use and co-treatment with potentially interacting medications Eur S. The risk of motor vehicle accidents involving drivers with prescriptions for codeine or i Sogn og Fjordane [Use of lithium in the Norwegian counties Oslo and Sogn og Fjordane]. Tidsskr Nor The use of lithium, valproate or lamotrigine for psychiatric conditions in children and adolescents in Norway 2004-2007 - a prescription database study. J Affect Disord 2009; Bramness JG, Skurtveit S, Neutel I, M\u00f8rland J, Engeland A. An increased risk of road traffic accidents after prescriptions of lithium or valproate? Pharmacoepidemiol Drug Saf 2009;18:492-6. Bramness JG, Weitoft GR, Hallas J. Use of lithium in the adult populations of Denmark, Norway and Sweden. J Affect Disord 2009;118:224-8. Devold H, Molden of statins and CYP3A4 inhibitors before and after introduction of new reimbursement policy. Brit J Clin Pharmacol 2009;67:234-41. Engeland Furu K. Validation of disease registration in pregnant women in the Medical Birth Registry of Norway. Acta Obstet Prescription of codeine for non-malignant pain in Norway- a pharmacoepidemiological study Gjerden P , Bramness and potential abuse of anticholinergic antiparkinson drugs in Norway: a , between the use of anticholinergic antiparkinson drugs and safety and receptor drug-binding profiles of Eur of antipsychotic and anticholinergic antiparkinson drugs in Norway after the withdrawal orphenadrine. J Clin Pharmacol 2009;68:238-42. Hartz I, Lundesgaard E, Tverdal A, Skurtveit S. Disability pension is associated with the use of benzodiazepines 20 years later: A prospective study. Scand J Public Health 2009;37:320-6. Hartz I, Tverdal A, Skurtveit S. A comparison of self-reported data on disability pension status with data from a nation- wide administrative register. Nor J Epidemiol 2009;19:169-172. Hartz I, Tverdal A, Skurtveit S. Social inequalities in use of potentially addictive drugs in Norway - use among disability pensioners. Nor J Epidemiol 2009;19:209-218. Hauge Aavitsland P . Sales of oseltamivir in Norway prior to the emergence of oseltamivir resistant influenza A(H1N1) viruses in 2007-08. Bramness Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database S, Hunskaar S. Psychotropic drug use in the Norwegian general population in 2005: data from the Norwegian Prescription Database Pharmacoepidemiol Drug Saf 2009;18:572-8. Landmark CJ, Larsson P , Rytter E, Johannessen SI. Antiepileptic drugs in epilepsy and other disorders - a population- based study of prescriptions. Epilepsy Res 2009; 87: 31-9. Selmer R, Sakshaug S, Skurtveit S, Furu K, Tverdal A. Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education. Brit J Clin Pharmacol 2009;67:355-62. Skurtveit S, Furu K, Introduction of low dose transdermal buprenorphine - did it influence use of potentially addictive drugs in chronic non-malignant pain patients? Eur J Pain 2009;13:949-53. Skurtveit Skrivarhaug T, M\u00f8rland J, Bramness J, Engeland A. Road traffic accident risk in patients with diabetes mellitus, receiving blood glucose-lowering drugs. Prospective follow-up Engeland A, Furu K. Use of antirheumatic drugs in mothers and fathers before and during pregnancy - a population-based cohort study Pharmacoepidemiol Drug Saf 2009;18:737-42. Winther Legemiddelshopping av vanedannende medikamenter addictive drugs in Repeated dispensing of codeine is associated with high consumption of benzodiazepines. Nor J Epidemiol 2008;18:185-90. Berg A, Furu Norwegian. Bramness JG, Buajordet I, Skurtveit S. The role of pharmacoepidemiological studies in the market withdrawal of cariso - prodol (Somadril\u00ae) in Europe. Nor J Epidemiol 2008;18:167-72.Bramness JG, Skurtveit S. Carisoprodol should be taken of the market. South Med J 2008;101:1074-5. Bramness JG , Skurtveit S, Neutel CI, M\u00f8rland J, Engeland A. Minor increase in risk of road traffic accidents after prescrip - tions of T, Dalen I. Pharmacologically inappropriate prescriptions for elderly patients in general practice: How common? Baseline data from The Prescription Peer Academic Detailing (Rx-PAD) study. Scand J Prim Health Care 2008;26:80-5. Engeland JG, AK, R\u00f8nning M, Skurtveit S, Furu K. Prescription druguse among fathers and mothers before and during pregnancy. A population-based cohort study of 106,000 pregnancies in Norway 2004-06. registerbasert kohortstudie. [Traffic accident risks associated with the prescription of medicinal drugs: a registry-based cohort study] A, J, B. an arctic population: the Troms\u00f8 Study. BMC Health Serv Res 2008;8:117. Furu K. Establishment of the nationwide Norwegian Prescription Database (NorPD) - New opportunities for research in pharmacoepidemiology in Norway. Nor J Epidemiol 2008; Neutel CI, M\u00f8rland J. Road traffic accident risk related to prescriptions of the hypnotics zopiclone, zolpidem, of antipsychotic medication: linking population-based prescription database to the HUNT study. Pharmacoepidemiol Drug Saf 2008;17:372-7. Litleskare I, Blix H, in Tidsskr opioider til norske kreftpasienter cancer in Laegeforen Bramness JG, Tverdal A. Benzodiazepine use in all alcohol consumers predicts use of opioids in patients 20 years later - a follow-up study of 13 390 men and women aged 40-42 years. Pharmacoepidemiol Drug Saf 2008;17:926-933. Skurtveit S, Selmer R, Tverdal A, Furu K. The validity of self-reported prescription medication use among adolescents varied by therapeutic class. J Clin Epidemiol 2008;61:714-17. Str\u00f8m H, Sakshaug S, Skurtveit S. Use of statins in patients receiving oral blood glucose-lowering drugs. Nor J Epidemiol 2008;18:191-94. 2007: Al-Haroni M, Skaug N. Incidence of antibiotic prescribing in dental practice in Norway and its contribution to national consumption. J Antimicrob Chemother 2007;59:1161-6. Blix f\u00e6rre forskrivninger? [The use of antidepressants amongst children and adolescents - did the warnings lead to fewer prescriptions?] Tidsskr Nor Laegeforen 2007;127:2653-5. In Engeland A, Skurtveit S. Carisoprodol use and abuse in Norway. for patients in opioid maintenance treatment in Norway. Drug Alcohol Depend 2007;90:203-9. Bramness JG, Skurtveit S, M\u00f8rland J, Engeland A. The risk of road traffic accidents after prescriptions of carisoprodol. Accid Anal Prev 2007;39:1050-5. Engeland A, Skurtveit S, M\u00f8rland J. Risk of road traffic accidents associated with the prescription of medicinal drugs: a registry-based cohort study. Ann Epidemiol A, Nafstad P . Use of anti-asthmatic medications as a proxy for prevalence of asthma in children and adolescents in Norway: a nationwide prescription database analysis. Eur J Clin Pharmacol of statin prescribing in Norwegian coun- ties with high, average and low statin consumption - an individual-level prescription database N, Hausken T, P . A large community outbreak of waterborne giardiasis-delayed detection in a non-endemic urban area. M, Skurtveit S. Switching statins in Norway after new reimbursement policy - a nationwide prescription study. Br J Clin Pharmacol 2007;64:476-81. Torkildsen O, Grytten N, Myhr av flunitrazepam etter 1999. [Changes in the sale and of in Norway, Tidsskr Dalen I, Rognstad S, Lindback M. Can antibiotic prescriptions in respiratory tract infections be improved? A cluster-randomized educational intervention in general practice--the Prescription Peer Academic Detailing (Rx-PAD) Study [NCT00272155]. S, Brekke M, Dalen I. A cluster-randomized educational intervention to reduce inappropriate prescription patterns for elderly patients in general practice--The Prescription Peer Academic Detailing (Rx-PAD) study [NCT00281450]. diabetes mellitus? [How and who receiving medication for diabetes mellitus?] Tidsskr Nor Laegeforen 2006;126:768-70. Prescription An important tool for detailed information on drug use]. Nor J Epidemiol 2004;14:53-56. 2001: Furu K. Drug utilisation in a public health perspective: Establishing a national prescription register in Norway. Nor J Epide - Health Bestilling/Order: E-mail:publikasjon@fhi.noTelephone: +47 21 07 "}